Parathyroid Scintigraphy: Optimization of 99mTc-sestamibi/123I subtraction SPECT/CT by Tunninen, Virpi
Virpi Tunninen
Parathyroid Scintigraphy
Optimization of 99mTc-sestamibi/123I subtraction SPECT/CT
Julkaisu 1500 • Publication 1500
Tampere 2017
 
 
Tampereen teknillinen yliopisto. Julkaisu 1500 
Tampere University of Technology. Publication 1500 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Virpi Tunninen 
 
Parathyroid Scintigraphy 
Optimization of 99mTc-sestamibi/123I subtraction SPECT/CT 
 
 
Thesis for the degree of Doctor of Philosophy to be presented with due permission for 
public examination and criticism in Auditorium 126, at Tampere University of Technology 
- Pori, on the 13th of October 2017, at 12 noon.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tampereen teknillinen yliopisto - Tampere University of Technology 
Tampere 2017 
 
 
 
 
Doctoral candidate: Virpi Tunninen 
Department of Nuclear Medicine 
Satakunta Central Hospital 
Finland 
 
Supervisor: Hannu Eskola, Professor 
Faculty of Biomedical Sciences and Engineering 
Tampere University of Technology 
Finland 
 
Instructors: Tomi Kauppinen, Adjunct Professor 
Helsinki University Central Hospital  
Finland 
 
Matti Koskinen, Adjunct Professor 
Finland 
 
Pre-examiners: Jari Heikkinen, Adjunct Professor 
Department of Medical Physics 
The Social and Health Care Joint Authority of South Savo, 
Mikkeli Central Hospital 
University of Eastern Finland 
Finland 
 
Piotr Slomka, Professor 
Artificial Intelligence In Medicine Program 
Department of Imaging, Cedars-Sinai Medical Center  
David Geffen School of Medicine, University of California 
Los Angeles 
USA 
 
Opponent: Mika Teräs, Professor 
University of Turku, Institute of Biomedicine 
Turku University Hospital, Department of Medical Physics 
Finland 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISBN 978-952-15-4011-0 (printed) 
ISBN 978-952-15-4021-9 (PDF) 
ISSN 1459-2045 
 
 
 iii 
 
Tiivistelmä 
Lisäkilpirauhasten liikatoiminnassa eli hyperparatyreoosissa yksi tai useampi lisäkilpi-
rauhanen tuottaa verenkiertoon liikaa lisäkilpirauhashormonia, mikä johtaa seerumin 
kalsiumpitoisuuden nousuun. Potilaalla voi olla monentyyppisiä oireita, joista tavan-
omaisin on osteoporoosi. Lisäkilpirauhasten liikatoiminnan ainoa parantava hoito on 
leikkaus, joka tehdään tavallisesti mini-invasiivista tekniikkaa käyttäen. Edellytys tälle 
on liikatoimisen lisäkilpirauhasen tarkka paikantaminen. 
 
Liikatoimisen lisäkilpirauhasen paikantaminen tehdään tavallisesti isotooppitutkimus-
menetelmällä. Käytettävissä on yksi tutkimusaine, 
99m
Tc-sestamibi, joka ei kuitenkaan 
ole spesifinen lisäkilpirauhaskudokselle vaan kertyy lisäksi esimerkiksi kilpirauhaseen. 
Lisäkilpirauhasen erottamiseksi kilpirauhasesta on kehitetty erilaisia menetelmiä ja käy-
tettävissä on myös erilaisia kuvaustekniikoita. Lopputuloksena on suuri määrä erilaisia 
tutkimusprotokollia, joiden herkkyys ja spesifisyys vaihtelevat suuresti. 
  
Tämän väitöskirjatyön tavoitteena oli löytää optimaalinen tutkimusprotokolla liikatoi-
misen lisäkilpirauhasen paikantamiseen isotooppimenetelmiä käyttäen. Suomessa käy-
tössä olevat tutkimusprotokollat selvitettiin ja erilaisia protokollia testattiin potilaiden 
avulla. Lupaavimmaksi osoittautunutta menetelmää optimoitiin erilaisten testikohteiden 
eli fantomien avulla. 
 
Työssä osoitettiin, että kaksoisisotooppimenetelmä 
99m
Tc-sestamibi- ja 
123
I-
merkkiaineita käyttäen on ylivoimainen yhden isotoopin käyttöön verrattuna. 
99m
Tc-
sestamibi/
123
I -SPECT/CT –protokolla on erittäin herkkä ja spesifinen tutkimusmene-
telmä liikatoimisten lisäkilpirauhasten paikantamisessa. Tutkimusmenetelmästä saatava 
kolmiulotteinen anatominen informaatio edesauttaa lisäksi adenooman tarkassa paikan-
tamisessa. 
 
Kuvauksessa ja kuvankäsittelyssä käytetyillä menetelmillä on merkittävä vaikutus 
99m
Tc-sestamibi/
123
I SPECT/CT –tutkimuksen lopputulokseen. Tarkasti optimoitu 
99m
Tc-sestamibi/
123
I SPECT/CT –tutkimus on yksinään riittävä menetelmä liikatoimisen 
lisäkilpirauhasen paikantamiseen, eikä lisäkuvauksia tarvita. Käytettävä menetelmä on 
kuitenkin syytä testata tunnettuja fantomeja käyttäen kussakin sairaalassa optimaalisen 
lopputuloksen saavuttamiseksi. Tämän väitöskirjatyön tuloksia hyödynnetään lisäkilpi-
rauhasten gammakuvauksen suosituksen laatimisessa. 
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Abstract 
Hyperparathyroidism is a common endocrine disorder caused by one or more hyper-
functioning parathyroid glands secreting excess amounts of parathyroid hormone. This 
leads to hypercalcemia that may lead to numerous clinical manifestations, such as oste-
oporotic fractures. Surgery is the only curative treatment, with current trends towards 
minimally invasive operations. A prerequisite for targeted operation is a sensitive and 
specific preoperative localization that is, also capable of identifying ectopic glands and 
multiple gland disease. 
 
Preoperative localization is performed using nuclear  medicine, i.e., scintigraphic tech-
niques, with 
99m
Tc-sestamibi being the imaging agent of choice. Unfortunately, 
99m
Tc-
sestamibi is not a specific agent for parathyroid tissue, and several protocols are in use 
with variable sensitivity and specificity figures. 
 
The aim of this thesis was to find the optimal protocol for parathyroid scintigraphy with 
the highest sensitivity and specificity. Subsequently, the national status of protocols was 
investigated. These protocols were tested in the clinical environment and finally the 
protocol of choice was optimized with the use of phantoms. 
 
Our results indicate that the dual-isotope method with 
99m
Tc-sestamibi and 
123
I is supe-
rior when compared with the use of 
99m
Tc-sestamibi alone.
99m
Tc-sestamibi/
123
I subtrac-
tion SPECT/CT is a highly sensitive and specific protocol for parathyroid scintigraphy 
and should be preferred over planar acquisition techniques due to important anatomical 
3D information. However, acquisition and processing parameters have a profound effect 
on the outcome of 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT. The protocol should 
therefore be tested with known anthropomorphic phantoms. With careful optimization, 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT is an adequate technique for parathyroid 
scintigraphy without additional acquisitions. The results of this thesis will provide 
guidelines for proposing recommendations for parathyroid scintigraphy. 
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1 Introduction 
Hyperparathyroidism (HPT) is a common endocrine disorder caused by one or more hyperfunction-
ing parathyroid glands that secrete excess amounts of parathyroid hormone and raise the blood cal-
cium level. Surgery is the only curative treatment, and current trends are towards minimally inva-
sive operations. A prerequisite for targeted operation is a sensitive and specific preoperative locali-
zation that is capable of identifying ectopic glands and multiple gland disease. 
 
Preoperative localization is performed using nuclear medicine techniques, with 
99m
Tc-sestamibi 
being the imaging agent of choice. Unfortunately, 
99m
Tc-sestamibi is not a specific agent for para-
thyroid tissue, and it is also taken up by adjacent thyroid tissue. Two methods have evolved to over-
come this problem: the dual-phase method and the dual-tracer method. The dual-phase method re-
lies on the fact that thyroid and the parathyroid tissues have different washout kinetics for 
99m
Tc-
sestamibi. By acquiring images immediately after the injection of 
99m
Tc-sestamibi and then 2 to 3 
hours later, the focally increasing uptake will reveal the enlarged parathyroid gland. In the dual-
isotope method, 
99m
Tc-sestamibi is combined with 
123
I, which is taken up by the thyroid gland only. 
Subtracting the thyroid image from the 
99m
Tc-sestamibi image leaves only the enlarged parathyroid 
glands in the subtraction image. 
 
The dual-phase method is attractive due to its technical simplicity and low cost. Unfortunately, the 
technique fails to detect parathyroid adenomas with rapid 
99m
Tc-sestamibi clearance and has low 
sensitivity for identifying multiple-gland disease. These pitfalls can be avoided by using the techni-
cally more difficult dual-isotope method, where thyroid-seeking 
123
I is acquired simultaneously with 
99m
Tc-sestamibi, and 
123
I images are subtracted from the 
99m
Tc-sestamibi images. In this method, the 
enlarged parathyroid gland shows up as residual activity in the subtraction images.  
Several acquisition techniques with various corrections and adjustable parameters can be used with 
both methods. Both planar imaging (with parallel hole or pinhole collimators) and three-
dimensional (3D) imaging (SPECT and SPECT/CT) are widely used. To increase sensitivity, the 
techniques are often combined in clinical practice. The imaging protocols are not, however, stand-
ardized and a large variety of protocols with variable sensitivity figures are used. 
 
This thesis originated from the question: ”How should it be done?” as results of parathyroid scintig-
raphy were not reliable according to the endocrine surgeon at Satakunta Central Hospital at that 
time. In this thesis, parathyroid scintigraphic methods and acquisition techniques were evaluated 
with a group of clinical patients suffering from primary or secondary hyperparathyroidism. The 
effect of the acquisition and processing techniques and the optimization of the 
99m
Tc/
123
I subtraction 
SPECT/CT protocol were studied using an anthropomorphic phantom. 
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2 Literature review 
2.1 Physics of dual-isotope imaging 
2.1.1 Gamma camera 
Traditional nuclear medicine has been using the gamma camera based on the scintillation detector 
“The Anger Camera” for more than 50 years (Anger 1958). The basic principles of the gamma 
camera are invariable, regardless of numerous technical improvements (Brownell et al. 1990, Fahey 
1996, O'Connor M et al. 2002, Peterson et al. 2011, Bailey et al. 2013) and are briefly discussed 
here.  
 
Figure 1. The basic principle of a gamma camera. The dashed lines represent the gamma photons. 
 
Gamma photons originating from the patient travel through the collimator holes and reach the 
NaI(Tl)-crystal, where the photons transfer their energy to crystal electrons in a photoelectric effect, 
as shown in Figure 1. As a result, visible wavelength photons are detected by photomultiplier (PM) 
tubes, where light is in turn converted into an electric signal in a series of dynodes. The signal is 
collected from of all the PM tubes, and the location of the scintillation and the energy of the incom-
ing gamma photon are calculated (Cherry et al. 2003). 
 
The image formation of a gamma camera is not a mathematically exact process. Incoming gamma 
photons do not experience a photoelectric effect in the crystal with 100% efficiency and there is 
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some fluctuation in the amount of light produced in the scintillation process. Moreover, the number 
of photons that interact with the photocathodes (inside PM tube), the number of electrons produced 
in the photocathodes, and  the electrical pulse output of each photomultiplier tube (proportional to 
the gain of each tube) are also not exactly the same for all identical incoming gamma photons 
(Cherry et al. 2003). These steps account for the uncertainty in measuring the incoming gamma 
photon energy, which results in the limited energy resolution of the gamma camera. The typical 
measure of a modern gamma camera is approximately 9% (Cherry et al. 2003). 
 
The collimator is an essential part of the gamma camera. It is, however, the limiting factor in the 
performance of the system.  Collimators can be classified as parallel-hole, pinhole, and focusing 
collimators. The characteristics of the parallel-hole collimator are dependent on the collimator 
thickness, hole diameter and septal thickness, as shown in Figure 2. Together these define the ac-
ceptance angle, in which a photon needs to enter the hole in order to pass through without interac-
tion (Cherry et al. 2003). As the acceptance angle increases, the sensitivity of the collimator in-
creases, but at the same time the spatial resolution decreases. Thus, the choice of the collimator is a 
tradeoff between sensitivity and resolution (Fahey et al. 1992). 
 
Septal penetration is a phenomenon where gamma photons pass through the collimator septa and 
reach the NaI(Tl) –crystal as shown in Figure 2. This leads to blurring of the images, as all photons 
are considered to hit the crystal surface perpendicularly. Septal penetration is a significant issue 
with higher-energy radionuclides and, appears as a streak artifact in an image (McKeighen et al. 
1974, Dobbeleir et al. 1999).  
 
 
 
 
 
 
Figure 2.  A gamma camera equipped with a parallel hole collimator (left) and the cross-section of 
the parallel hole collimator (right) where l = thickness, d = hole diameter, and  t = the thickness of 
the septa.  
 
The pinhole collimator is a large cone with a single small aperture at the tip of the cone (Figure 3). 
It creates a magnified image very similar to a traditional camera obscura. Nowadays, the use of the 
pinhole collimator is mainly limited to planar imaging. It is, however, very good in the imaging of 
small structures due to its superior spatial resolution (Beekman et al. 2007). Due to its design and 
the thickness of the cone wall, the pinhole collimator does not suffer from the septal penetration 
phenomenon (McKeighen et al. 1974). There focusing collimators are not applied in parathyroid 
scintigraphy and are therefore outside the scope of this thesis. 
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Figure 3.  A gamma camera equipped with a pinhole collimator (left) and the cross-section of the 
pinhole collimator (right). 
 
 
2.1.2 SPECT/CT 
Single photon emission computed tomography (SPECT) acquisition with a gamma camera is nowa-
days part of normal clinical routine. During tomographic acquisition, the gamma camera detectors 
rotate around the patient and static projection images are acquired between ~2 to 5 degrees over 180 
or 360 degrees around the patient (Figure 4). These projection images are reconstructed into trans-
axial slices using a reconstruction algorithm. The traditional filtered back projection (FBP) algo-
rithm has been replaced by iterative algorithms that give a more detailed image without the typical 
streak artifact seen in an FBP image (Hudson et al. 1994, Vandenberghe et al. 2001, Cherry et al. 
2003). 
 
  
 
Figure 4. The principle of SPECT acquisition (left) and reconstruction (right). The gamma camera 
detectors rotate around the patient and acquire static projection images (left). The projection imag-
es are reconstructed into transaxial slices with a reconstruction algorithm (right). One transaxial 
slice is shown in the middle (right). 
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The introduction of the combined SPECT and computed tomography (CT) device enables the exact 
anatomical localization and attenuation correction of nuclear medicine images. Multimodality, i.e., 
SPECT/CT imaging, is now playing an increasingly important role in the diagnosis and staging of 
disease (Buck et al. 2008, Townsend 2008). In Finland, there are 46 gamma cameras (at the end of  
2016) and 34 of those are equipped with CT. With newer cameras (less than 5 years), 19 of 20 are 
equipped with CT. 
 
 
 
Figure 5. A modern SPECT/CT camera. 
2.1.3 SPECT image quality 
SPECT images are degraded by several physical phenomena. The primary problems originate from 
the patient as gamma photons experience both photoelectric effect and Compton scattering in pa-
tient. Photon attenuation is corrected using a CT-based attenuation map “µ-map”, where linear at-
tenuation coefficient values are derived from Hounsfield values in a CT-image. This correction is 
incorporated in a reconstruction algorithm that has become a clinical standard (Ritt et al. 2011, 
Seret et al. 2012). Scatter correction, in its simplest form, is a passive method because, the pho-
topeak can be narrowed in order to avoid scattered photons. Correction is usually based on acquir-
ing additional energy windows and by applying subtraction-based correction techniques, such as the 
triple energy window (TEW) method (Ogawa et al. 1991, Ichihara et al. 1993). In addition, there are 
also more complex correction methods available, where the scatter is estimated and corrected, for 
example, based on Monte Carlo simulation (Buvat et al. 1994). However, these methods require 
additional programs or algorithms and are not applicable in basic clinical work (Hutton et al. 2011). 
 
The limited spatial resolution of the camera gives rise to a third phenomenon, the partial volume 
effect. The activity of active small regions (smaller than approximately twice the spatial resolution 
of the imaging system) is spread to the surroundings and underestimated (Cherry et al. 2003, Ritt et 
al. 2011, Frey et al. 2012). Some correction can be achieved with the use of the resolution recovery 
that is included in vendor-specific reconstruction algorithms (Seret et al. 2012). 
 
In addition to scatter, attenuation and limited resolution, image quality is affected by other factors, 
such as patient movement during or between SPECT and CT acquisition, patient organ movement, 
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radiotracer movement in the patient, and noise in images (statistics are limited due to radiation dose 
issues). 
2.1.4 Simultaneous dual-isotope imaging  
The simultaneous acquisition of two radiopharmaceuticals in the same study offers several ad-
vantages over two separate acquisitions. For example, simultaneous acquisition offers the possibil-
ity to examine two different processes in a single study, thereby reducing total examination time 
and the probability of patient movement and excludes registration errors. Thus, perfectly registered 
images for image subtraction or comparison are produced (Links 1996). Simultaneous dual-isotope 
imaging has been applied in myocardial studies (Bai et al. 2007, Du et al. 2014), in studies of brain 
perfusion and receptor uptake, (Brinkmann et al. 1999, Dresel et al. 1999) and in parathyroid scin-
tigraphy (Neumann et al. 1997). 
 
There are several physical factors that need to be examined before applying the dual-isotope method 
in clinical work. These important factors are dependent on the combination of isotopes, but include 
the cross-contamination of isotopes, the effect of collimator selection, and the effects of energy 
window selection on uniformity, resolution, and sensitivity (Madsen et al. 1993, Inoue et al. 2003).  
2.1.5 Cross-contamination 
The major problem with dual-isotope imaging is so-called cross-contamination or “crosstalk”, 
where photons of one radionuclide are detected in the energy window of the other and vice versa. 
With 
99m
Tc (140 keV) and 
123
I (159 keV), there are three types of cross-contamination. First, the 
primary photons of 
99m
Tc are detected in the 
123
I window and the primary photons of 
123
I are detect-
ed in the 
99m
Tc window due to finite energy resolution. Second, scattered 
123
I photons are detected 
in the 
99m
Tc window and third, the high-energy photons of 
123
I are detected in both the 
99m
Tc and 
123
I energy windows (Devous et al. 1992, Links 1996, Links et al. 1996, Hapdey et al. 2006, Du et 
al. 2007, Du et al. 2009). 
 
 
Figure 6. The spectra of 
99m
Tc (black) and 
123
I (grey) acquired with a LEHR collimator at a dis-
tance of 20cm from the source in air. 
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The amount of cross-contamination depends on the activity of the 
99m
Tc and 
123
I used, the local up-
take of each isotope, and also on the positioning and width of the energy windows. It has been 
shown by several authors that there are significant amounts of cross-contamination in both the 
99m
Tc and 
123
I energy windows (Hapdey et al. 2006, Du et al. 2007). This can also be seen in Figure 
6. Much of the cross-contamination in the 
99m
Tc window is from primary 
123
I 159 keV photons, and 
may contain significant high frequency information. Crosstalk caused by higher-energy photons is 
low-frequency by nature due to multiple scattering and affects a larger area, resulting in reduced 
general image contrast (Devous et al. 1992, Links 1996, Du et al. 2009). 
2.1.6 Cross-contamination compensation 
Cross-contamination of 
99m
Tc and 
123
I can severely degrade the image quality and quantitative accu-
racy, and makes simultaneous dual-isotope imaging with 
99m
Tc and 
123
I less clinically useful. Sever-
al methods have been suggested to correct the cross-contamination caused by the simultaneous use 
of 
99m
Tc and 
123
I. The use of narrow or asymmetric energy windows is probably the most common 
approach to avoid cross-contamination. However, results have been somewhat conflicting, as both 
major limitations and accurate quantitation have been reported (Devous et al. 1992, Ivanovic et al. 
1994, Neumann et al. 1997, Brinkmann et al. 1999, Dresel et al. 1999, Dontu et al. 2004, Du et al. 
2007, Neumann et al. 2008). Using asymmetric windows is an easy and straightforward method, but 
large cross-contamination components between 
123
I and 
99m
Tc are not eliminated using asymmetric 
windows. The method also leads to the loss of counting efficiency and large variations in flood field 
uniformity, as shown in Figure 7, that  could cause artifacts in the reconstructed images  (Ivanovic 
et al. 1994). 
 
 
 
Figure 7. An asymmetric energy window and the resulting flood field uniformity image with 
123
I. 
 
If a narrow energy window is used, more scattered photons are excluded, but at the same time sensi-
tivity is decreased. This in turn decreases the signal-to-noise –ratio. The use of narrow energy win-
dows is not a very efficient method to exclude scattered photons because the loss of photon energy 
in Compton scattering is not very high. As an example, if a 
99m
Tc photon is scattered at an angle of 
45 degrees, it has lost only 7% of the original energy and is still included in a rather narrow energy 
window (Cherry et al. 2003). 
 
Subtraction-based methods estimate the cross-contamination component in primary energy win-
dows and subtract the data to yield an uncontaminated result. Different approaches have been pro-
posed, either 
123
I and 
99m
Tc images are partially subtracted from each other (Dresel et al. 1999) or a 
specific scatter image is acquired, and this is then partially subtracted from the 
123
I image 
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(Brinkmann et al. 1999). The triple-energy window (TEW) and a modified version of TEW have 
also been applied (Ichihara et al. 1993, Matsudaira et al. 1997, Ogasawara et al. 1998). 
 
An attempt to correct for cross-contamination using subtractive methods assumes that an image 
acquired in the 
99m
Tc window is the sum of the 
99m
Tc photons and the 
123
I cross-contamination pho-
tons, and that the image recorded in the 
123
I window is the sum of the 
123
I photons and the 
99m
Tc 
cross-contamination photons. It also assumes that there is no spatial variation in the cross-
contamination image. This approach has been shown to be false; the spatial distribution of the pho-
tons recorded in the scatter window is not the same as the spatial distribution of the photons record-
ed in the photopeak window (Ivanovic et al. 1994). This is especially true with 
123
I cross-
contamination in a 
99m
Tc image; the 
123
I cross-contamination in the 
99m
Tc window is dominated by 
the spatially uncorrelated scatter and the septal penetration of high energy photons (Brinkmann et 
al. 1999). A major difficulty with a subtraction-based approach is the accurate determination of the 
cross-contamination fraction, which is greatly dependent on the activity ratios of the radioisotopes 
used and is also dependent on object (size, shape) and depth (Kadrmas et al. 1999, Hannequin et al. 
2000, Hapdey et al. 2006). 
 
More complex methods, such as spectral factor analysis (Hapdey et al. 2006), artificial neural net-
work (El Fakhri et al. 2001, Bai et al. 2007), or model-based methods ((Du et al. 2007, Du et al. 
2009, Shcherbinin et al. 2012, Du et al. 2014), have been used. These methods can provide images 
with less noise than subtraction-based methods. The disadvantage of modeling-based methods lies 
in the complexity of the models used. Accurately modeling multiple orders of scatter in inhomoge-
neous media is difficult and implementing such methods in current clinical work is not a very easy 
task (Kadrmas et al. 1999). 
2.1.7 High energy photons of 123I and septal penetration 
 
 
Figure 8. The spectrum of 
123
I in air. 
 
In addition to 159 keV photons, 
123
I also emits high energy photons of more than 300 keV (Figure 
8) that are capable of penetrating the septa of the collimator. This is a potential cause of artifacts 
when imaging with 
123
I, as increased scatter decreases the resolution and contrast of the image. At 
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the same time, the sensitivity of 
123
I varies as a function of distance as high-energy photons pene-
trate through the collimator septa into the crystal and behave as a camera would without the colli-
mator (Dobbeleir et al. 1999, Inoue et al. 2003). Thus, the amount of septal penetration varies dur-
ing SPECT acquisition and distortions in the projection images cause reconstruction artifacts 
(Macey et al. 1986). 
 
The characteristics of various collimators have been studied for 
123
I imaging and 
99m
Tc/
123
I imaging 
with a general preference towards medium-energy collimators (Macey et al. 1986, Ivanovic et al. 
1994, Geeter et al. 1996, Dobbeleir et al. 1999, Inoue et al. 2003, Verberne et al. 2005, Small et al. 
2006).The use of medium-energy collimators reduces the influence of septal penetration of high-
energy gamma photons of 
123
I due to thicker septa. Unfortunately, medium-energy collimators gen-
erally provide lower spatial resolution compared to that of low-energy collimators, which may in-
fluence the detection of small structures (Dobbeleir et al. 1999, Inoue et al. 2003). 
 
Collimator selection for dual-isotope applications is thus always a compromise in terms of resolu-
tion, sensitivity, and the septal penetration of photons. It should be noted that the physical character-
istics for 
123
I imaging and simultaneous dual-isotope imaging with 
123
I can differ even between low-
energy collimators that provide similar sensitivity and spatial resolution (Gilland et al. 1994, Inoue 
et al. 2003, Kobayashi et al. 2003). It has therefore been suggested that the physical characteristics 
of each camera-collimator system used for dual-isotope imaging should be investigated before use 
in clinical studies (Ivanovic et al. 1994, Inoue et al. 2003). 
2.2 The parathyroid glands 
2.2.1 Anatomy and physiology 
The parathyroid glands are small endocrine glands in the neck that are normally located behind the 
thyroid gland (Figure 9). The weight of a normal parathyroid gland ranges from 20 mg to 45 mg 
and is smaller than 7 mm in diameter. Approximately 90% of individuals have four parathyroid 
glands, about 4% have five glands, and about 5% have three glands. Parathyroid glands are derived 
from the epithelial lining of the third and fourth pharyngeal pouches, with the superior glands (P4) 
originating from the fourth pouch, and the inferior glands (P3) originating from the higher third 
pouch (Hindie et al. 2009). Due to the migration of embryological tissues, it is possible that the lo-
cation of parathyroid glands vary significantly (especially P3 because of the longer route). Parathy-
roid glands can be found intrathyroidal, within the thyrothymic ligament, within the thymus, in the 
mediastinum, or remain high in the neck (Kettle et al. 2006, Hindie et al. 2009). 
 
 
Figure 9. The parathyroid glands are situated behind the thyroid gland. 
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Parathyroid glands control the amount of calcium in the blood and within the bones by producing 
parathyroid hormone (PTH). PTH keeps the calcium, phosphate and vitamin D levels stable by 
means of several actions. These actions include stimulating renal tubular calcium reabsorption, uri-
nary phosphate excretion and the activity of the 1α-hydroxylases, the synthesis of calcitriol, increas-
ing calcium absorption from the gastrointestinal tract, and stimulating osteoclastic and osteoblastic 
activity in the bone that results in the release of calcium and phosphate from the bone (Hindie et al. 
2009). 
2.2.2 Hyperparathyroidism  
Primary hyperparathyroidism is a common endocrine disorder, where hyperactive parathyroid 
glands cause hypercalcemia and elevated parathyroid hormone levels. About 85% of all primary 
hyperparathyroidism cases are caused by a single adenoma, a benign tumor of a parathyroid gland. 
About 15% of cases are caused by parathyroid hyperplasia, a condition where more than one gland 
is enlarged (Hindie et al. 2009). Secondary hyperparathyroidism results from any medical condition 
that produces hypocalcaemia, which in turn stimulates the parathyroid glands. The most common 
cause is renal failure, resulting in hyperplastic changes in the parathyroid glands. Occasionally, one 
or more of the glands can become autonomous which results in tertiary hyperparathyroidism 
(Ahmad et al. 2004, Hindie et al. 2009). 
 
The typical clinical signs of hyperparathyroidism are osteoporotic fractures. There are, however, a 
number of symptoms associated with hyperparathyroidism that involve the kidneys (i.e., impaired 
renal function), the digestive tract (i.e., constipation), the cardiovascular system (hypertension), and 
even cognitive impairment and neuropsychiatric symptoms. The diagnosis of hyperparathyroidism 
is based on laboratory findings, where ionized calcium (Ca-ion) and parathyroid hormone (PTH) 
levels are elevated. Patients should be referred for parathyroid scintigraphy only when the above-
mentioned diagnostic criteria are met. Parathyroid scintigraphy is thus not a diagnostic study, but 
performed for the localization of the enlarged parathyroid gland (Hindie et al. 2009). 
2.2.3 Minimally invasive parathyroidectomy – need for localization 
Surgery is the only curative treatment for hyperparathyroidism. The classical surgical approach to 
primary hyperparathyroidism is based on bilateral neck exploration that involves the identification 
of at least four parathyroid glands and the removal of the enlarged ones. With an experienced sur-
geon, bilateral neck exploration has a success rate of 95% (Clark 1995). A famous phrase by 
Doppman “The only thing to localize in primary hyperparathyroidism is an experienced surgeon”, 
which was probably true considering the imaging methods available at that time (Doppman 1968). 
 
The current trend is towards minimally invasive parathyroidectomy. This technique is superior to 
classical approaches and results in reduced complication rates and operation times, shorter hospital 
stays, lower total costs, and improved cosmetic results (Johnson et al. 2007, Shindo et al. 2008, 
Greene et al. 2009, Augustine et al. 2011, Udelsman et al. 2011). 
 
The main reasons for failed surgery are ectopic glands and undetected multiple abnormal glands 
(Carty 2004, Phitayakorn et al. 2006, Hindie et al. 2009).  It is very important that surgical proce-
dures are carried out correctly in the first place because the accuracy of localizing residual hyperac-
tive glands is significantly lower before reoperative parathyroidectomy than before initial surgery 
(Witteveen et al. 2010). The risk of complications is also increased in the case of reoperation (Taieb 
et al. 2013, Whitcroft et al. 2014). The introduction of minimally invasive procedures thus under-
scores the importance of sensitive and accurate imaging methods before operation  (Hindie et al. 
2009). 
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Figure 10. Minimally invasive parathyroidectomy (image courtesy of endocrine surgeon Jussi Aal-
to, Satakunta Central Hospital, Pori, Finland). 
2.3 Parathyroid scintigraphy 
2.3.1 History 
Various radionuclides, i.e., tracers such as 
67
Ga-citrate 
75
Se -methionine, 
57
Co-B12 vitamin, and a 
combination of 
131
I-toluidine blue, 
99m
TcO4, and 
113m
In, and a combination of 
131
I-toluidine blue and 
99m
TcO4, have been used for parathyroid scintigraphy since the early 1960s (Kang et al. 1968, 
Skretting et al. 1977, Cann et al. 1980, Zwas et al. 1987). 
 
One of the most widely used techniques was the 
201
Tl/
99m
Tc subtraction technique, but with an av-
erage sensitivity of only 55% (Ferlin et al. 1983, Young et al. 1983, Doppman et al. 1991).  
201
Tl 
had suboptimal imaging properties due to low gamma energy, and the radiation dose to the patient 
was high mainly due to the long half-life of the radionuclide. Thus, there was a need for better radi-
otracers for parathyroid scintigraphy. 
 
2.3.2 99mTc-sestamibi 
99m
Tc-sestamibi was first introduced in the late 1980´s as an alternative to 
201
Tl in myocardial perfu-
sion imaging. It was soon reported that it could also be used for parathyroid imaging (Coakley et al. 
1989), and further research confirmed that it was at least as effective as 
201
Tl in parathyroid locali-
zation (O'Doherty et al. 1992, Geatti et al. 1994). 
 
The exact mechanism of sestamibi uptake was not clear, but it was suggested that cellular uptake 
and the retention of 
99m
Tc-sestamibi were determined by both mitochondrial and plasma membrane 
potentials (Chiu et al. 1990).  Metabolically active tissues, which are rich in mitochondria, may thus 
take up sestamibi more avidly than tissues with less (O'Doherty et al. 1992). 
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Although sestamibi was found to be a superior imaging agent when compared with 
201
Tl, several 
factors associated with negative imaging were also discovered. Biological factors, such as the lack 
of oxyphilic cells and the presence of P-glycoprotein and multidrug resistance protein (MDR) gene 
products, have been shown to have a negative effect on sestamibi uptake in parathyroid tissue (Pons 
et al. 2003, Palestro et al. 2005, Mihai et al. 2006, Kannan et al. 2014). Furthermore, low preopera-
tive parathyroid hormone (PTH) and ionized calcium levels (Calva-Cerqueira et al. 2007, Swanson 
et al. 2010), low serum vitamin D levels (Kannan et al. 2014), the use of calcium channel blockers 
(Friedman et al. 2004), multiglandular disease, and a small volume of parathyroid glands are also 
known to have a negative effect on the sensitivity of parathyroid scintigraphy (Chiu et al. 2006). 
The low radiochemical purity of 
99m
Tc-sestamibi has also been suggested as an interference in the 
detection of parathyroid glands (Karam et al. 2005). 
 
2.3.3 Two methods of sestamibi 
Similar to 
201
Tl, 
99m
Tc-sestamibi is not a specific tracer for parathyroid tissue, it is also taken up by 
adjacent thyroid tissue. Two methods have been developed to overcome this problem. 
 
In the dual-tracer method, 
99m
Tc-sestamibi is used together with another tracer that is taken up only 
by the thyroid gland, with 
99m
Tc-pertechnetate or with 
123
I (the latter being usually called the dual-
isotope method).  When the thyroid image is subtracted from the 
99m
Tc-sestamibi image, the en-
larged parathyroid tissue is shown as residual activity in the subtraction image (Figure 11). 
 
 
   
        
Figure 11. The dual-isotope method of sestamibi. Anterior planar images were acquired using a 
parallel-hole collimator. A 
99m
Tc-sestamibi image is shown on the left, a 
123
I image is shown in the 
middle, and a subtracted image revealing the parathyroid adenoma is shown on the right 
 
First attempts with 
99m
Tc-sestamibi and 
123
I were performed in two subsequent acquisitions 
(Coakley et al. 1989, Wei et al. 1992, Casas et al. 1993, Weber et al. 1993, Halvorson et al. 1994, 
Hindie et al. 1995). However, this sequential acquisition was prone to motion artifacts and did not 
gain widespread acceptance. 
99m
Tc-sestamibi was also combined with 
99m
Tc-pertechnetate, but it did 
not gain public acceptance, again due to motion artifacts and high thyroid uptake (Wei et al. 1994, 
McBiles et al. 1995, Chen et al. 1997, Rubello et al. 2000, Ho Shon et al. 2001, Krausz et al. 2001). 
 
It was soon discovered that 
99m
Tc-sestamibi could be used with a so-called dual-phase method. The 
method is based on the different washout kinetics of the tracer between normal thyroid and abnor-
mal parathyroid tissue (Taillefer et al. 1992). When images are acquired in the early and late phases, 
the focally increasing uptake will reveal hyperfunctioning parathyroid tissue (Figure 12). 
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Figure 12. The dual-phase method of sestamibi. Anterior planar images were acquired using a 
parallel-hole collimator. The early phase images acquired 10 minutes after the injection of 
99m
Tc-
sestamibi are shown on the left and the late phase images acquired 2.5 hours after the injection of 
99m
Tc-sestamibi are shown on the right (images courtesy of Jussi Haanpää, Seinäjoki Central Hos-
pital, Seinäjoki, Finland). 
 
Although a technically simply and elegant protocol, several authors reported that the difference in 
washout kinetics may not be accurate even with approximately one third of all patients who may 
have rapid washout of 
99m
Tc-sestamibi (Leslie et al. 1995, Rossitch et al. 1995, Chen et al. 1997, 
Lorberboym et al. 2003, Arveschoug et al. 2007). Small parathyroid adenomas or hyperplastic 
glands, especially common in multiglandular disease, that blend into the thyroid at an early phase 
and wash out at the same rate are likely to be missed (Caveny et al. 2012, Taieb et al. 2012). 
 
Several attempts, such as the use of time-activity curves and factor analysis, calculating thyroid 
count ratios between early and late images, and the use of reduced-time-window scanning, have 
been suggested as ways to improving the sensitivity and specificity of the dual-phase method 
(Billotey et al. 1994, Blocklet et al. 1997, Kacker et al. 2000, Gordon et al. 2002). It is hardly a sur-
prise therefore that widely variable sensitivities of the dual-phase method, ranging from 50% to 
100%, have been reported (Geatti et al. 1994, Billy et al. 1995, McBiles et al. 1995, Martin et al. 
1996, Caixas et al. 1997, Chen et al. 1997, Gordon et al. 2002). 
 
While the dual phase method struggled with the rapid washout phenomenon, Hindié and co-workers 
switched to the simultaneous dual-isotope method using 
123
I and 
99m
Tc-sestamibi to avoid patient 
movement and achieved excellent total sensitivity results of 92% (Hindie et al. 1997). Several pub-
lications from this same group have since been published describing applications for primary hy-
perparathyroidism, secondary hyperparathyroidism, and patients with multiglandular disease 
(Hindie et al. 1998, Jeanguillaume et al. 1998, Hindie et al. 1999, Hindie et al. 2000).  
 
To the best of our knowledge, a total of 34 articles using the simultaneous dual-isotope method 
have been published employing various acquisition techniques (Pubmed 19.3.2017). Interestingly, 
there has been growing interest recently towards the dual isotope method, as shown in Figure 13. 
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Figure 13. The annual number of published papers based on dual-isotope parathyroid studies from 
1997 to 2016 
 
The simultaneous dual-isotope and the dual-phase method have been compared using the same pa-
tients and the same acquisition session in only 11 publications (Table 1).The results of these com-
parisons are clear; the dual-isotope method is superior in terms of sensitivity in all studies. 
 
Table 1. Published studies comparing the sensitivity of the dual-isotope method and the dual-phase 
method using the same group of patients. Pinhole and/or LEHR refers to planar imaging. 
 
  Dual-phase Dual-isotope 
Authors n Technique Sensitivity Technique Sensitivity 
(Neumann et al. 1997) 15 SPECT 53% SPECT 88% 
(Hindie et al. 1998) 30 pinhole, LEHR 79% pinhole, LEHR 94% 
(Wakamatsu et al. 2003) 39 LEHR 39% LEHR 56% 
(Taieb et al. 2007) 35 SPECT 78% pinhole 86% 
(Caveny et al. 2012) 37 pinhole, LEHR 66% pinhole, LEHR 94% 
(Tunninen et al. 2013) 24 SPECT 13% SPECT 77% 
(Klingensmith et al. 2013) 33 pinhole 43% pinhole 66% 
(Schalin-Jantti et al. 2013) 21 SPECT/CT 19%*) LEHR 59%*) 
(Krakauer et al. 2015) 91 several 65% several 93% 
(Ryhanen et al. 2015) 269 LEHR 35%*) LEHR 63%*) 
(Lee et al. 2016) 360 SPECT 78% pinhole 86% 
*) accuracy 
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The majority of the studies have been performed using various acquisition techniques. Thus, the 
difference in the sensitivity figures is not only dependent on the method used but also on the acqui-
sition technique. However, if we look at studies performed with similar acquisition techniques, it is 
clear that the dual-isotope method is significantly more sensitive than the dual-phase method (Fig-
ure 14). 
 
 
 
Figure 14. Published studies comparing the sensitivity of the dual-isotope method (dark grey) and 
the dual-phase method (light grey). Studies that used the same acquisition technique with both 
methods within the same group of patients are included. Neumann et al. used SPECT-technique; 
other comparisons are made with planar techniques. 
 
 
2.3.4 Acquisition techniques 
During the early years of 
99m
Tc-sestamibi imaging, planar imaging was the most often applied ac-
quisition technique (using parallel-hole or pinhole collimators), as SPECT was not yet technically 
highly developed (lack of body-contouring systems, most cameras were equipped with one detec-
tor), and the FBP reconstruction algorithm did not produce very high quality images, not to mention 
the long time required for computation. 
 
If planar imaging is used, there is a general consensus that all planar parathyroid protocols, includ-
ing pinhole imaging, achieve significantly higher sensitivity compared with those performed with 
parallel-hole collimator alone (Fujii et al. 1999, Ho Shon et al. 2001, Arveschoug et al. 2002, 
Tomas et al. 2008, Klingensmith et al. 2013). Planar imaging with pinhole collimator was also rec-
ommended as an essential part of the parathyroid scintigraphy in the  EANM parathyroid guidelines 
in 2009 (Hindie et al. 2009). An example of a patient case acquired with both parallel-hole and pin-
hole collimators is shown in Figure 15. 
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Figure 15. An example of a planar subtraction image showing a parathyroid adenoma. A planar 
anterior image acquired using a parallel-hole collimator is shown on the left and a planar anterior 
image acquired using a pinhole collimator is shown on the right. Both images were acquired from 
the same patient. 
 
The high resolution of pinhole collimator also enables the detection of small thyroid nodules. It has 
been shown that the “iodine-cold” nodules with 99mTc-sestamibi uptake may indicate thyroid malig-
nancy (Onkendi et al. 2012, Greilsamer et al. 2015). These iodine-cold nodules also create false-
positive residual activity in subtraction images that can be easily interpreted as a parathyroid ade-
noma. Although the pinhole collimator offers the highest resolution possible in nuclear medicine, it 
has been replaced by SPECT and SPECT/CT have become clinical routine. 
 
 
 
Figure 16. An example of an iodine-cold thyroid nodule. Anterior planar images were acquired 
using a pinhole collimator. A 
99m
Tc-sestamibi image is shown on the left, a 
123
I image is shown in 
the middle, and a subtracted image revealing the parathyroid adenoma and false-positive residual 
activity (an arrow) is shown on the right. 
 
As SPECT became part of normal clinical routine in nuclear medicine, it also became integrated 
into parathyroid imaging protocols (Figure 17). SPECT, when compared with planar imaging, in-
creases sensitivity and provides more precise localization, especially with patients with previous 
neck surgery, even when imaging was performed only during the early phase (Moka et al. 2000, 
Moka et al. 2000, Even-Sapir et al. 2001, Civelek et al. 2002, Schachter et al. 2004, Slater et al. 
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2005, Ingui et al. 2006, Lavely et al. 2007, Wimmer et al. 2008, Prommegger et al. 2009, Thomas et 
al. 2009, Taubman et al. 2011).  
 
Simultaneous dual-isotope subtraction SPECT was introduced for parathyroid imaging in 1992, first 
with 
123
I
 
and 
201
Tl. 
201
Tl, however,
 
was soon replaced by 
99m
Tc-sestamibi, and the technique was 
applied in 15 patients with primary HPT with sensitivity of 88% and specificity of 97% (Neumann 
1992, Neumann et al. 1997). The same method was used with 19 patients with secondary HPT but 
with lower sensitivity of 77% (Neumann et al. 1998), and with 14 patients with secondary HPT who 
had previously undergone parathyroid surgery with sensitivity of 100% (Neumann et al. 2000). A 
study from the same clinic showed that in a group of 350 patients 
99m
Tc-sestamibi/
123
I subtraction 
SPECT showed a smaller number of false-negative scans compared with all other protocols 
(Sharma et al. 2006). 
 
 
 
Figure 17. An example of a 
99m
Tc-sestamibi/
123
I subtraction SPECT transaxial image (left), a sagit-
tal image (middle), and a coronal image (right). An adenoma is shown with an arrow. 
 
As was the case with SPECT, SPECT/CT was also rapidly applied to parathyroid scintigraphy (Fig-
ure 18) and was shown to be significantly more specific when compared with SPECT alone with the 
dual-isotope method  (Neumann et al. 2008, Hassler et al. 2013) and also with 
99m
Tc-sestamibi 
alone (Wimmer et al. 2009, Pata et al. 2010). SPECT/CT also allows for accurate attenuation cor-
rection that improves image contrast and tumor-to-background ratio. Exact anatomical information 
also assists in the preoperative planning of minimally invasive surgical approaches and results in 
ever shorter surgical times (Gayed et al. 2005, Ingui et al. 2006, Krausz et al. 2006, Serra et al. 
2006, Lavely et al. 2007, Ruf et al. 2007, Harris et al. 2008, Papathanassiou et al. 2008, 
Prommegger et al. 2009, Thomas et al. 2009, Pata et al. 2011, Taubman et al. 2011, Taieb et al. 
2012, Taieb et al. 2013, Wong et al. 2015). SPECT/CT has also been used with 
99m
Tc-sestamibi 
alone only in early phase (Martinez-Rodriguez et al. 2011, Mandal et al. 2015). 
 
The main disadvantage of SPECT/CT in addition to increased time and cost is the additional radia-
tion exposure received by the patient (Gayed et al. 2005, Dasgupta et al. 2013). However, the addi-
tional dose of approximately 1 mSv may be justified when considering the risks of repeated imag-
ing or the risks associated with repeated general anesthesia and surgical intervention (Levine et al. 
2009). 
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Figure 18. An example of 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT transaxial image (left), a sag-
ittal image (middle), and a coronal image (right). An adenoma is shown with an arrow. 
 
Controversial studies have also been published. The precise benefit of SPECT/CT has been ques-
tioned and several authors have suggested that SPECT/CT should only be used for locating ectopic 
parathyroid glands (Gayed et al. 2005, Buck et al. 2008). 
 
It is important to note that these early studies of SPECT or SPECT/CT are not quite applicable to-
day because there have been significant improvements in imaging technology and image recon-
struction algorithms (Ruf et al. 2007). Some of the studies are also inferior in quality due to the ac-
quisition and processing parameters used (Ali et al. 2011). 
2.3.5 Combined protocols 
Although superior in term of resolution, the pinhole image lacks the three-dimensional information 
and accurate anatomical localization that are, offered by a modern SPECT/CT. In order to benefit 
from both advantages, these techniques are often combined in clinical practice (Lavely et al. 2007, 
Taieb et al. 2007, Nichols et al. 2008, Bahador et al. 2015, Guerin et al. 2015). 
 
2.3.6 Image processing with dual-isotope imaging 
Image processing with planar dual-isotope imaging is a relatively straightforward procedure. A re-
gion of interest is usually drawn around the thyroid gland on both the 
99m
Tc-sestamibi and the 
123
I 
images, and a normalization factor is calculated as a ratio of the 
99m
Tc-sestamibi and 
123
I maximum 
pixel counts. The 
123
I image is then multiplied by this factor and then the scaled 
123
I image is sub-
tracted from the 
99m
Tc-sestamibi image. This process is somewhat iterative, as the normalization 
factor can easily be adjusted in the case of under-subtraction or over-subtraction. 
 
Image processing of 
99m
Tc-sestamibi/
123
I subtraction SPECT or SPECT/CT starts with the recon-
struction of the 
99m
Tc-sestamibi and 
123
I projection images. After reconstruction, the 
123
I images are 
multiplied using a normalization factor (a ratio of thyroid maximum voxel counts in 
99m
Tc-
sestamibi images and 
123
I images) and the scaled 
123
I images are then subtracted from the 
99m
Tc-
sestamibi images to create subtraction images where the enlarged parathyroid glands are visible. 
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2.3.7 The protocol of choice 
Parathyroid scintigraphy with 
99m
Tc-sestamibi is the method of choice for the preoperative localiza-
tion of enlarged parathyroid adenomas, it being superior to ultrasound, magnetic resonance imag-
ing, or CT imaging (Geatti et al. 1994, Peeler et al. 1997, Ishibashi et al. 1998). 
 
Unfortunately, 
99m
Tc-sestamibi is not a specific agent for parathyroid tissue. As a result, two meth-
ods are currently available in addition to several acquisition techniques and numerous adjustable 
parameters. Several clinical protocols have evolved with varying sensitivities and currently there is 
no consensus on how the parathyroid scintigraphy should be performed (Mihai et al. 2009). As the 
official guidelines published by the European Association of Nuclear Medicine (EANM) and the 
Society of Nuclear Medicine Practice (SNM) do not agree, it is difficult to assemble an optimal 
protocol for clinical use (Hindie et al. 2009, Greenspan et al. 2012). 
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3 Aims and objectives of the study 
The aim of this thesis was to find out how to best conduct parathyroid scintigraphy using only the 
clinical tools available. In other words, to answer the question: ”how to best perform the parathy-
roid scintigraphy?”. The main objectives are listed below. 
 
 
1) To evaluate the national status of the clinical parathyroid scintigraphy protocols used in Fin-
land  
 
2) To compare the sensitivity and specificity of a single-tracer method and a dual-isotope 
method 
 
3) To evaluate the sensitivity and specificity of the planar and tomographic acquisition tech-
niques used for parathyroid scintigraphy 
 
4) To evaluate the properties of three different collimators for dual-isotope imaging with 99mTc 
and 
123
I 
 
5) To optimize the acquisition and processing parameters of 99mTc/123I subtraction SPECT/CT 
 
 
The first objective was realized in Study I, where a complete national status of parathyroid scintig-
raphy protocols were assessed and updated in a follow-up study (Tunninen et al. 2016). The second 
objective was realized in Study II, where the single-tracer method and the dual-isotope method were 
compared on an intrapatient basis. The third objective regarding the acquisition techniques was real-
ized in Study II and Study III, again using an intrapatient comparison. The fourth objective was 
accomplished in Study IV, where the physical properties of three different collimators used for du-
al-isotope imaging with 
99m
Tc and 
123
I where evaluated. Finally, the last objective was realized in 
Study V, where the optimal acquisition and processing parameters of 
99m
Tc/
123
I subtraction 
SPECT/CT were examined. 
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4 Material and Methods 
This study comprised five consecutive studies (publications I-V) carried out from 2008 to 2017 at 
Satakunta Central Hospital, Pori. Additional measurements for Study V were also performed (un-
published) to evaluate the effect of the acquisition arc (360 vs 180) and matrix size (128 vs 256) 
on the outcome of 
99m
Tc/
123
I subtraction SPECT/CT with LEHR and LEUHR collimators. 
4.1 Request for information 
All instructions regarding the clinical protocols for parathyroid scintigraphy were requested by e-
mail from all the departments of nuclear medicine in Finland (n = 25) in September 2008 and again 
in January 2010. Instructions concerning the parathyroid scintigraphy, acquisition and image pro-
cessing parameters and all instructions targeted at patients were received from all the departments 
performing parathyroid scintigraphy. A follow-up study was also conducted in April 
2016(Tunninen et al. 2016). 
4.2 Patients 
In total, the studies comprised 226 patients (51 patients in Study II and 175 patients in Study III). 
All patients were clinical patients referred for parathyroid scintigraphy at Satakunta Central Hospi-
tal, Finland. Patients for Study II were studied between June 2010 and February 2011, and patients 
for Study III between March 2011 and June 2016. Institutional approval for the use of patient acqui-
sition data and other information concerning hyperparathyroidism was granted by the Medical Di-
rector of Satakunta Hospital District on 5
th
 April 2011. Both Study II and Study III were exempt 
from institutional ethical committee approval according to Finnish legislation. Informed consent 
was waived. 
 
All patients had biochemical evidence of hyperparathyroidism (elevated total serum calcium (Ca-
ion) and parathyroid hormone level (PTH)). From this original cohort, patient data were included 
for this retrospective study if the patient proceeded to surgery, and if post-operative Ca-ion and 
PTH results were available. The final study group comprised 118 patients (24 patients in Study II 
and 94 patients in Study III). 
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4.3 Phantoms 
Various phantoms were used in Studies IV and V. An overview of phantoms is shown in Table 2. 
Detailed information on all phantoms and sources used are presented in Study IV and V. The setup 
of the anthropomorphic phantom is presented in Figure 19. 
 
Table 2. An overview of the phantoms used in Studies IV and V 
 
Study Phantom Isotope Activity Concentration 
IV The Jaszczak phantom
1
 with hot spot insert 
99m
Tc 1500 MBq ~250kBq/ml 
IV Two identical 1000 ml bottles 
123
I
 
99m
Tc
 
40MBq 
40MBq 
40kBq/ml 
40kBq/ml 
V The Thorax phantom
2
 
99m
Tc 350 MBq ~180kBq/ml 
V A thyroid gland phantom
3
 
123
I 
99m
Tc 
7MBq 
7MBq 
500 kBq/ml 
500 kBq/ml 
V A spherical phantom
4
 
99m
Tc 75kBq 300kBq/ml 
 
1
Data Spectrum Corporation, Durham, NC, USA (http://www.spect.com/pub/Flanged_Jaszczak_Phantoms.pdf)  
2
Radiology Support Devices, Long Beach, CA, USA (http://www.rsdphantoms.com/pages/heartthoraxcardiac.html) 
volume of  ~8200ml 
3
Radiology Support Devices, Long Beach, CA, USA (http://www.rsdphantoms.com/pages/fissionproductphantom.html) 
volume of ~14 ml. 
4
Data Spectrum Corporation, Durham, NC, USA (http://www.spect.com/pub/Hollow_Sphere_Sets.pdf), inner diameter 
of ~8mm, volume of ~0,25ml) representing an adenoma (later referred as adenoma) 
 
 
   
 
Figure 19. The anthropomorphic phantom (left), the thyroid gland phantom and the spherical 
phantom representing an adenoma (middle) and the thyroid and an adenoma attached inside the 
anthropomorphic phantom for Study V (right). 
 
Additional measurements for Study V were also performed with the same phantom. The measure-
ments were, however, performed in a separate session because they could not be performed during 
Study V due to radionuclide decay in the phantom (unpublished). In the additional study, the thy-
roid gland phantom was filled with 
123
I and 
99m
Tc (concentration of 600 kBq/ml, total activity of ). 
The adenoma was filled with 
99m
Tc at a concentration of 700 kBq/ml and attached behind the thy-
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roid gland. The thyroid and adenoma were then inserted into the thorax phantom, which was then 
filled with 350 MBq of 
99m
Tc. The activities were measured in a similar manner as in Study V. 
4.4 Patient imaging, image processing and review 
All patient acquisitions were performed in the Department of Nuclear Medicine of Satakunta Cen-
tral Hospital, Pori, Finland. Three different gamma cameras were used.  A Siemens Symbia Intevo 
T2 SPECT/CT and a Siemens Symbia T SPECT/CT (Siemens, Erlangen, Germany) were used for 
all SPECT/CT imaging with a Low Energy High-Resolution (LEHR) collimator. A Philips Skylight 
(Philips, Milpitas, CA, USA) was used for planar pinhole imaging in Study II and Study III. All 
cameras are used in clinical work and subjected to strict quality control measures. 
 
The acquisition protocols used in Study II are outlined together with the resulting images for review 
in Figure 20. The parameters used for the acquisition and reconstruction and for the processing 
steps are described in detail in Study II. 
 
 
 
Figure 20. Acquisitions and processing steps for producing images 1-5 in Study II. 
 
In Study II, all patient images were anonymized and the images were reviewed by four experienced 
nuclear medicine physicians (PV, MS, AA, JS) from three different hospitals. All findings were 
finally classified as true positive, false positive, true negative, or false negative using surgical and 
histopathological findings with post-operative Ca-ion and PTH levels as the reference standard. 
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The acquisitions used in the Study III are outlined together with the resulting images for review in 
Table 3. The parameters for the acquisition and reconstruction and the processing steps are de-
scribed in detail in Study III. 
 
Table 3. Acquisitions and resulting images in Study III. 
 
Acquisition Collimator Resulting images for review 
SPECT/CT LEHR 
99m
Tc-sestamibi, 
123
I and subtraction SPECT/CT images 
Planar Pinhole 
99m
Tc-sestamibi, 
123
I and subtraction pinhole images 
 
All patient images were anonymized and the images were reviewed by one experienced nuclear 
medicine physician (MS) in Study III. All findings were finally classified as true positive, false pos-
itive, true negative, or false negative with surgical and histopathological findings with post-
operative Ca-ion and PTH levels as the reference standard. 
4.5 Phantom imaging and image processing 
All phantom acquisitions were performed in the Department of Nuclear Medicine of Satakunta Cen-
tral Hospital, Pori, Finland. A Siemens Symbia Intevo T2 SPECT/CT was used for all acquisitions 
and measurements. LEHR, Low Energy Ultra High-Resolution (LEUHR) and Medium Energy 
Low-Penetration (MELP) collimators were used for the acquisitions. 
 
The acquisitions and measurements performed in Study IV are outlined in Table 4. Comprehensive 
information on the acquisition and processing parameters are presented in Study IV. SPECT spatial 
resolution was also measured using the acquisition matrix 256256 (unpublished) using otherwise 
identical acquisition and processing parameters as with the acquisition matrix 128128. 
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Table 4. Measurements performed in Study IV. 
 
Number Measurement Parameter (unit) 
1 Intrinsic uniformity Intrinsic uniformity in the UFOV (%) 
2 System sensitivity Sensitivity (cpm/µCi) 
3 System spatial resolution at various distances FWHM (mm), FWTM (mm) 
4 SPECT spatial resolution Visibility of channels 
5 SPECT uniformity Reconstructed uniformity (%rms) 
6 Spectrum at various distances without scatter Spectrum (-) 
7 Spectrum at various distances with scatter Spectrum (-) 
8 Scatter-to-photopeak –ratio without scatter Ratio (%) 
9 Scatter-to-photopeak –ratio with scatter Ratio (%) 
10 Cross-contamination Ratio (%) 
Abbreviations used in table: Useful Field of View (UFOV), Full width at half maximum (FWHM), Full width at tenth 
maximum (FWTM). 
 
Scatter-to-photopeak –ratio is defined as:  acquired counts in lower scatter window as a percentage 
of counts acquired in the main window with equal window widths. The cross-contamination is de-
fined as: acquired counts in 
99m
Tc window as a percentage of counts acquired in 
123
I window while 
acquiring 
123
I source or acquired counts in 
123
I window as a percentage of counts acquired in 
99m
Tc 
window while acquiring 
99m
Tc source. Parameters presented in Table 4 were measured or calculated 
using clinical tools on Siemens Syngo and Hermes workstations. 
 
For the purpose of study V, a total of six  SPECT/CT acquisitions were performed with the anthro-
pomorphic phantom. LEHR, LEUHR, and MELP collimators were used with clinical (asymmetric 
123
I energy window) and test energy windows (symmetric 
123
I energy window). Eight reconstruc-
tions were performed for each (Number of iterations (6, 8, 16, or 32) and scatter correction on/off) 
resulting in a total of 48 image sets. Comprehensive information on the acquisition and processing 
parameters are presented in Study V. All images were anonymized and scored from 0 to 5 based on 
visual appearance. For quantitative analysis, the mean values for the contrast and visual scores were 
calculated for each combination of collimator, energy window, and processing parameters. Detailed 
information is presented in publication V. 
 
For quantitative analysis, a volume of interest (VOI) was drawn around the adenoma using the 
fused CT image as a reference (with corresponding background VOI). An image contrast C for 
sphere was calculated using the equation (1): 
 
%100


background
backgroundadenoma
C
CC
C     [1] 
where Cadenoma is the number of counts in the sphere, and Cbackground is the number of counts in the 
background area 
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A total of four SPECT/CT scans were performed with LEHR and LEUHR collimators in addition to 
the original acquisitions in Study V (unpublished). The SPECT/CT acquisitions were performed 
with detectors configured at a 180 angle (H-mode) and a 90 angle (L-mode) as shown in Figure 
21. With H-mode, 180 degrees of rotation were acquired (projection data over 360), with L-mode 
90 degrees of rotation were acquired (projection data over 180, the anterior arc). The acquisition 
parameters are presented in Table 5. In addition, the phantom was acquired using the clinical pin-
hole protocol in Study III. 
 
 
 
 
 
 
 
Figure 21. Detectors set in H-mode (left) and in L-mode (right). 
 
Table 5. Acquisition parameters for SPECT/CT in additional measures to Study V 
    
Acquisition Parameter SPECT/CT 360 SPECT/CT 180 
Detector configuration 180 (H-mode) 90 (L-mode) 
Acquisition arc (total) 360 anterior 180 
Orbit Body-contour Body-contour 
Collimators LEHR, LEUHR LEHR, LEUHR 
Matrix 256256 256256 
Zoom 1 1 
Pixel size 4.8 mm, 2,4mm 4.8 mm, 2,4mm 
Acquisition mode Step-and-Shoot Step-and-Shoot 
Views 96 (3,75 per projection) 48 (3,75 per projection) 
Time per projection 33 s 66s 
Energy windows Test energy windows Test energy windows 
Voltage 130kVp 130kVp 
Collimation 22.5 mm 22.5 mm 
Rotation time 0.8 s, 0.8 s, 
Pitch 1,5 1,5 
Dose modulation CARE Dose AEC+DOM CARE Dose AEC+DOM 
Reference exposure 80 mAs 80 mAs 
 
99m
Tc-sestamibi and 
123
I SPECT images (with attenuation correction) were reconstructed on a Sie-
mens Syngo workstation using the FLASH 3D-algorithm with six parameter settings (8, 16, or 32 
iterations, 8 subsets, Gaussian 9.00 filter, with and without TEW scatter correction). All SPECT/CT 
datasets were also converted to the matrix size 128128 and reconstructed in a similar manner. 
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123
I SPECT images were multiplied by a normalization factor (as the ratio of the thyroid maximum 
voxel counts in the 
99m
Tc and 
123
I SPECT images to create normalized 
123
I SPECT images, which 
were then subtracted from the 
99m
Tc SPECT images. In total, eight group of images were recon-
structed (48 image sets in total) for the purpose of data analysis. 
 
All images were subjected to visual evaluation and classified into two groups according to the pres-
ence of artifacts in the image. The images classified in the better group (no obvious artifacts) were 
further evaluated quantitatively. For quantitative analysis, a VOI was drawn around the adenoma 
using the fused CT image as a reference (with corresponding background VOI). An image contrast 
C for sphere was calculated using the equation (1). 
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5 Results 
 
5.1 Parathyroid scintigraphy protocols 
The status of clinical parathyroid scintigraphy protocols in Finland was assessed in Study I. In total, 
769 parathyroid scintigraphy studies were performed in 19 hospitals, ranging from 7 to 209 studies 
per year (40,239,9). Both dual-phase and dual-tracer methods (with 123I or 99mTcO4) were in use 
with a large variety in the activities used, especially with 
99m
Tc-sestamibi/
123
I (Table 6). 
 
 
 
Table 6. Parathyroid scintigraphy methods, radionuclides and the activities used with parathyroid 
scintigraphy in Finland in 2010. 
 
Method % of hospitals A (
99m
Tc) A (
123
I) A (
99m
TcO4) 
Dual-tracer, 
99m
Tc- sestamibi/
123
I 58 150-800 MBq 10-30 MBq - 
Dual phase, 
99m
Tc-sestamibi 37 740 MBq - - 
Dual-tracer, 
99m
Tc- sestamibi/
99m
TcO4 5 740 MBq - 50 MBq 
 
All acquisition techniques (planar imaging with parallel-hole and pinhole collimator, SPECT and 
SPECT/CT) were used with an emphasis on classic anterior imaging with parallel-hole collimator 
(Figure 22). SPECT/CT was used in only eight hospitals (42%). 
 
Imaging methods and techniques were combined in most hospitals, and result in 1 to 4 acquisitions 
per patient study. There was also heterogeneity in the timing of the acquisitions. All early-phase 
acquisitions were started 5 to 15 minutes after the 
99m
Tc-sestamibi injection, but the starting time of 
the late-phase acquisition varied from 1.5 to 4 hours after the 
99m
Tc-sestamibi injection. 
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Figure 22. The acquisition techniques used with parathyroid scintigraphy (all methods combined) 
in Finland in 2010. 
 
 
In addition to a variation in methods and imaging techniques, there was also variation in acquisition 
protocol parameters. This resulted in 18 protocols being used in 19 hospitals. The imaging methods 
and acquisition techniques for each hospital are summarized in Table 7. 
 
Table 7. Parathyroid scintigraphy methods and acquisition techniques with parathyroid scintigraphy 
in Finland in 2010. Each hospital is represented in a column. 
 
Hospital number 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 
Method 
Dual-Phase x x x x x x x 
            
Dual-Tracer 
       
x x x x x x x x x x x x 
Early phase 
LEHR x x 
 
x x 
 
x x x x x x x x x 
 
x x x 
Pinhole 
         
x 
    
x x x x 
 
Pinhole/oblique 
              
x 
 
x x 
 
SPECT 
 
x x 
  
x 
  
x 
 
x x 
 
x 
 
x 
   
CT 
        
x 
 
x x 
   
x x 
  
Late phase 
LEHR x x 
 
x x 
 
x x x 
  
x x 
      
Pinhole 
         
x 
         
Pinhole/oblique 
                   
SPECT 
 
x x x x x 
 
x 
    
x 
      
CT 
   
x x 
  
x 
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5.2 Comparison of the single-tracer and the dual-isotope methods 
Five different imaging protocols were compared in Study II. All image sets generated with the dual-
isotope method (
99m
Tc-sestamibi/
123
I) were more sensitive than any image set acquired with 
99m
Tc-
sestamibi alone, as shown in Table 8. Statistical comparison is presented in Study II. 
 
Table 8. Sensitivity, specificity and accuracy for the dual phase method and the dual-isotope meth-
od (average values for physicians and for acquisition techniques). 
 
Method Sensitivity (%) Specificity (%) Accuracy (%) 
Dual-isotope 72% 95% 88% 
Single tracer 17% 99% 75% 
5.3 Comparison of acquisition techniques with the dual-isotope method 
Planar imaging protocols with LEHR and pinhole collimator, SPECT/CT, and SPECT/CT com-
bined with the planar pinhole protocol were studied in Study II and Study III. No difference in the 
sensitivity, specificity, or accuracy between the acquisition techniques using the dual-isotope meth-
od was found in Study II (results in Study II, Table 2) (Table 9). 
 
As Study III was conducted for a longer period from 2011 to 2016, more experience with dual-
isotope SPECT/CT had been gained, and the sensitivity of SPECT/CT was now much higher at 
94%. In addition, when SPECT/CT was combined with pinhole imaging, the sensitivity and speci-
ficity were slightly higher than with SPECT/CT alone, but the difference was not significant (results 
in Study III, Table 2 with statistical comparison). However, additional pinhole imaging resulted in a 
changed diagnosis in eight patients (8.5% of patients). The results are presented in Table 9. 
 
Table 9. Sensitivity and specificity for the dual-isotope method with planar and tomographic acqui-
sition techniques. 
 
Study Acquisition Technique 
Sensitivity 
(%) 
Specificity 
(%) 
II Planar AP with LEHR 69 96 
II Planar AP with pinhole 78 94 
II  SPECT/CT 68 96 
III SPECT/CT 94 98 
III SPECT/CT + pinhole 97 99 
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5.4 Collimator properties for 99mTc/123I  subtraction SPECT/CT 
The physical characteristics of the LEHR, LEUHR, and MELP collimators for dual-isotope imaging 
with 
99m
Tc and 
123
I were examined with phantoms in Study IV. System sensitivity with 
99m
Tc was 
well in line with the specifications given by Siemens. Sensitivity with the 
123
I symmetric energy 
window was higher with the low-energy collimators when compared with the sensitivity of 
99m
Tc, 
which is caused by the septal penetration of high-energy gamma photons of 
123
I. The use of an 
asymmetric energy window with 
123
I reduced sensitivity compared with the symmetric energy win-
dow. With MELP collimators, reduction was approximately 43%, but with low-energy collimators 
only 15%. This was also due to the septal penetration of high-energy gamma photons of 
123
I. It was 
also noticed that with the asymmetric 
123
I energy window, the uniformity was only 11.9%, whereas 
intrinsic uniformity was very good for both the 
99m
Tc and 
123
I symmetric energy windows. 
 
 
Figure 23. System spatial resolution for MELP, LEHR, and LEUHR collimators. The spatial 
resolution values are presented for each collimator. FWHM for 
99m
Tc (mm) is shown in the first 
column, FWHM for 
123
I (mm) is shown in the second column,  FWTM for 
99m
Tc (mm) is shown in 
the third column, and FWTM for 
123
I (mm) is shown in the fourth column. 
 
As expected, system resolution was best for the LEUHR collimator and lowest for the MELP colli-
mator, as shown in Figure 23. There was no difference in resolution for 
99m
Tc and 
123
I in terms of 
FWHM values for the collimators. Septal penetration was again noticed, as was the case for LE 
collimators, and FWTM was larger with 
123
I than that with 
99m
Tc.  There was no difference with 
symmetric and asymmetric energy windows for 
123
I.  
 
SPECT spatial resolution with the MELP collimators was inadequate for the acquisition of small 
structures. Hence, only the two largest hollow channels (volume filled with radioactive solution) 
could be identified. The LEHR and LEUHR collimators performed better, as channels in sectors 3 
and 4 could be identified, respectively. In addition to Study IV, SPECT spatial resolution was also 
measured using the acquisition matrix 256256 (unpublished). The acquisition matrix with smaller 
pixel size did not increase resolution (based on visual analysis) for the MELP collimators. For the 
LEHR collimators, a sharpening of the details could be seen. For the LEUHR collimators, channels 
in sector 2 could also be identified in addition to a similar sharpening as that seen with the LEHR 
collimator. An example is shown in Figure 24. 
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Figure 24.  An example of SPECT resolution for MELP (left), LEHR (middle), and LEUHR (right) 
collimators with a 128128 acquisition matrix (upper row) and with a 256256 acquisition matrix 
(lower row). SPECT spatial resolution with the MELP collimators was poor compared to those of 
LEHR and LEUHR collimators.  The acquisition matrix with smaller pixel size did not increase 
resolution for the MELP collimators. For the LEHR and LEUHR collimators, a sharpening of the 
details could be seen. 
 
The spectrum of 
99m
Tc in air was similar for all collimators and the distances between the source 
and the collimator. Scattering material increased the amount of scatter, but there was no change in 
the shape as a function of distance or between collimators. There was no difference in scatter-to-
photopeak -ratio between the collimators or as a function of distance for 
99m
Tc (scatter-to-photopeak 
-ratio was 13.0% to 14.7%). 
 
 
Figure 25. Spectrum of 
123
I at 5 cm from the detector in air for MELP, LEHR, and LEUHR collima-
tors. 
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The spectrum of 
123
I was very different for the LEHR, LEUHR, and MELP collimators. The effect 
of 
123
I high-energy gamma photons was perceptible (Figure 25). The scatter-to-photopeak -ratio for 
123
I was highest for the LEUHR-collimator. The scatter-to-photopeak -ratio was not constant, but 
changed as a function of distance for the low-energy collimators and also for the MELP collimator, 
as shown in Figure 26. 
  
 
 
Figure 26. Scatter- to-photopeak –ratio (%) in air with 123I for LEUHR (dotted), LEHR (lined), and 
MELP (grey) collimators at a distance of 10 cm, 20 cm, 30 cm, and 40 cm between the collimator 
and the source. 
 
Cross-contamination measurements showed similar contamination of the 
99m
Tc in the 
123
I window 
for all collimators (4.7 to 5.1%). The asymmetric energy window for 
123
I reduced the 
99m
Tc-
contamination approximately to half (1.8 to 2.6%). 
123
I contamination in the 
99m
Tc window was 
significantly higher for all collimators being 28.3 to 50.6%, as shown in Figure 27. 
 
 
Figure 27. 
123
I contamination in the 
99m
Tc energy window for MELP (left), LEHR (middle), and 
LEUHR (right) collimators. The contamination is expressed as a percentage of 
123
I counts in the 
99m
Tc energy window vs 
123
I counts in the 
123
I energy window. 
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5.5 Optimization of 99mTc-sestamibi/123I subtraction SPECT/CT  
The anthropomorphic parathyroid phantom was set up to mimic a small, low intensity adenoma or 
hyperplasia in Study V. Thus, it was expected that it would be difficult to visualize. The visual ap-
pearance of the images varied from a nonvisible adenoma to a clear image, and visual scores were 
between 0 and 5. This was in correlation with the calculated contrast for the adenoma that was be-
tween 0.4% and 80.9% (Figure 28). 
 
Figure 28. Visual score of an image as a function of contrast of an adenoma. The visual scoring is 
based on the clinical appearance of the images (the intensity of adenoma, the presence of artefacts) 
and scored by a single reviewer. 
 
The collimator and energy window had the highest effect on the visual scores, as shown in Figure 
29. The LEUHR collimator in combination with the symmetric energy window for 
123
I (test energy 
window) yielded the best visual scores. The effect of scatter correction was low. 
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Figure 29. The mean visual score (columns, axis on the left) and contrast (line, axis on the right) 
for MELP, LEHR, and LEUHR collimators (mean calculated for all energy windows and 
processing parameters) is shown on the left, for clinical (asymmetric 
123
I window) and test 
(symmetric 
123
I window) energy windows (mean calculated for collimators and processing 
parameters) is shown in the middle, and for scatter correction on or off  (mean calculated for all 
collimators and energy windows) on the right. 
 
 
 
Figure 30. The mean visual score (columns, axis on the left) and contrast (line, axis on the right) of 
an adenoma with  processing parameters (combined for all collimators and energy windows). “6-“ 
indicates six iterations and scatter correction off, “6+” indicates six iterations and scatter 
correction on. 
 
The mean values for contrast for the reconstruction parameters were higher with an increasing 
number of iterations (mean for all collimators and energy window settings). However, the visual 
scores were highest with 16 iterations. When the iterations were increased to 32, the visual appear-
ance of the images decreased due to increased noise in the images. 
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Phantom images with the highest visual scores and with the current clinical protocol are presented 
in Figure 31. 
 
Figure 31. Transverse (left), sagittal (middle), and coronal (right) images of the phantom and an 
adenoma situated in the crosshair. The upper row shows images acquired with clinical protocol 
(LEHR collimators, asymmetric 
123
I energy window, 8 iterations, 8 subsets, no scatter correction). 
The middle row shows images acquired with LEHR collimators and a symmetric 
123
I window (8 
iterations, 8 subsets, with scatter correction). The lower row shows images acquired with LEUHR 
collimators and a symmetric 
123
I window (16 iterations, 8 subsets, no scatter correction). An arrow 
shows “the edge artefact”. 
In addition to Study V, the optimization of dual-isotope SPECT/CT was further evaluated (un-
published). A combination of two collimator pairs (LEHR, LEUHR), two acquisition arcs (180 and 
360), and two acquisition matrix sizes 128128 and 256256 were assessed. All reconstructed 
images were subjected to visual evaluation. The adenoma was clearly visible in all phantom images, 
but there was a difference in the presence of artifacts in the image. In the first classification, it was 
noticed that all images acquired with detectors in L-mode were faintly blurred with more subtrac-
tion artifacts present. These images were not subjected to quantitative evaluation. An example of an 
artifact is shown in Figure 32 in comparison with a corresponding image without any artifacts (de-
tectors in H-mode, otherwise the same collimator, matrix size, and processing parameters). 
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Figure 32. An example of an artifact (arrow) present in a sagittal image acquired with detectors in 
L-mode (left) and a flawless image acquired with detectors in H-mode (right). The adenoma is situ-
ated in the crosshair. 
 
Further visual evaluation of the LEHR and LEUHR images with detectors in H-mode showed that 
all images acquired with the LEHR collimator (both matrix sizes) had more subtraction artifacts 
present compared with those acquired with the LEUHR collimator. These images were also exclud-
ed from quantitative evaluation. An example of an artifact is shown in Figure 33. 
 
 
 
Figure 33. An example of an artefact (an arrow) present in images acquired with LEHR collima-
tors (transverse (left), sagittal (middle), coronal (right)). The adenoma is situated in the crosshair. 
 
For quantitative analysis, contrast values were calculated for the adenoma for both matrix sizes and 
for all processing parameters. The contrast of the adenoma was between 79.4% and 172.6%. The 
lowest contrast was achieved with 128×128 matrix size and 8 iterations without scatter correction. 
The highest contrast values were with 256×256 matrix size, 32 iterations, and scatter correction. 
The results are shown in Figure 34.  
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Figure 34. The mean contrast values of an adenoma acquired with LEUHR collimators in H-mode 
with a matrix size of 128×128 (lined columns) and 256×256 (dotted columns). “8-“ indicates eight 
iterations and scatter correction off, “8+” indicates eight iterations and scatter correction on. 
 
The visual appearance of the adenoma was very similar in all images acquired with the LEUHR 
collimators in H-mode. An example of the highest and the lowest contrast is shown in Figure 35. 
 
 
 
 
 
Figure 35. An example of the highest contrast (upper row) and the lowest contrast (lower row) of 
images acquired with LEUHR detectors in H-mode. Transverse (left), sagittal (middle), and coronal 
(right) images are shown.  Images in the upper row were processed with the parameters 256256 
matrix size, and 32 iterations with scatter correction. Images in the lower row were processed with 
the parameters 128128 matrix size and 8 iterations without scatter correction.  
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The phantom was acquired using the clinical pinhole protocol used in Study III. The adenoma could 
not be visualized in the subtraction pinhole image as shown in Figure 36. 
 
 
 
Figure 36. The pinhole images of the phantom. 
99m
Tc image on the left, 
123
I-image in the middle, 
and a subtraction image on the right. The adenoma cannot be visualized. 
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6 Discussion 
 
6.1 The method of choice with 99mTc-sestamibi 
Ten years ago, there was no national consensus on parathyroid scintigraphy protocols in Finland 
(Study I). As a result, both dual-phase and dual-tracer methods were in use according to the person-
al preferences in each hospital. The superiority of the dual-tracer method with 
123
I, i.e., the dual-
isotope method, was shown in Study II, where any dual-isotope protocol was significantly more 
sensitive than any dual-phase protocol. This has been recently acknowledged by several authors 
(Caveny et al. 2012, Klingensmith et al. 2013, Schalin-Jantti et al. 2013, Krakauer et al. 2015, 
Ryhanen et al. 2015, Lee et al. 2016). 
 
There has been a considerable change and all Finnish nuclear medicine departments performing 
parathyroid scintigraphy now use the dual-isotope method with 
99m
Tc-sestamibi and 
123
I as their 
first method of choice in parathyroid scintigraphy (Tunninen et al. 2016). The dual-isotope method 
is also recommended by the European Association of Nuclear Medicine (EANM) guideline (Hindie 
et al. 2009). However, this is not the case worldwide as dual-isotope protocols are considered rela-
tively complex and time-consuming. In addition, 
123
I is regarded as relatively expensive and it may 
not be readily available in some countries (Caveny et al. 2012). Dual-isotope protocols are also not 
recommended by the Society of Nuclear Medicine Practice (SNM) Guideline for Parathyroid Scin-
tigraphy 4.0 (Greenspan et al. 2012).  
 
Considering the superior sensitivity of the dual-isotope method shown in this thesis, the additional 
cost of 
123I (approximately 200 € per patient) and the additional radiation dose (with a 35% thyroid 
uptake, the patient gets an estimated 4.4 mSv effective dose with a 20 MBq injection of 
123
I com-
pared to a 6.7 mSv dose from 750 MBq of 
99m
Tc-sestamibi)) can be considered acceptable (Hindie 
et al. 2009). 
 44 
 
6.2 Acquisition techniques in comparison 
Planar imaging with parallel-hole collimator has been the traditional clinical method with most nu-
clear medicine studies. Planar imaging with LEHR collimator was also the most common acquisi-
tion technique with parathyroid imaging in Finland as shown in Study I. The pinhole collimator was 
rarely used, which was surprising considering the superiority of pinhole imaging shown by several 
authors (Arveschoug et al. 2002, Ho Shon et al. 2008, Tomas et al. 2008, Hindie et al. 2009, Ali et 
al. 2011, Klingensmith et al. 2013). Those findings are in line with Study II, where anterior planar 
imaging with pinhole collimator had the highest sensitivity of 78%. 
 
At the time of Study I, SPECT and SPECT/CT were only used in 63% and 42% of the hospitals, 
respectively. There has been a notable change, as according to our recent survey, 89% of the hospi-
tals are now using SPECT/CT with parathyroid scintigraphy (Tunninen et al. 2016). 
 
In Study II, we could not demonstrate the increased sensitivity of 
99m
Tc-sestamibi/
123
I subtraction 
SPECT/CT when compared with 
99m
Tc-sestamibi/
123
I subtraction pinhole imaging. This finding was 
in line with Hassler and co-workers who showed an equal sensitivity of 
99m
Tc-sestamibi/
123
I sub-
traction SPECT/CT and 
99m
Tc-sestamibi/
123
I subtraction pinhole protocols  (Hassler et al. 2013). 
The average sensitivity of 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT in Study II was 68%. This 
study was performed at the early stage of adopting the 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT 
protocol. As Study III was conducted during a longer period of five years, more experience had 
been gained and the sensitivity of 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT was now much high-
er at 94%. 
 
The use of 
99m
Tc-sestamibi/
123
I subtraction pinhole imaging alone was not addressed in Study III, as 
the pinhole image lacks the three-dimensional information as well as the accurate anatomical locali-
zation offered by SPECT/CT. Based on the findings in Study III, the combined protocol of 
99m
Tc-
sestamibi/
123
I subtraction SPECT/CT and 
99m
Tc-sestamibi/
123
I subtraction planar pinhole offers 
higher sensitivity and specificity of 
99m
Tc-sestamibi/
123
I subtraction parathyroid scintigraphy com-
pared to SPECT/CT alone, although the difference was not significant. 
 
This finding is in sharp contrast with those of Bhatt and co-workers who achieved lower sensitivity 
with combined SPECT/CT and pinhole compared with pinhole imaging alone  (Bhatt et al. 2015). A 
partial reason for this result might be the rapid washout phenomenon, as Bhatt and co-workers start-
ed SPECT/CT 45 minutes after the 
99m
Tc-sestamibi injection. Another explanation could be the 
acquisition and processing parameters used as, based on the figures shown in the publication, image 
acquisition and/or processing may not have been optimal. The study of Bhatt and co-workers was 
conducted right after the installation of SPECT/CT, so it is likely that the inferior results of 
99m
Tc-
sestamibi/
123
I subtraction SPECT/CT compared with those of pinhole imaging are the consequence 
of a lack of experience. 
 
The combination of 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT and anterior planar pinhole was 
tested with additional measures in Study V. The adenoma was clearly visible in optimized 
99m
Tc-
sestamibi/
123
I subtraction SPECT/CT but could not be visualized in the pinhole image, which is line 
with the findings of Dontu and co-workers (Dontu et al. 2004). Thus, it is suggested that carefully 
optimized SPECT/CT does not benefit from additional planar pinhole images. On the other hand, 
the ultimate resolution of the pinhole collimator is highly useful in recognizing thyroid nodules. 
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6.3 The choice of the collimator 
Parathyroid localization places high requirements on the spatial resolution of the imaging system 
due to the small size of the parathyroid gland. At the same time, the dual-isotope method with 
99m
Tc-sestamibi and 
123
I addresses the challenges posed by the cross-contamination of isotopes and 
the septal penetration of the high energy iodine gamma photons. Collimators optimized for 
99m
Tc 
have problems with the septal penetration of 
123
I high energy gamma photons. Several authors have 
suggested the use of medium-energy collimators for 
123
I imaging and also for dual-isotope imaging 
(Macey et al. 1986, Geeter et al. 1996, Inoue et al. 2003, Small et al. 2006). However, the resolution 
of medium-energy collimators is inadequate for detecting small structures, as shown in Study IV 
and V. 
 
Although the LEUHR collimator was inferior to the LEHR and MELP collimators in terms of septal 
penetration and cross-contamination, as shown in Study IV, the ultra-high resolution of the LEUHR 
collimator yielded the best results, as shown in Study IV and V. Our finding of the preference of 
LEUHR collimators over LEHR collimators is in line with the findings of Fahey and co-workers 
(Fahey et al. 1992). 
 
It should be kept in mind that the most important information in parathyroid scintigraphy is in the 
99m
Tc-sestamibi image. The 
123
I image is mainly used for removal of the thyroid gland. Although 
99m
Tc image is contaminated with 
123
I photons, their spatial distribution is different because para-
thyroid glands are separated from thyroid glands (excluding rare cases of intrathyroidal parathyroid 
glands). Therefore, the selection of the collimator should be based on 
99m
Tc-sestamibi image opti-
mization. 
6.4 Cross-contamination 
Dedicated cross-contamination correction methods were not used in any hospital using the dual-
isotope method in Study I, but the amount of cross-contamination was minimized with narrow 
and/or asymmetric energy windows. This approach has also been used by other authors as the only 
option for correcting cross-contamination in clinical work, with the exception of some early at-
tempts using  cross-contamination factors (Hindie et al. 1997, Hindie et al. 1998, Jeanguillaume et 
al. 1998, Neumann et al. 1998, Hindie et al. 1999, Hindie et al. 2000, Dontu et al. 2004, Neumann 
et al. 2008). 
 
Although shifting the 
123
I window to the right to minimizes 
99m
Tc-contamination in the 
123
I window, 
uniformity is decreased, as shown in Study IV, and this in turn creates subtraction artifacts in 
99m
Tc-
sestamibi/
123
I subtraction SPECT/CT, as shown in Study V. The use of the asymmetric 
123
I window 
is thus not recommended.  
 
By contrast, the contamination of 
123
I in the 
99m
Tc energy window is much higher regardless of the 
collimator used. Shifting the 
99m
Tc window to the left has been shown to be ineffective in reducing 
123
I crosstalk (Ivanovic et al. 1994) and was therefore not tested here. The use of the scatter correc-
tion method did not improve visual scores in Study V with an adenoma of very low activity. The 
adenoma of higher activity had higher contrast in additional measures to Study V, but there was 
very little difference in the visual appearance of images. 
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It was expected that the efficacy of the TEW method is limited with 
99m
Tc and 
123
I due to the close 
proximity of the photopeaks (Yang et al. 1997). However, applying the scatter correction to clinical 
practice (acquisition of additional scatter windows) has no drawbacks, as it is easy to produce imag-
es with and without scatter correction being applied. 
6.5 Acquisition parameters 
The slight distortion detected in the SPECT images acquired with detectors in L-mode in Study V 
was not noticed with patient images in a preliminary test of our earlier studies. However, this slight 
distortion was seen as there was no motion or breathing artifacts with a stationary phantom. This 
phenomenon results from variable spatial resolution and has been reported by several authors 
(Knesaurek 1987, Knesaurek et al. 1989, Groch et al. 2000, Notghi et al. 2010). To the best of our 
knowledge, L-mode has not been applied with dual-isotope parathyroid subtraction SPECT by any 
other author and, according to our results, it is not recommended. 
 
The use of the 256256 matrix size (voxel size of 2,32,32,3 mm) improved the contrast of the 
adenoma with LEUHR collimators when compared with the 128128 matrix size (voxel size of 
4.64,64.6 mm). The improved contrast is associated with improved reconstructed resolution due 
to the smaller voxel size and the partial-volume effect, as shown in the results of Kappadath 
(Kappadath 2011). Changing the matrix size from 128128 to 256256 of course decreases the 
counts per voxel to 1/8 compared to counts per voxel in the 128128 matrix, and thus decreases the 
signal-to-noise ratio. However, it is also beneficial to use a higher acquisition matrix, as it is possi-
ble to rebin the imaging matrix of 256256 to a lower size if counts per voxel are too low in a pa-
tient study. 
6.6 Image reconstruction and processing 
The effect of various reconstruction algorithms was not tested in this study as only vendor-specific 
Flash 3D was available. However, a significant impact on image quality was noticed in Study V as 
the parameters of the reconstruction algorithm were adjusted, which is in line with previously pub-
lished results (Nichols et al. 2007, Bar et al. 2011, van Hoorn et al. 2013, Ekjeen et al. 2015).  The 
effect of improving the resolution as a function of the increasing number of iterations has been 
shown by van Hoorn and co-workers, but only with a reconstruction algorithm that  included resolu-
tion recovery (as Flash 3D) (Kappadath 2011, van Hoorn et al. 2013). Kappadath showed that the 
reconstructed resolution improved in a power-law fashion with the product of iterations and subsets. 
To reach the highest possible resolution, the product of iterations and subsets needs to be high 
enough in order to reach the plateau in the resolution curve (i.e., reconstructed resolution as a func-
tion of the  product of iterations and subsets) (Kappadath 2011). It is also well known that image 
noise increases with the product of iterations and subsets and was also shown in Study IV. The 
range for the product of iterations and subsets needs to be carefully selected for optimal trade-off 
between image noise and spatial resolution with clinical studies, which is also an important topic for 
further studies. 
 
The first 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT study by Neumann and co-workers had a quite 
low sensitivity of 70% (Neumann et al. 2008), although they used high activity 
99m
Tc-sestamibi and 
had many years of experience with subtraction SPECT (Neumann et al. 1997, Neumann et al. 1998, 
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Neumann et al. 2000). In their study, they used Siemens T6 SPECT/CT with very similar acquisi-
tion parameters to those we used in Study III. However, they only used four iterations and eight 
subsets in reconstruction in comparison to our eight iterations and eight subsets in Study III and an 
even higher number in Study V. According to the results of Study V, this is one possible explana-
tion behind the low sensitivity reported by Neumann and co-workers (Neumann et al. 2008). 
 
The subtraction step is performed after the reconstruction of the 
99m
Tc and 
123
I images and is per-
formed to remove the thyroid gland from the image. If there is no difference in the spatial distribu-
tion of the 
99m
Tc and 
123
I images, the subtraction of a 
123
I image should produce an image contain-
ing only noise and reconstruction artifacts (Brinkmann et al. 1999). 
 
It was shown in Study IV that there is a small difference in the resolution of the 
99m
Tc and 
123
I im-
ages, especially in the FWTM values. There was also variation as a function of distance in the sen-
sitivity of 
123
I, the scatter-to-photopeak ratio of 
123
I, and the cross-contamination of 
123
I in the 
99m
Tc 
window caused by the septal penetration of high-energy gamma photons of 
123
I. These results are in 
line of those of Brinkmann and Ivanovic(Ivanovic et al. 1994, Brinkmann et al. 1999). 
 
As a result, even optimal processing of identical 
99m
Tc and 
123
I images does not give a flawless sub-
traction image. Typical subtraction artifacts are “blobs” surrounding the thyroid gland, the so-called 
“edge artifacts”. To the best of our knowledge, this artifact has not been described earlier in connec-
tion with parathyroid scintigraphy. This was also the main cause of artifacts in Study II and in Study 
III. A careful optimization of the protocol, as shown in Study V, should be able to minimize this 
artifact.  
 
Although the previously mentioned effects degrade the quantitative precision, the parathyroid scin-
tigraphy analysis does not benefit from a quantitative approach (Nichols et al. 2007). In Study V, a 
quantitative approach was used to compare various acquisition and processing parameters. Howev-
er, clinical work is based solely on the visual appearance of the subtraction image and the corre-
sponding anatomical reference in the CT image. Thus, accurate quantitation is not obligatory, as is 
the case, for example, in neurologic applications (Brinkmann et al. 1999). 
6.7 The optimal protocol 
99m
Tc-sestamibi/
123
I subtraction imaging with pinhole collimators has been the protocol of choice 
for several authors. Although the sensitivity figures have been high (Hindie et al. 1998), pinhole 
imaging lacks the 3D anatomical information offered by modern SPECT/CT (Taieb et al. 2012, 
Taieb et al. 2013, Wong et al. 2015). However, the sensitivity figures of the first 
99m
Tc-
sestamibi/
123
I subtraction SPECT/CT were not as high as with planar pinhole imaging (Neumann et 
al. 2008, Bhatt et al. 2015). This might explain why 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT is 
not very extensively applied worldwide. To date, only three clinical studies (Tunninen et al. 2013 
(Hassler et al. 2013, Bhatt et al. 2015) have been published on the 
99m
Tc-sestamibi/
123
I subtraction 
SPECT/CT protocol in addition to that of Neumann and co-workers (Neumann et al. 2008). 
 
We were able to reach the sensitivity of 94% with 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT in 
Study III, and it was even further improved with the additional use of a pinhole imaging. Although 
the combined use of acquisition techniques is favored by many authors, it increases the acquisition 
time and thus increases the cost of the study and the discomfort of the patient. According to our 
phantom experiments, with the careful optimization of 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT 
protocol, it is possible to exclude the pinhole imaging in the clinical protocol. 
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It is well known that a large parathyroid adenoma can be easily visualized with all protocols in clin-
ical use. However, the clinical problem involves patients with secondary hyperparathyroidism with 
relatively inactive hyperplastic glands, and patients with multiglandular disease, where the patient 
has more than one enlarged parathyroid glands (Hindie et al. 2015). Nichols stated already ten years 
ago “any technical innovation that aids in the accuracy of the localization process should be em-
ployed” (Nichols et al. 2007). An almost identical comment by Minisola was published recently 
“The time has come for optimally combining the best that technology has to offer in this scenario 
with the best surgical expertise, for ensuring maximum benefit to patients” (Minisola et al. 2016). 
In this scenario, the benefit of an additional pinhole imaging needs to be carefully evaluated. 
 
The dual-isotope SPECT/CT is a highly sensitive and specific method for localizing an enlarged 
parathyroid adenoma. However, there are several aspects that have a profound effect on the final 
outcome of the study. With unoptimized choices, the optimal protocol may turn into a worst case 
scenario. These aspects are summarized in Figure 37. 
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6.8 Conclusions 
All patients referred for parathyroid scintigraphy have already been diagnosed with primary hy-
perparathyroidism (also with secondary or tertiary hyperparathyroidism), with diagnosis based on 
laboratory findings. The question is whether the parathyroid scintigraphy protocol is capable of lo-
calizing the enlarged glands. Each patient should be studied with the highest accuracy in order to 
localize all the enlarged parathyroid glands immediately (Taieb et al. 2012, Hindie et al. 2015). 
Missing an enlarged gland (in multiglandular disease or in the case of double adenoma) will be-
come exposed after surgery causing elevated Ca-ion and PTH levels. For the patient, it means re-
peated studies with additional radiation doses and repeated surgery with an increased complication 
rate (Taieb et al. 2013, Whitcroft et al. 2014). In this scenario, all possible efforts should be made to 
use the parathyroid scintigraphy protocol to yield as accurate results as possible. The combined pro-
tocol with pinhole imaging might also give additional information on thyroid nodules, and thus ex-
clude false positive findings and the referring of the patient for further studies in the case of thyroid 
malignancy(Onkendi et al. 2012, Greilsamer et al. 2015). 
 
The 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT protocol is a highly efficient and modern protocol 
for the localization of enlarged parathyroid glands. A sensitive and specific preoperative localiza-
tion, also capable of identifying ectopic glands and multiple gland disease, is a prerequisite for min-
imally invasive surgery, a modern treatment for hyperparathyroidism (Hindie et al. 2009). However, 
an international debate continues as to whether imaging is best performed using a dual-phase meth-
od with 
99m
Tc-sestamibi alone or using the dual-isotope method with 
99m
Tc-sestamibi and 
123
I 
(O'Doherty et al. 2003, Hindie et al. 2009, Greenspan et al. 2012). Several options for acquisition 
technique and the selection of parameters have led to a large variety of protocols being used, with a 
large variety of sensitivity and specificity figures (Mihai et al. 2009). A number of studies have also 
been published with insufficient information on the acquisition and processing techniques used, and 
this confuses the field even more as inferior results may also arise from the use of unoptimized 
technique (Sharma et al. 2006, Ali et al. 2011, Bhatt et al. 2015). 
 
The clinical audit procedure assesses the local practice against the defined good practice (Decree of 
the Ministry of Social Affairs and Health on the medical use of radiation 423/2000 
https://www.stuklex.fi/en/ls/20000423 ). However, there are still a number of studies within nuclear 
medicine, including parathyroid scintigraphy, where the good practice has not been well defined. In 
order to build good practice for parathyroid scintigraphy, a need exists for more research and also 
for external quality assurance carried out by independent outside observers. 
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7 Summary and conclusions 
This thesis studied the parathyroid scintigraphy protocols. The aim was to find the optimal protocol 
with the highest sensitivity and specificity possible. We have shown that the dual-isotope method 
with 
99m
Tc-sestamibi and 
123
I is superior to the use of 
99m
Tc-sestamibi alone. Combining the 
99m
Tc-
sestamibi/
123
I subtraction method with the SPECT/CT technique is a highly sensitive and specific 
protocol for parathyroid scintigraphy and should be preferred over planar acquisition techniques due 
to important anatomical 3D information. On the other hand, 
99m
Tc-sestamibi/
123
I subtraction 
SPECT/CT is a highly technical protocol that requires experience and the thorough testing of each 
step in the protocol. With careful optimization, superior sensitivity and specificity with accurate 
anatomical information can be accomplished. The main findings of this study can be summarized as 
follows: 
 
1) The dual-isotope method with 99mTc-sestamibi and 123I is superior when compared with a 
single-tracer method with 
99m
Tc-sestamibi alone 
2) 99mTc-sestamibi/123I subtraction SPECT/CT is a highly sensitive and specific protocol for 
parathyroid scintigraphy and should be preferred over planar acquisition techniques due to 
important anatomical 3D information 
3) With careful optimization, 99mTc-sestamibi/123I subtraction SPECT/CT is an adequate tech-
nique for parathyroid scintigraphy without additional acquisitions 
4) 99mTc-sestamibi/123I subtraction SPECT/CT should be optimized with the following aspects: 
a. The SPECT acquisition should be done with the highest resolution achievable in or-
der to minimize subtraction artifacts 
b. The use of symmetrical energy windows is preferred over asymmetrical windows 
c. The use of scatter correction increases the contrast of an adenoma, but may decrease 
the visual appearance if the number of counts is low 
d. The use of a higher number of iterations in reconstruction increases the contrast and 
the visual appearance of an adenoma 
 
5) All combinations of collimator and camera together with acquisition and processing parame-
ters should be tested in each center with known phantoms in order to achieve the highest 
quality possible 
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Summary 
The goal of this study was to describe current 
clinical parathyroid scintigraphy (PS) proto-
cols in Finland. Methods: All departments of 
nuclear medicine in Finland were contacted, 
and instructions regarding PS were requested. 
Results: Instructions regarding PS were re-
ceived from all of the departments that per-
form PS (n = 19). Seven hundred and sixty-
nine PS studies were performed in 2009 (be-
tween 7 and 209 per hospital). Three methods 
of PS were used. The dual-phase method with 
99mTc-sestamibi is used in seven hospitals, the 
dual-tracer method with 123I/99mTc-sestamibi 
in eleven, and 99mTcO4/99mTc-sestamibi in one 
hospital. The activities of 99mTc-sestamibi, 123I 
and 99mTcO4 were 150–800 MBq, 10–30 MBq 
and 50 MBq, respectively. The anterior image 
with parallel-hole collimators, the anterior 
image with pinhole collimator, the oblique 
angles with pinhole collimator, SPECT and hy-
brid CT with SPECT were acquired in 84%, 
26%, 16%, 63%, and 42% of the hospitals, re-
spectively. Because the imaging techniques 
were combined, one to four acquisitions were 
performed per patient. Scatter and attenu-
ation correction were used in five protocols. A 
correction for crosstalk of 123I and 99mTc 
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gamma energies was not used, but the amount 
of crosstalk was decreased by using narrow or 
asymmetric energy windows in all dual isotope 
protocols. Conclusion: 19 hospitals used 18 dif-
ferent study protocols. Thus, significant varia-
bility exists in the current practice of PS in Fin-
land. The protocols should be tested with 
known phantoms to determine any differences 
in sensitivities for detecting small active struc-
tures. Further studies with phantoms are 
needed to determine the optimal imaging tech-
niques. The results of these phantom studies 
will provide guidelines for proposing national 
recommendations for PS. 
 
Schlüsselwörter 
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Zusammenfassung 
Das Ziel dieser Studie war die Beschreibung ak-
tueller klinischer Protokolle für die Neben-
schilddrüsen (NSD)-Szintigraphie in Finnland. 
Methoden: Alle nuklearmedizinischen Abtei-
lungen in Finnland wurden angeschrieben und 
um die Vorschriften für die NSD-Szintigraphie 
gebeten. Ergebnisse: Wir erhielten die Vor-
schriften aller Abteilungen, die NSD-Szintigra-
phien durchführen (n = 19). Im Jahr 2009 er-
folgten 769 szintigraphische NSD-Unter-
suchungen (7 bis 209 je Krankenhaus). Drei 
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Methoden wurden für die NSD-Szintigraphie 
verwendet. Die Dual-Phasen-Methode mit 
99mTc-Sestamibi wird in sieben Krankenhäu-
sern eingesetzt, die Doppelnuklid-Methode 
mit 123I/99mTc-Sestamibi in elf und mit 
99mTcO4/99mTc-Sestamibi wird in einer Klinik 
gearbeitet. Die Aktivitäten von 99mTc-Sestami-
bi, 123I bzw. 99mTcO4 betrugen 150–800 MBq, 
10–30 MBq und 50 MBq. Aufnahmen von vor-
ne mit Parallelloch-Kollimatoren oder mit dem 
Pinhole-Kollimator, Schrägaufnahmen mit 
dem Pinhole-Kollimator, Aufnahmen mit 
SPECT und CT/SPECT-Hybridscanner wurden 
in 84%, 26%, 16%, 63% bzw. 42% der Klini-
ken akquiriert. Da die Methoden kombiniert 
wurden, erfolgten je Patient ein bis vier Da-
tenakquisitionen. In fünf Protokollen wurde 
nach Streuung und Abschwächung korrigiert. 
Eine Korrektur der Überlagerung von 123I- und 
99mTc-Gammastrahlungen fand nicht statt, je-
doch wurde das Ausmaß der Überlagerungen 
dadurch reduziert, dass man bei allen Doppel-
nuklid-Protokollen enge oder asymmetrische 
Energiefenster verwendete. Schlussfolgerung: 
In 19 Krankenhäusern kamen 18 verschiedene 
Studienprotokolle zum Einsatz. In der aktuel-
len Praxis der NSD-Szintigraphie besteht da-
her in Finnland eine signifikante Variabilität. 
Die Protokolle sollten an bekannten Phanto-
men getestet werden, um alle Sensitivitäts-
unterschiede bei der Darstellung kleiner akti-
ver Strukturen aufzudecken. Weitere Studien 
an Phantomen sind erforderlich, um die opti-
male Bildtechnik zu definieren. Die Ergebnisse 
dieser Phantomstudien ermöglichen es, Richt-
linien für nationale Empfehlungen für die 
NSD-Szintigraphie zu erstellen.  
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99mTc-sestamibi was first introduced as a 
parathyroid imaging agent in 1989 (9). It is 
least as effective as 201Tl in parathyroid 
localisation and quickly replaced 201Tl 
because of its  
● higher target-to-background ratio,  
● better imaging characteristics with 
99mTc and  
● favourable dosimetry (29).  
 
The problem with 99mTc-sestamibi is that it 
is a non-specific tracer for parathyroid tis-
sues and is taken up by adjacent thyroid tis-
sue. Two methods have been used to over-
come this problem:  
● the dual-phase method and  
● the dual-tracer method. 
 
The dual-phase method is based on the dif-
ferent washout kinetics of the tracer be-
tween the normal thyroid and the abnor-
mal parathyroid tissue (37). It requires only 
a single radionuclide and a comparison of 
the two images acquired ~15 and 150 min-
utes after the injection. However, any inter-
ference with the assumed difference in kin-
etics, such as the rapid washout of the ab-
normal parathyroid tissue, limits the effi-
cacy of detection of parathyroid disease 
with dual-phase 99mTc-sestamibi scinti-
graphy (25). Other limiting factors such as 
vitamin D deficiency have also been pro-
posed (34). 
In the dual-tracer method, 123I or 99mTc-
pertechnetate is used simultaneously with 
99mTc-MIBI. The 123I or 99mTc-pertech-
netate is taken up by the thyroid gland only. 
The thyroid image is subtracted from the 
99mTc-sestamibi image. This process helps 
to visualise the parathyroid tissue.  
With 99mTc-pertechnetate, the thyroid 
image must be acquired before the 99mTc-
sestamibi is injected and without moving 
the patient. Sequential imaging has the risk 
of motion artefacts and thus problems with 
alignment. With 123I, simultaneous im-
aging is possible, but using two isotopes 
brings new problems such as the cross-over 
of two photopeaks. 
Whichever method is used, several 
techniques can be selected for the acquisi-
tion (e. g., planar acquisitions with paral-
lel-hole or pinhole collimators, single 
photon emission computed tomography 
(SPECT) or computed tomography 
(CT)). Within each acquisition technique, 
several choices must be made. The timing 
of the acquisition, the acquisition length, 
the collimators used, the energy window 
placements, the various corrections and 
the processing protocols are examples of 
these choices. 
Few direct comparisons exist between 
the different imaging techniques, and little 
evidence supports the superiority of one 
over another. Thus, the optimal protocol 
for parathyroid scintigraphy PS with 99mTc-
MIBI is still not clear. As a result, many dif-
ferent protocols are in clinical use today, 
and these protocols have variable sensitiv-
ities ranging from 34% to 100% (26). 
Because no national guidelines or rec-
ommendations exist for PS, variable proto-
cols have presumably also been used in 
clinical practice in Finland. Variability has 
raised some concerns among nuclear medi-
cine professionals, who have discussed the 
standardisation of the PS protocols. The 
first priority is the sensitivity of the study 
because large differences should not exist 
between hospitals nationally. Other impor-
tant aspects are the time required for the 
study, the patient discomfort and the total 
cost of the study. 
The goal of this study was to determine 
which methods are in current clinical use 
for PS in Finland and how imaging and 
image processing are performed in daily 
clinical practice. To our knowledge, this in-
formation has not previously been pub-
lished for any country. 
Methods 
All departments of nuclear medicine in 
Finland (n = 25) were contacted in Septem-
ber 2008, and instructions regarding clini-
cal protocols for PS were requested. If in-
structions were unclear or some informa-
tion was missing, the department was con-
tacted by telephone or by email. All depart-
ments were contacted again in January 
2010, and the information was updated. 
The results presented here were extracted 
from these documents. All departments in 
Finland performing PS took part in this 
survey. Therefore, we have very realistic re-
sults on the current clinical status of PS in 
Finland. 
Results 
Response 
Instructions were received from all of the 
departments performing PS (n=19). These 
instructions included details regarding pa-
tient preparation, acquisition and data pro-
cessing. 
Methods in use 
Three methods of PS are being used in Fin-
land in 2010 (Tab. 1). The dual-phase 
method with 99mTc-sestamibi is used in 7 
hospitals. The dual-tracer method with 123I 
and 99mTc-sestamibi is used in 11 hospitals, 
and 99mTcO4/99mTc-sestamibi is used in 1 
hospital. 
Six hospitals using dual-tracer method 
with 123I and 99mTc-sestamibi combine this 
method with the dual-phase method and 
repeat acquisitions 2–3 hours after the 
99mTc sestamibi injection. 
Alternative methods have been used in 
two hospitals (e. g., when iodine was un-
available or if the patient had not followed 
instructions for medication). However, 
the number of alternative studies is low, 
and thus they are excluded from this 
study. 
Number of studies 
Seven hundred and sixty-nine parathyroid 
studies were performed in 2009. The 
number of studies varied from 7 to 209 per 
hospital (Fig. 1). 
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Tab. 1 Parathyroid scintigraphy protocols in 
Finland in 2010 
method % 
dual-tracer with 123I/99mTc-sestamibi 58 
dual phase 99mTc-sestamibi 37 
dual-tracer with 99mTcO4/99mTc-sestamibi  5
Radionuclides and activities 
In the dual-phase method, the 99mTc-sesta-
mibi activity was 740 MBq in all hospitals. 
In the dual-tracer method with 123I/99mTc-
sestamibi, the 99mTc-activity was 150–800 
MBq, and the 123I activity was 10–30 MBq. 
(Iodine was given as a capsule in 4 hospitals 
and as an injection in 7 hospitals). In the 
dual-tracer method with 99mTcO4/99mTc-
sestamibi, the 99mTc-pertechnetate activity 
was 50 MBq, and the 99mTc-sestamibi activ-
ity was 740 MBq. 
Imaging techniques  
Dual-phase method 
In the dual-phase method, the early phase 
acquisition starts 7–15 minutes after the 
99mTc-sestamibi injection. The late phase 
acquisition starts 1,5–4 hours after the 
99mTc-sestamibi injection. 
A static anterior (AP) image is acquired 
with parallel-hole collimator in 71% of 
the hospitals in both the early and the late 
phase. A pinhole collimator was not used 
at all in any hospitals that use the dual-
phase protocol. SPECT is used in the early 
phase in 43% of the hospitals and in the 
late phase in 71% of the hospitals. All hos-
pitals using SPECT in the early phase also 
used SPECT in the late phase. A hybrid CT 
with SPECT is used in 29% of the hospi-
tals during the late phase. Altogether, 2 to 
4 acquisitions are performed per patient. 
Imaging techniques used in hospitals 
using the dual-phase method are pres-
ented in Figure 2a. 
Dual-tracer method 
In the dual-tracer method, the acquisition 
begins 5–10 minutes after the 99mTc-sesta-
mibi injection. The optional late phase ac-
quisition was used in 42% of the hospitals, 
and it starts 2–3 hours after the 99mTc-sesta-
mibi injection. A static AP image is ac-
quired with parallel-hole collimator in 
92% of the hospitals in the early phase and 
in 33% of the hospitals in the late phase. A 
static AP image is acquired with a pinhole 
collimator in 42% of the hospitals in the 
early phase and in 8% of the hospitals in the 
late phase. Oblique angles are acquired in 
25% of the hospitals in the early phase and 
not used at all in the late phase. SPECT is 
used in 42% of the hospitals in the early 
phase and in 17% of the hospitals in the late 
phase. Hybrid CT with SPECT is used in 
42% of the hospitals in the early phase and 
in 8% of the hospitals in the late phase. One 
to four acquisitions are performed per pa-
tient. Imaging techniques used in hospitals 
using the dual-phase method are presented 
in Figure 2b. 
All methods combined 
If all methods are combined, the static AP 
image is acquired with parallel-hole colli-
mator in 84% of the hospitals (n = 16). A 
static AP image is acquired with a pinhole 
© Schattauer 2010 Nuklearmedizin 5/2010
189 V. Tunninen et al.: Parathyroid scintigraphy in Finland
Fig. 1  
The number of para-
thyroid scintigraphy 
studies in Finnish 
hospitals in 2009 
Fig. 2  
Imaging techniques 
in hospitals used for 
parathyroid scinti-
graphy  
(static AP: anterior 
image with parallel-
hole collimator;  
■ early phase;  
■ late phase) 
a) dual-phase 
method with  
99mTc-sestamibi 
b) dual-tracer meth-
ods_ with 99mTc-
 sestamibi and 123I or 
99mTc-pertechetate 
c) summarised for all 
hospitals (■) 
a) 
b) 
c) 
collimator in 26% of the hospitals (n = 5). 
Oblique angles are acquired in 16% of the 
hospitals (n = 3). SPECT is used in 63% of 
the hospitals (n = 12), and hybrid CT with 
SPECT is used in 42% of the hospitals (n = 
8). The imaging techniques are summa-
rised for all methods in Figure 2c. 
These imaging techniques are combined 
in each hospital in a variety of ways (Tab. 
2). Examples of three different protocols 
are presented in Figure 3. The timeline 
represents the time requirements for the 
different protocols. 
Energy windows and corrections 
Correction for crosstalk of the 123I and 
99mTc gamma photons is not used in any 
hospital. The amount of crosstalk to the 
99mTc-window is minimised by using ener-
gy window widths of 10–16%. The amount 
of crosstalk to the 123I-window is minimis-
ed by using energy window widths of 
10–15% and an asymmetric window set-
ting (the window centre is at 160–167 keV). 
Scatter correction is used with SPECT 
acquisition in four hospitals using the dual-
tracer method with 123I and 99mTc-MIBI. 
CT-based attenuation correction is used in 
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Tab. 2 Imaging techniques used in parathyroid scintigraphy in Finland in 
2010: The dots indicate which method is used in each hospital and which 
acquisition techniques are used in the early and/or late phase. (The hospital 
numbers are the same as in Figure 1.)  
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hospital number 
method 
acquisitions  
in the  
acquisitions
DP: dual phase method; DT: dual tracer method with either iodine or tech-
netium; AP: anterior image with parallel-hole collimator; PIN: anterior image 
with pinhole collimator; OBL: oblique images with a pinhole collimator; 
acquisitions: total number of acquisitions per patient 
Fig. 3 Three examples of the time requirements of different parathyroid scintigraphy protocols  
(AP: anterior image with a parallel-hole collimator) 
five hospitals using the dual-tracer method 
with 123I and 99mTc-MIBI. Scatter and/or 
attenuation correction is not used in the 
single isotope studies. 
Processing protocols 
In the dual-phase method, early and late pla-
nar images are displayed together. When 
SPECT imaging is used, SPECT images are re-
constructed using iterative reconstruction al-
gorithms, and the early and late images (i. e. 
transverse, coronal and sagittal slices) are dis-
played together. Subtraction of the late images 
from the early images is not used in any of the 
hospitals using the dual-phase method.  
In the dual-tracer method, planar im-
ages of the thyroid and parathyroids are 
subtracted. Subtraction is performed after 
normalisation of the images. The normal-
isation is performed according to the total 
counts or the maximum counts per pixel in 
the thyroid area. The amount subtracted 
varies based on the visual appearance of the 
image, and several subtraction factors are 
used simultaneously. If SPECT imaging is 
used, the subtracted SPECT images are re-
constructed using an iterative reconstruc-
tion algorithms transverse, and the coronal 
and sagittal slices are displayed. Subtrac-
tion of late and early images is not used in 
any of the hospitals using the dual-tracer 
method combined with the dual-phase 
method. 
Data processing is performed mainly by 
medical physicists, but technologists or 
physicians may also be involved. Several 
hospitals report that data processing can be 
performed by any of these professionals. 
Discussion 
The imaging and processing protocols in 
Finland were chosen in each department so 
that a large variety exists in the protocols. 
We found only two clinical protocols that 
were identical in all aspects. As a result, 18 
protocols are in use in 19 hospitals (alter-
native protocols are excluded). 
The debate continues as to whether PS is 
best performed using the dual-tracer 
method or the dual-phase method (30). At 
the same time, various imaging techniques 
are in clinical use with both methods, and 
each of the techniques can be modified in 
several ways.  
All methods (i. e., the dual-phase 
method or the dual-tracer method with 
123I or 99mTcO4) presented in the latest 
European Association of Nuclear Medi-
cine (EANM) Parathyroid Scintigraphy 
Guideline (18) are being used in Finland. 
The dual-tracer method with 123I/99mTc-
sestamibi is the method most often used 
(in 57,9% of the hospitals in Finland). 
This method is combined with the late 
phase imaging in a little less than half of 
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the hospitals using the dual-tracer 
method. The EANM guideline states that 
“delayed images (2 h post-injection) are not 
useful and do not add to the sensitivity of 
the subtraction protocol” (18). However, 
the opposite opinion has also been pres-
ented (35). 
A great variation exists in the number of 
studies per hospital. Because the success 
rate of the visualisation of parathyroid ade-
nomas is related to the experience of the 
imaging unit, keeping the standards high 
with a low number of studies may be chall-
enging (3). 
The activity of 99mTc-sestamibi was 
similar in all hospitals using the dual-phase 
method but varied greatly in the hospitals 
using the dual-tracer method. The smallest 
activity of 99mTc-sestamibi was 150 MBq, 
and other hospitals used activities between 
550–800 MBq. The reference level given by 
the Finnish radiation safety authorities for 
PS is 800 MBq. Therefore, increasing the 
activity in some hospitals might be worth 
considering. The use of small activities 
might be related to the poor visualisation of 
small parathyroid nodules. 
The starting time of the late phase im-
aging varied from 1,5 to 4 hours after the 
injection of the 99mTc-sestamibi. Because 
the accuracy of the dual-phase technique is 
based on the different washout kinetics of 
the tracer between the normal thyroid and 
the abnormal parathyroid tissue, timing of 
the acquisition has great importance on the 
results. Even with correct timing, using the 
dual-phase method may result in some ab-
normal parathyroids being missed because 
of the rapid washout of the abnormal para-
thyroid tissue (25). 
All imaging techniques presented in the 
latest EANM Parathyroid Scintigraphy 
guideline (18) except pinhole SPECT are 
used in Finland. If all three methods are ob-
served as a whole, the AP image is acquired 
with a parallel-hole collimator in 84% of 
the Finnish hospitals (n = 16), The AP 
image is acquired with a pinhole collimator 
in 26% of hospitals (n = 5), and oblique im-
ages are acquired with a pinhole in 16% of 
hospitals (n=3). SPECT is acquired in 63% 
(n = 12), and CT is acquired in 42% (n = 8) 
of the hospitals performing PS. 
Because pinhole collimator has much 
better spatial resolution than parallel-hole 
collimator (8), we were surprised to see that 
pinhole collimator is used so rarely. The use 
of pinhole collimators increases the sensi-
tivity of PS compared to parallel-hole colli-
mators (2, 39) and is even preferred to 
SPECT (19). Pinhole-SPECT might be the 
optimal imaging technique for PS (6), but it 
is rarely possible with modern gamma 
cameras. The rare use of the pinhole colli-
mator is partially explained by the instru-
mentation in the hospitals. Hospitals that 
have a pinhole collimator but do not use it 
have several reasons for their behaviour. 
The time required for the collimator 
change is too long. The use of the pinhole 
collimator is awkward, and SPECT is often 
preferred. Clinical experience with the new 
generation SPECT-CT results in a prefer-
ence for planar imaging protocols. To our 
knowledge, no publications compare im-
aging protocols with a pinhole collimator 
and a SPECT-CT. 
The use of SPECT is also surprising. 
Only a little more than half of the hospitals 
use SPECT, even though all hospitals have 
gamma cameras that are capable of per-
forming SPECT imaging. In spite of a few 
controversial reports (7, 40), SPECT has 
been shown to improve sensitivity signifi-
cantly compared to planar imaging with 
parallel-hole collimators (25, 27, 36) be-
cause it provides more information about 
the depth of the parathyroid tumour and 
its anatomic location. Planar imaging 
might even be completely unnecessary if 
SPECT is used (38). 
Because SPECT-CT technology was 
implemented in clinical practice, this 
methodology was also applied in PS. This 
method provides precise anatomic locali-
sation of the lesion, resulting in better 
planning of surgical procedures (11). 
SPECT-CT is superior to CT or SPECT 
alone in correctly detecting the exact posi-
tion of abnormal parathyroid glands. It 
has also been shown to have significant 
additional value over conventional SPECT 
for ectopic parathyroid adenomas or with 
patients who had distorted neck anatomy 
due to previous operations (14, 22, 31, 
32). 
The integrated SPECT-CT also makes 
CT-based attenuation correction possible. 
The use of attenuation correction does not 
necessarily improve traditional SPECT, but 
the image contrast and the tumour-to-
background ratio improve. The sensitivity 
of the parathyroid SPECT may also be im-
proved (33). 
Controversial reports have also been 
published. One paper recommends that 
SPECT-CT be used only for locating ec-
topic parathyroid glands (14). The main 
disadvantage of SPECT-CT is the patient’s 
additional radiation exposure. However, 
the additional dose may be justified when 
considering the risks of repeated imaging 
or the risks associated with a repeated gen-
eral anaesthetic and surgical intervention. 
The use of low-dose CT parameters can re-
tain much of the advantages of SPECT-CT 
while reducing the associated radiation 
burden (24). 
The popularity of SPECT-CT with PS is 
increasing as new systems are installed. The 
precise benefit of SPECT-CT is still a 
matter of debate, and a definite role for 
SPECT/CT has not yet been confirmed (5). 
However, the use of SPECT-CT is increas-
ing in Finland. Currently in Finland, a 
SPECT-CT is installed in 11 of the 19 hos-
pitals performing PS, and it is used in 8. Of 
those three not using it, two have had their 
systems installed recently, so new tech-
niques have not yet been applied to PS. 
Although SPECT and SPECT-CT im-
aging are becoming very helpful, they can-
not replace the standard planar and pin-
hole protocols that are still essential for op-
timal resolution in the thyroid bed region 
and for correct diagnoses (18). 
When the dual-tracer method with 123I 
is used, the crosstalk between the two 
radionuclides and the septal penetration of 
high-energy photons of 123I should be 
tested before clinical use (12, 20, 21). Dedi-
cated crosstalk correction methods were 
not used in any hospital using the dual-
tracer method with 123I, but the amount of 
crosstalk was minimised with narrow and/
or asymmetric energy windows. Pinhole 
collimators are useful in part because they 
do not suffer from septal penetration prob-
lems (8). 
Imaging and processing protocols in 
Finland have been chosen in each depart-
ment, resulting in a large variety in proto-
cols. One to four acquisitions are perform-
ed for each patient with various imaging 
techniques because building a clinical para-
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thyroid study protocol can be very confus-
ing, and conflicting reports are published 
on sensitivity figures of various methods 
and imaging techniques. Although the sen-
sitivity of PS may be improved by adopting 
a variety of imaging strategies (1, 23, 35), 
implementing various strategies increases 
the acquisition time and thus increases the 
cost of the study and the discomfort for the 
patient. To find the optimal clinical proto-
col, extensive technical phantom studies 
are needed. 
Surprisingly, the technical details of PS 
have not been thoroughly studied. To our 
knowledge, only six published studies exist 
that use any kind of phantoms in parathy-
roid imaging optimisation (4, 10, 13, 15, 17, 
28). Only two of these use the dual-tracer 
method using 99mTc and 123I (10, 17). An 
adequate comparison of various imaging 
techniques using phantoms is indispens-
able for reaching any kind of consensus and 
harmonisation of protocols. 
In the meantime, existing protocols 
should be tested with known phantoms to 
find differences in the ability to accurately 
show and locate adenoma-like structures 
of various sizes and activities. Thus, a 
need exists for external quality assurance 
by independent outside observers (16). 
We are planning to carry out a national 
quality assurance project of PS in co-op-
eration with the Finnish Society of Nu-
clear Medicine. As stated in EU-legis-
lation concerning clinical audit, building 
a national good practice is the first step to 
harmonisation. 
Conclusion 
The optimal technical aspects for 99mTc-
sestamibi parathyroid scintigraphy are still 
not clear. As a result, many different 
methodologies are in clinical use today. 
This study showed that significant variabil-
ity exists in the methods and imaging tech-
niques of PS in Finland. 
The imaging techniques must be opti-
mised to reach the highest sensitivity possi-
ble and to minimise the time required for 
the study, the patient discomfort and the 
total cost of the study. Further studies with 
phantoms are needed. The results of the 
phantom studies will provide guidelines for 
proposing national recommendations for 
parathyroid scintigraphy . 
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Objectives. We compared �ve parathyroid scintigraphy protocols in patients with primary (pHPT) and secondary hyperparathy-
roidism (sHPT) and studied the interobserver agreement. e dual-tracer method (99mTc-sestamibi/123I) was used with three
acquisition techniques (parallel-hole planar, pinhole planar, and SPECT/CT). e single-tracer method (99mTc-sestamibi) was
used with two acquisition techniques (double-phase parallel-hole planar, and SPECT/CT).us �ve protocols were used, resulting
in �ve sets of images. Materials and Methods. Image sets of 51 patients were retrospectively graded by four experienced nuclear
medicine physicians. e �nal study group consisted of 24 patients (21 pHPT, 3 sHPT) who had been operated upon. Surgical
and histopathologic �ndings were used as the standard of comparison. Results. irty abnormal parathyroid glands were found
in 24 patients. e sensitivities of the dual-tracer method (76.7–80.0%) were similar (𝑃𝑃 𝑃 1𝑃𝑃). e sensitivities of the single-
tracer method (13.3–31.6%) were similar (𝑃𝑃 𝑃 𝑃𝑃𝑃2𝑃). All diﬀerences in sensitivity between these two methods were statistically
signi�cant (𝑃𝑃 𝑃 𝑃𝑃𝑃12). e interobserver agreement was good. Conclusion. is study indicates that any dual-tracer protocol with
99mTc-sestamibi and 123I is superior for enlarged parathyroid gland localization when compared with single-tracer protocols using
99mTc-sestamibi alone. e parathyroid scintigraphy was found to be independent of the reporter.
1. Introduction
99mTc-methoxyisobutylisonitrile (99mTc-sestamibi), �rst
introduced by Coakley and coworkers as a parathyroid
imaging agent in 1989 [1], is the imaging agent of choice
for parathyroid scintigraphy (PS) [2]. Unfortunately, 99mTc-
sestamibi is not a speci�c tracer for parathyroid tissue but
is taken up by adjacent thyroid tissue. is problem can be
overcome by using either a single-tracer (double phase) or a
dual-tracer method.
In the single tracer method, it is assumed that thyroid
and parathyroid tissues have diﬀerent washout kinetics for
99mTc-sestamibi [3]. By acquiring images in the early and late
phases, the focally increasing uptake will reveal hyperfunc-
tioning parathyroid tissue. In the dual-tracer method, 99mTc-
sestamibi is used combined with 123I or 99mTc-pertechnetate,
which are taken up by the thyroid gland only. Subtracting
the thyroid image from the 99mTc-sestamibi image provides
visualization of the parathyroid tissue alone [4].
With both single-tracer and dual-tracer methods, several
acquisition techniques can be used (i.e., planar acquisitions
with parallel-hole or pinhole collimators and SPECT or
SPECT/CT), and several choices can be made about the
settings used for each technique (e.g., matrix size, energy
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settings, and acquisition time). ere are several studies that
provide comparisons between the diﬀerent imaging methods
or techniques, although there is little evidence supporting the
superiority of one over another, resulting in the use of various
study protocols today [5, 6].
�e have previously shown that there is signi�cant vari-
ability in the current practice of PS in Finland [7]. is is
also true in other countries, with reported sensitivities for
localizing abnormal parathyroid tissue ranging from 34% to
100% [8].
As a result of our previous study, the clinical protocol of
parathyroid scintigraphy in Satakunta central hospital was
changed in June 2010. Pinhole and SPECT/CT acquisition
techniques were included to increase the sensitivity of the
study. Additional late phase imaging was also included to
bene�t from the double phase method as well.
e goal of this study was to compare the sensitiv-
ity and speci�city of a single-tracer method and a dual-
tracer method with various acquisition techniques. e
dual-tracer method (99mTc-sestamibi/123I) was used with
three acquisition techniques (parallel-hole planar, pinhole
planar, and SPECT/CT). e single-tracer method (99mTc-
sestamibi) was used with two acquisition techniques (double
phase parallel-hole planar, and SPECT/CT). In addition, the
agreement between the �ndings of four experienced nuclear
medicine physicians was studied.
2. Methods
2.1. Patients. is was a retrospective single-center study
of �y-one patients referred for PS between June 2010
and February 2011 in Satakunta Central Hospital, Finland.
Patient data were included if there was biochemical evidence
of hyperparathyroidism, if scintigraphy was requested for
preoperative tumor localization, and if the patient proceeded
to surgery. Histopathological �nding was used as the gold
standard. e �nal study group consisted of 6 men and 18
womenwith amean age of 62.3 years (range, 32.1–86.8 years).
Twenty-one patients had pHPT. Preoperative plasma intact
parathyroid hormone (iPTH) values ranged from 69 ng/L to
277 ng/L (mean 190 ng/L, normal values 10–65 ng/L), and
values for preoperative serum calcium (Ca) ranged from
1.37mmol/L to 1.73mmol/L (mean 1.48mmol/L, normal
values 1.16–1.3mmol/L). ree patients had sHPT due
to renal failure. Preoperative iPTH values ranged from
210 ng/L to 400 ng/L (mean 380 ng/L), values for preoper-
ative Ca ranged from 1.21mmol/L to 1.8mmol/L (mean
1.45mmol/L). Twenty-seven patients did not proceed to
surgery for a variety of reasons (patient condition, death,
and other illnesses). is study was exempt from institu-
tional review board approval according to Finnish legislation.
Informed consent was waived.
2.2. Imaging: Doses and Acquisition. Patients received
20MBq of 123I (MAP Medical Technologies) intravenously.
Two hours later, 550MBq of 99mTc-sestamibi (Mallinckrodt
Medical B.V.) was injected intravenously. Ten minutes aer
the 99mTc-sestamibi administration, imaging was started.
Five diﬀerent image sets were acquired. e order and
the timing (aer the injection or 99mTc-sestamibi) of the
acquisitions and the resulting image sets are presented in
Figure 1.
First, a static 10-minute anterior image of the neck
and chest was acquired using a low-energy, high-resolution,
parallel-hole collimator (LEHR) (256 × 256 matrix; 1.85x
zoom). Next, a static 10-minute anterior image of the neck
was acquired from a distance of 10 cm from the patient’s
skin using a 5mm diameter pinhole collimator (256 × 256
matrix; 2.19x zoom). Acquisitions were performed with the
same dual-head gamma camera (Skylight; Philips). All data
were collected in dual-energy windows. e 99mTc window
was centered at 140 keV and had a 10% width (range,
133–147 keV). e 123I window was centered at 159 keV and
had a 10% width (range, 151–167 keV). Narrow windows
were used to minimize crosstalk between isotopes.
One hour aer the 99mTc-sestamibi injection, the
SPECT/CT acquisition was started (Symbia T; Siemens).
SPECT data were acquired in a step-and-shoot sequence
with a noncircular orbit (180∘ detector con�guration; low-
energy, parallel-hole, high-resolution collimators; 128 ×
128 matrix; 4.8mm pixel size; 48 views for each detector
(3,75∘ per projection); 33 s/projection; total scan time,
32min). All data were collected in dual-energy windows.
e 99mTc window was centered at 140 keV and had a
15% width (range, 129.5–150.5 keV). e 123I window was
placed with a 4% oﬀset above 159 keV and had a 15%
width (range, 153.4–177.3 keV). e 4% oﬀset was used to
minimize the spillover of the 99mTc photopeak into the 123I
photopeak. Aer the SPECT acquisition was complete, the
patient remained still on the table for the CT acquisition.
A topogram scout scan (130 kVp, 30mA, anterior view)
was performed �rst, and limits for the CT acquisition were
set (from the neck to the diaphragm). en, a helical CT
scan was performed (130 kVp, 2 × 2.5mm collimation, 0.8 s
rotation time, 1.5 pitch). e dose was controlled by tube-
current modulation (CARE Dose AEC+DOM; Siemens),
with the reference exposure set to 30mAs.
Finally, a static 10-minute anterior image of the neck
and chest was acquired using a low-energy, high-resolution
collimator with a Siemens Symbia T-gamma camera (256 ×
256 matrix; 1.85x zoom (32.2 cm �eld)). e same energy
settings as those in the SPECT acquisition were used. Eleven
of the patients did not complete this �nal image due to limited
camera time or patient-related reasons. A 99mTc intrinsic
�ood was used for both energy windows in both cameras. It
was veri�ed that the image-�eld uniformity was acceptable
for all energy windows used.
2.3. Image Processing. All planar images were analyzed in a
Hermes workstation (Hermes Medical Solutions). For dual-
tracer images, a normalization factor (NF) was de�ned as
the ratio of the thyroid maximum pixel counts in the 123I
and 99mTc-sestamibi images. Gradient subtraction images
were created by multiplying the 99mTc-sestamibi image with
10 successive NFs (with 20% steps from 20% to 200% of
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Starting time
Acquisition
Image set
Planar AP
LEHR collimator
10-minute image
Planar AP
pinhole collimator
10-minute image
SPECT/CT
LEHR collimator
33-minute acq.
Planar AP
LEHR collimator
10-minute image
1
Raw data 123I99mTc-MIBI
Processing
2 34 5
123I99mTc-MIBI
123I/CT99mTc-MIBI/CT 99mTc-MIBI
10 min 20 min
99mTc-
reconstruction
123I-
reconstruction
99mTc-123I
normalization
and
subtraction
99mTc-123I
normalization
and
subtraction 99mTc-123I
1 h 1 h 35 min
normalization and subtraction
F 1: e orders and the timings of the acquisitions and the resulting image sets. Set 1: 99mTc-sestamibi, 123I, and subtraction images
with parallel-hole collimator. Set 2: 99mTc-sestamibi, 123I, and subtraction images with pinhole collimator. Set 3: 99mTc-sestamibi double phase
images with parallel-hole collimator. Set 4: 99mTc-sestamibi SPECT/CT. Set 5: 99mTc-sestamibi, 123I, and subtraction SPECT/CT images.
the original NF), and the 123I image was subtracted from
each normalized 99mTc-sestamibi image, resulting in 10
subtraction images to avoid oversubtraction [9, 10]. e
�nal image sets consisted of 99mTc-sestamibi and 123I images
and gradient subtraction images (image set 1 acquired with
LEHR, image set 2 with pinhole). 99mTc-sestamibi early- and
late-phase images were displayed side-by-side on the Hermes
workstation (image set 3).
SPECT images were reconstructed on the Siemens Syngo
workstation (Siemens) using the FLASH 3D algorithm (8
iterations, 8 subsets, �aussian 9.00 �lter). No scatter cor-
rection was used. e initial NF was de�ned as the ratio of
the corresponding thyroid maximum voxel counts in 99mTc-
sestamibi and 123I SPECT data. 123I SPECT data were multi-
plied byNF to create normalized 123I SPECTdata, whichwere
then subtracted from 99mTc-sestamibi SPECT data to create
the subtraction SPECT dataset, as described by Neumann
and coworkers [4].e NF was adjusted until the subtraction
SPECT images were subjectively satisfactory. CT data were
reconstructed on the Siemens Syngo workstation (Siemens)
for attenuation correction using the B08s kernel, and for
fusion display purposes with a B40s medium kernel. e
CT images were downsampled to match the SPECT image
matrix and converted from Houns�eld units into e�ective
attenuation values at 140 keV (99mTc) and 159 keV (123I).
e �nal image sets consisted of 99mTc-sestamibi SPECT/CT
data (image set 4) and 123I, 99mTc-sestamibi, and subtraction
SPECT/CTdata (image set 5).e accuracy of the SPECT/CT
data coregistration was checked. All image processing was
performed by an experienced medical physicist.
2.4. Image Interpretation. All patient image datasets were
anonymized before review by four experienced nuclear
medicine physicians, who were blinded to all patient-related
information. Five image sets (Figure 1) were reviewed.
Datasets 1, 2, and 3 were read in separate reading sessions.
Image sets 4 and 5 were reviewed in a single session in
this order, with the physician being aware that the datasets
belonged to the same patient.
Each quadrant in relation to the thyroid gland (right
upper, right lower, le� upper, and le� lower) was classi�ed on
a 3-point scale (0 = negative, 1 = uncertain, and 2 = positive).
e image review criteria for positive �nding were as follows:
(a) for image sets 1 and 2: clear abnormal residual activity
on the planar subtraction images, (b) for image set 3: focally
increased uptake that persisted or increased in intensity from
early to late images, (c) for image set 4: focally increased
uptake outside the normal 99mTc-sestamibi biodistribution
that had an anatomic correlation in the CT images, and
(d) for image set 5: clear abnormal residual activity on the
subtraction SPECT images that had an anatomic correlation
in the CT images.
2.5. Surgery and Histologic Analysis. All patients were oper-
ated upon by an endocrine surgeon using an open technique.
e surgeon was aware of all initial scintigraphic results prior
to surgery. All glands were not identi�ed for all patients.
Postoperative iPTH and Ca values were reviewed to con�rm
surgery success.emean interval between scintigraphy and
surgery was 181 days (range, 29–457 days). A histopatholog-
ical analysis was performed for all excised tissue.
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2.6. Data Analysis. To estimate the sensitivity, speci�city, and
accuracy for the localization for each image set, scores of 0-
1 were considered negative and scores of 2 were considered
positive. Findings were classi�ed as true positive, false posi-
tive, true negative, or false negative with histologic analysis as
the reference standard. For each patient, four scores, one for
each quadrant, were assigned. e false-positive image rate
was de�ned as the ratio of false positives to the sum of true
positives plus false positives [11].
2.7. Statistical Methods. e sensitivity, speci�city, and accu-
racy of each image set were calculated for each physician
separately. A McNemar test was performed to compare the
sensitivities, speci�cities, and accuracies between the image
sets.e results from physician 1 were chosen when compar-
ing the image sets, as he had the most experience with the
imaging methods and techniques used. e Mann-Whitney
𝑈𝑈 nonparametric test was used to compare the size of the
visualized and nonvisualized glands. A McNemar test was
also used to analyze the accuracy of the diﬀerent physicians.
e diﬀerences for each method/technique were analyzed
separately. 𝜅𝜅 coeﬃcients were used to quantify the agreement
between the results from the four physicians. Positive kappa
values within the ranges of 0.01–0.20, 0.21–0.4, 0.41–0.60,
0.61–0.80, and 0.81–1.00 were interpreted as “very weak,”
“weak,” “medium,” “good,” and “very good” agreement,
respectively [12]. A 𝑃𝑃 value <0.05 was considered statistically
signi�cant. Statistical analyses were conducted using SAS
9.2 (SAS Institute Inc., Cary, NC, USA) and SPSS statistical
analysis soware (SPSS Inc., Chicago, IL, USA).
3. Results
3.1. Histological Findings. Altogether, 30 enlarged glands
were found in 24 patients. Twenty patients had a solitary
parathyroid adenoma, two patients had double adenomas,
and two patients had multiglandular disease. e mean
weight of the abnormal parathyroid glands was 677mg
(weight information was not available for four glands).
e postoperative serum Ca values were normalized for
all patients. e postoperative iPTH values were normalized
for 17 patients. For 7 patients, these values were slightly
elevated (ranged from 80 ng/L to 134 ng/L (mean 90 ng/L),
but decreased from the preoperative values (ranged from
138 ng/L to 400 ng/L (mean 165 ng/L)). Four glands were
visualized in the operation for these patients.
e pathological �ndings together with the image �nd-
ings for physician 1 are listed in Table 1.
3.2. 99𝑚𝑚𝑇𝑇c-Sestamibi versus 123I/99𝑚𝑚𝑇𝑇c-Sestamibi. All image
sets with 123I/99mTc-sestamibi were signi�cantly more sensi-
tive than any image set with 99mTc-sestamibi, regardless of
the acquisition technique (Tables 2 and 3). 99mTc-sestamibi
SPECT/CT (image set 4) had the highest speci�city (100%),
as there were no false-positive readings (Table 2).
99mTc-sestamibi SPECT/CT revealed only 4 abnormal
glands, while 123I/99mTc-sestamibi subtraction SPECT/CT
revealed 23 abnormal glands (Table 1). A representative
patient case is shown in Figure 2.
3.3. Planar AP with LEHR versus Planar AP with Pinhole
versus SPECT/CT. ere was no diﬀerence in the sensitivity,
speci�city, or accuracy between the acquisition techniques
using 99mTc-sestamibi alone. ere was also no diﬀerence in
the sensitivity, speci�city, or accuracy between the acquisi-
tion techniques using 123I/99mTc-sestamibi (Tables 2 and 3).
Although there was no diﬀerence in the sensitivity,
SPECT/CTmay oﬀer invaluable three-dimensional informa-
tion about the location of the enlarged parathyroid adenomas
together with anatomical information (Figure 3).
3.4. False-Positive Findings. Ten patients had 12 diﬀerent
false-positive �ndings (40 false-positive �ndings if all physi-
cians and image sets are summed up). e false-positive
�ndings are presented in Table 4.
Four of these were due to cold thyroid nodules in 123I
images, causing erroneous interpretation in the subtraction
image (Figure 4). Uneven 123I uptake caused thus 55% of all
false-positive �ndings.
One patient had clear uptake in the 99mTc-sestamibi
image below the thyroid as seen in planar images. All
physicians interpreted this as a positive �nding in the planar
images. In the SPECT/CT images, it was revealed that the
uptake was in the cervical vertebra (Figure 5). is bone
uptake caused 20% of all false-positive �ndings.
ree false positive �ndings were due to the “edge eﬀect”
in 123I/99mTc-sestamibi subtraction SPECT/CT images
(residual activity around the thyroid lobes aer subtraction).
is artefact caused 10% of all false-positive �ndings.
Four positive �ndings were caused by an error in image
interpretation, mainly in double phase 99mTc-sestamibi
images. Diﬃculty in setting the line between the positive and
the negative �ndings caused 15% of all false-positive �ndings.
As seen in Table 4, 123I/99mTc-sestamibi dual-tracer
method with various acquisition techniques produced 90%
of all false-positive �ndings. Subtraction SPECT/CT yielded
the lowest percentage of false positives when compared to
the other subtraction methods. e double phase 99mTc-
sestamibi method produced only 10% of all false-positive
�ndings. e false-positive image rate (%) is presented in
Table 5.
3.5. False-Negative Findings. ere was only one abnormal
parathyroid gland (number 10, Table 1) that was visual-
ized in all image sets and by all of the physicians. us
23 patients had 29 diﬀerent false-negative �ndings (267
false-negative �ndings if all physicians and image sets are
summed up). 99mTc-sestamibi/123I subtraction planar images
with parallel-hole collimator produced 13.9% of all false-
negative �ndings, 99mTc-sestamibi/123I subtraction planar
images with pinhole collimator produced 9.7% of all false-
negative �ndings, 99mTc-sestamibi double phase images with
parallel-hole collimator produced 22.8% of all false-negative
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T 1: Number of adenomas and hyperplastic glands and image �ndings for physician 1.
Patient number Gland number Weight (mg) Findings for image set
1 2 3 4 5
1 1 170 FN FN NA FN FN
1 2 570 TP TP NA FN TP
2 3 980 TP TP FN FN TP
3 4 830 TP TP FN TP TP
4 5 1280 TP TP FN FN TP
4 6 840 TP FN FN FN TP
4 7 2140 TP TP FN FN TP
5 8 NA TP TP NA FN TP
6 9 1200 TP TP NA FN TP
7 10 960 TP TP TP TP TP
8 11 1880 TP TP TP FN TP
9 12 1160 FN TP FN FN FN
10 13 299 TP TP FN FN TP
11 14 200 FN FN FN FN FN
12 15 260 TP TP FN FN TP
13 16 570 TP TP TP TP TP
14 17 370 TP TP FN FN TP
15 18 300 TP FN NA FN FN
15 19 400 TP TP NA FN TP
15 20 NA TP TP NA FN TP
16 21 510 TP TP NA FN TP
17 22 340 TP TP FN FN TP
18 23 NA TP TP TP FN TP
19 24 420 FN FN TP FN FN
20 25 300 FN TP NA FN FN
20 26 NA TP TP NA FN TP
21 27 520 TP TP NA FN TP
22 28 400 TP TP FN FN TP
23 29 550 TP TP TP TP TP
24 30 160 FN FN FN FN FN
TP: true positive for abnormal parathyroid gland; FN: false negative for abnormal parathyroid gland; NA: image set not available for patient.
(a) (b)
F 2: 99mTc-sestamibi SPECT (a) and 123I/99mTc-sestamibi subtraction SPECT (b) coronal images for a 34-year-old man with secondary
hyperparathyroidism. ree hyperplastic parathyroid glands not visualized in coronal 99mTc-sestamibi image are clearly visible in the
subtraction SPECT coronal image (b).
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T 2: Sensitivity, speci�city, and accuracy for localization of abnormal parathyroid glands.
Image set Physician Sensitivity (%) Speci�city (%) Accuracy (%)
1
1 80.0 93.9 89.6
2 70.0 95.5 87.5
3 63.3 97.0 86.5
4 63.3 97.0 86.5
2
1 80.0 92.4 88.5
2 80.0 93.9 89.6
3 76.7 95.5 89.6
4 76.7 95.5 89.6
3
1 31.6 93.9 76.5
2 21.1 98.0 76.5
3 10.5 100.0 75.0
4 15.8 100.0 76.5
4
1 13.3 100.0 72.9
2 16.7 100.0 74.0
3 10.0 100.0 71.9
4 10.0 100.0 71.9
5
1 76.7 92.4 87.5
2 76.7 95.5 89.6
3 56.7 98.5 85.4
4 63.3 98.5 87.5
T 3: Statistical signi�cance for di�erences in sensitivity, speci�city, and accuracy for comparisons of image sets for physician 1.
Compared image sets 𝑃𝑃 for sensitivity 𝑃𝑃 for speci�city 𝑃𝑃 for accuracy
1 versus 2 NS NS NS
1 versus 3 0.0117 NS 0.0352
1 versus 4 1.907𝐸𝐸 𝐸 0𝐸 0.0455 0.0015
1 versus 5 NS NS NS
2 versus 3 0.0117 NS NS
2 versus 4 1.907𝐸𝐸 𝐸 0𝐸 0.0253 0.0041
2 versus 5 NS NS NS
3 versus 4 NS NS NS
3 versus 5 0.0117 NS NS
4 versus 5 3.815𝐸𝐸 𝐸 0𝐸 0.0253 0.0066
NS: not signi�cant.
�ndings, 99mTc-sestamibi SPECT/CT produced 39.3% of all
false-negative �ndings, and 99mTc-sestamibi/123I subtraction
SPECT/CT produced 14.2% of all false-negative �ndings (all
physicians and all image sets are summed up).
e smallest gland located in this series was 260mg.
ere were three smaller abnormal parathyroid glands
(160mg, 170mg, and 200mg) that could not be located with
any method or imaging technique by any of the physicians.
e mean gland size of false-negative and true-positive
�ndings for all physicians and image sets are presented in
Table 6 together with the statistical signi�cance.
3.6. Interobserver Variability. e 𝜅𝜅 coeﬃcient for the agree-
ment of the results between the four physicians for the �ve
study readings are shown in Table 7.
e highest agreement for accuracy was found for 99mTc-
sestamibi SPECT/CT, which did not have any false-positive
�ndings for any physician. e highest agreement for sen-
sitivity was found for the planar subtraction images of
123I/99mTc-sestamibi with the pinhole collimator.
4. Discussion
Our results clearly show that a dual-tracer method with
99mTc-sestamibi and 123I is superior to a single-tracermethod
with 99mTc-sestamibi for PS, regardless of the acquisition
technique used. is has been proposed by other authors as
well [4, 9, 13, 14].
To our �nowledge, this is the �rst study comparing planar
imaging with parallel-hole and pinhole collimators using the
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T 4: �e false-positive �ndings for all physicians.
Image set 1 2 3 5
Reason for FP % of FP
Patient number Physician Physician Physician Physician
1 2 3 4 1 2 3 4 1 2 3 4 1 2 3 4
2 RL RL
Uneven iodine uptake 553 RL RL RL RL RL RL RL RL RL RL
8 RU RU
22 RU RU RU RU RU RU RU RU
20 RL RL RL RL RL RL RL RL Bone uptake 20
4 LL
Edge eﬀect 1010 LL
24 RU RU
24 LL
Other 1524 RL RL RL
13 LU
19 LL
% of FP 27.5 37.5 10 25
FP: false positive, RU: right upper, RL: right lower, LU: le upper, and LL: le lower.
(a) (b) (c)
F 3:A 99mTc-sestamibi uptake in a parathyroid adenoma located behind the trachea. 123I/99mTc-sestamibi subtraction SPECT/CT images
(transversal (a), sagittal (b), and coronal (c)).
(a) (b) (c)
F 4: A cold nodule in the upper quadrant of a right thyroid lobe in the 123I image (b) causing a false-positive �nding in the subtraction
image (c).
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(a) (b) (c)
(d) (e) (f)
F 5: A 99mTc-sestamibi focal uptake inferior to the thyroid seen in the anterior image acquiredwith a pinhole collimator. 99mTc-sestamibi
(a), 123I (b), and subtraction image (c). All physicians interpreted this uptake as an abnormal parathyroid gland. e same patient seen in
123I/99mTc-sestamibi subtraction SPECT/CT images (transversal (d), sagittal (e), and coronal (f)). Focal uptake was due to bone uptake in the
cervical vertebra.
T 5: e false-positive image rate (%) for each image set and each physician.
Physician False-positive rate (%) for image set
1 2 3 4 5
1 14.3 17.2 33.3 0.0 17.9
2 12.5 14.3 20.0 0.0 11.5
3 9.5 11.5 0.0 0.0 5.6
4 2.1 3.1 0.0 0.0 1.0
Average 9.6 11.5 13.3 0.0 9.0
T 6: e mean gland size of false-negative and true-positive �ndings for all physicians and all image sets.
Image set
1 2 3 4 5
Smallest gland visualized 260 260 420 550 260
Mean weight of FN (mg) 300 420 485 420 300
Mean weight of TP (mg) 560 570 960 830 560
𝑃𝑃 (FN versus TP) 0.002 <0.001 0.046 0.026 <0.001
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T 7: e comparison of reader agreement (accuracy and sensitivity) between physicians.
𝜅𝜅 coeﬃcient for Physicians Image set
1 2 3 4 5
Accuracy
1 versus 4 0.56 0.84 0.67 0.97 0.62
1 versus 3 0.56 0.84 0.72 0.97 0.56
1 versus 2 0.69 0.84 0.59 0.92 0.69
4 versus 3 1.00 1.00 0.96 1.00 0.91
4 versus 2 0.86 0.78 0.84 0.89 0.59
3 versus 2 0.86 0.78 0.88 0.89 0.53
Sensitivity
1 versus 4 0.44 0.90 0.30 0.84 0.69
1 versus 3 0.44 0.90 0.41 0.84 0.57
1 versus 2 0.56 1.00 0.20 0.61 0.81
4 versus 3 1.00 1.00 0.77 1.00 0.86
4 versus 2 0.85 0.90 0.48 0.43 0.69
3 versus 2 0.85 0.90 0.61 0.43 0.57
123I/99mTc-sestamibi subtraction method with patients. We
could not demonstrate the improved sensitivity from the use
of the pinhole collimator that has been shown by several
authors when using 99mTc-sestamibi [15–20].
SPECT alone has been shown to improve sensitivity
compared with planar imaging with parallel-hole collimators
[6, 21–24]. SPECT/CT has been shown to oﬀer precise
anatomical localization and an improvement in diagnostic
speci�city and accuracy over conventional SPECT, especially
for patients with previous neck surgery or multiglandular
disease [5, 25–32]. e use of SPECT/CT also shortens
surgical times (when compared with SPECT alone) and
eventually lowers costs [33, 34]. Opposite opinions have also
been presented, and the use of SPECT/CT has been found to
be important only for locating ectopic parathyroid adenomas
[35, 36].
We could not demonstrate an increased sensitivity for
123I/99mTc-sestamibi subtraction SPECT/CT when com-
pared with planar 99mTc-sestamibi/123I subtraction image
sets. However, the use of 123I/99mTc-sestamibi SPECT/CT
decreased the false-positive rate for three observers when
compared with planar 123I/99mTc-sestamibi image sets.
e low sensitivity of double phase planar 99mTc-
sestamibi or 99mTc-sestamibi SPECT/CT cannot be explained
by the rapid washout of 99mTc-sestamibi, as 19 enlarged
parathyroid glands were visible in 123I/99mTc-sestamibi
SPECT/CT images that could not be visualized with 99mTc-
sestamibi SPECT/CT. A low sensitivity for a single tracer or
the double phase protocols has also been reported by other
authors [3, 37].
e low sensitivity of the 99mTc-sestamibi SPECT/CT in
this study could not be linked to the timing of the acquisi-
tion. SPECT acquisition was started approximately one hour
aer 99mTc-sestamibi injection. Lavely and coworkers were
able to demonstrate much better sensitivity for early-phase
SPECT/CT (62%) and also for early planar/delayed planar
imaging (56,5%) [5]. e timing of their early planar and
SPECT/CT acquisitions was almost identical to ours.
Our results for the 123I/99mTc-sestamibi subtraction
SPECT/CT are comparable to the results of Neumann and
coworkers [26], who demonstrated a sensitivity of 70% and
a speci�city of 96% in a group of 61 patients with primary
hyperparathyroidism.e increase of speci�city (when com-
pared with SPECT alone) was explained by reducing the
number of false positives.
ere were three abnormal parathyroid glands that were
visible in 123I/99mTc-sestamibi subtraction planar images
(with a parallel-hole or a pinhole collimator) but not visible
in 123I/99mTc-sestamibi subtraction SPECT/CT. is could
be due to rapid washout [38] as SPECT/CT was performed
one hour later than the planar images were acquired. us,
the timing of the various acquisitions should be considered
carefully, and SPECT/CT should be performed in the early
phase so as not to miss abnormal parathyroid gland(s) with
rapid washout [10].
e average false-positive rate was comparable to previ-
ous reports [6, 11]. In this retrospective study, the �ve image
sets were not reviewed together, which is normally done in
our clinical scenario. With careful observation of the 123I
images of the thyroid, it should be possible to decrease the
false-positive rate in subtraction images.
It seems that a major factor in�uencing detection of
abnormal parathyroid glands is their size. e diﬀerence of
mean gland size of false-negative and true-positive �ndings
was statistically signi�cant for all protocols used in this study.
ere was lower number of ectopic glands in this patient
group than could be expected [39]. ere might have been
small ectopic glands which were not recognized in scintig-
raphy or in surgery. is might explain the slightly elevated
iPTH values for 7 patients.
Several imaging protocols for PS with 99mTc-sestamibi
are in use, with a wide range of sensitivities (34–100%)
reported [8]. No large study exists that compares the accu-
racy of each [6]. We have shown the superiority of the
123I/99mTc-sestamibi subtraction method of PS. e high
popularity of the single-tracer method with 99mTc-sestamibi
alone can only be explained by its technical simplicity. It
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is true that the 123I/99mTc-sestamibi subtraction method,
especially SPECT/CT, is technically demanding. ere are
several possible sources of artifacts, such as scaling and
the subtraction process. In our opinion, the data processing
should be performed by an experienced medical physicist.
Even optimal processing of identical 99mTc and 123I
targets does not give �awless subtraction image, some activity
is always le around the edges. In this series, it was in few
cases interpreted as a positive �nding. To our knowledge, this
artefact has not been described earlier concerning parathy-
roid scintigraphy [40].
e overall interobserver agreement in this study was
good. e average 𝜅𝜅 coeﬃcient was 0.79 for accuracy and
0.70 for sensitivity. ese results are comparable to previous
results [12, 15].
One of the main limitations of this study is the number
of patients in the image set 3 (99mTc-sestamibi double phase
images). Another limitation of our study relates to the fact
that the delay phase was acquired with another gamma cam-
era. However, quality assurance measurements are routinely
performed for both cameras. ere are no diﬀerences in
important parameters regarding image quality.
e clinical PS protocol presented in this study, which
included various acquisitions, is quite time consuming.
e discomfort for the patient should be decreased by
rejecting unnecessary acquisitions. is study indicates
that the 123I/99mTc-sestamibi subtraction method combined
with any imaging technique is adequate to locate abnor-
mal parathyroid glands. However, 123I/99mTc-sestamibi sub-
traction SPECT/CT is recommended because it provides
accurate three-dimensional information about the location
of enlarged parathyroid adenomas together with anatom-
ical information (Figure 3) and may in�uence the surgi-
cal approach [14]. With SPECT/CT, it is also possible to
avoid some false-positive �ndings resulting from the 99mTc-
sestamibi uptake in bone structures. e additional use of
anterior pinhole images may be useful for recognizing cold
thyroid nodules and thus further reducing the false-positive
rate. Determining the optimal technical aspects (acquisition
and processing parameters, various physical corrections) still
requires further study.
5. Conclusion
e results of this study show that the 123I/99mTc-sestamibi
subtraction method combined with any imaging tech-
nique is superior for enlarged parathyroid gland local-
ization when compared with 99mTc-sestamibi alone with
any acquisition technique. 123I/99mTc-sestamibi subtraction
SPECT/CT is recommended because it provides accu-
rate three-dimensional information about the location of
enlarged parathyroid adenomas. e use of anterior pinhole
images may be useful for recognizing cold thyroid nodules
and thus reducing the false-positive rate.e overall interob-
server agreement for accuracy and for sensitivity in this study
was good. us the parathyroid scintigraphy is independent
of the reporter.
ere are two limitations that need to be acknowledged
regarding this study. e �rst limitation is the number of
patients in the 99mTc-sestamibi double phase group. Another
limitation relates to the fact that the delay phase was acquired
with another gamma camera.
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ABSTRACT 
Purpose: Tc-99m-sestamibi/I-123 subtraction SPECT/CT is a modern protocol for localization 
of parathyroid adenomas. This retrospective study evaluated whether the use of additional 
anterior Tc-99m-sestamibi/I-123 pinhole imaging improves the outcome of Tc-99m-
sestamibi/I-123 subtraction SPECT/CT in parathyroid scintigraphy (PS). 
Materials and Methods: PS using simultaneous dual isotope subtraction methods with Tc-
99m-sestamibi and I-123 and an acquisition protocol combining SPECT/CT and planar 
pinhole imaging was performed between March 2011 and June 2016 for 175 patients with 
primary or secondary hyperparathyroidism. All patients who proceeded to surgery with 
complete post-surgery laboratory findings were included in this study. SPECT/CT images 
alone and combined with pinhole images were evaluated. 
Results: There were 111 adenomas of which 104 and 108 adenomas were correctly 
visualized by SPECT/CT (7 false positive) or SPECT/CT with pinhole (3 false positive), 
respectively. Both sensitivity and specificity were higher with combined SPECT/CT with 
pinhole than with SPECT/CT alone (97% vs. 94% and 99% vs. 98%, respectively, not 
significant). The false-positive rate was 6% with SPECT/CT and decreased to 3% using 
combined SPECT/CT with pinhole. 
Conclusion: Tc-99m-sestamibi/I-123 subtraction SPECT/CT is a highly sensitive and specific 
protocol for PS. The use of additional anterior pinhole imaging increases both sensitivity and 
specificity of PS, although this increase is not statistically significant. Given the low cost and 
time required for this additional imaging with no additional radiation dose to the patient, 
we feel that the use of this additional pinhole imaging is justified to achieve the highest 
possible sensitivity and specificity for each patient to avoid reoperation. 
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Primary hyperparathyroidism is a common endocrine disorder caused by one or more 
hyperfunctioning parathyroid glands. Hyperfunctioning parathyroid glands secrete excess 
amounts of parathyroid hormone, which raises the blood calcium level. Secondary 
hyperparathyroidism, which is most commonly seen in patients with chronic kidney failure, 
refers to parathyroid gland hyperfunction in response to low blood calcium levels. Patient 
symptoms and laboratory findings contribute to identifying candidates for surgery, which is 
the only curative treatment for these indications (1). 
Preoperative localization of hyperfunctioning parathyroid glands is highly recommended to 
define surgical strategy, select patients for minimally invasive surgery, and reduce the rate 
of surgical conversion or failure. Imaging protocols should effectively provide morphologic 
and functional information in a noninvasive and cost effective manner (2). 
Today, scintigraphic imaging is usually performed using the dual-phase method, where only 
Tc-99m-sestamibi is used with early and late phase acquisitions. This method is based on the 
assumption that the kinetics of Tc-99m-sestamibi is different in thyroid and parathyroid 
glands, thereby revealing hyperfunctioning parathyroid glands in late phase images. This 
dual-phase method is attractive for its technical simplicity and low cost (3). Unfortunately, 
this technique has limits for detecting parathyroid adenomas with rapid Tc-99m-sestamibi 
clearance and low sensitivity for localizing multiple parathyroid glands due to parathyroid 
hyperplasia or differentiating thyroid nodules from parathyroid lesions (4). 
 
These pitfalls can be avoided with more technically demanding dual-isotope subtraction 
methods with I-123 and Tc-99m-sestamibi. Thyroid-seeking I-123 is acquired simultaneously 
with Tc-99m-sestamibi, and normalized I-123 images are subtracted from Tc-99m-sestamibi 
images. Residual activity in subtraction images reveals hyperfunctioning parathyroid glands. 
The advantages of this method have been shown in several recent studies, and it is also 
recommended in the European Association of Nuclear Medicine (EANM) guidelines (5-10).  
 
Several acquisition techniques can be used with each method. Both planar imaging (with 
parallel hole or pinhole collimators) and three-dimensional (3D) imaging (SPECT and 
SPECT/CT) are widely used. Although the trend is towards using 3D acquisition techniques, 
pinhole imaging remains a recommended part of any parathyroid imaging protocol and it is 
still considered superior owing to its much higher spatial resolution (9-14). 
 
However, pinhole imaging lacks the 3D anatomical information offered by modern SPECT/CT 
imaging which may be very helpful in planning the surgical approach and even in shortening 
surgical times (4, 14, 15). These techniques are often combined in clinical practice to 
increase sensitivity (3, 12, 16, 17). 
 
It would be tempting to simplify the parathyroid imaging protocol using only SPECT/CT 
imaging, but this would have to be performed without compromising on sensitivity or 
  
specificity. Some preliminary results have already been published using the dual-isotope 
method where SPECT/CT results were equivalent or even better than pinhole (7, 11, 18). 
However, contrasting data showing pinhole imaging alone yielded better results than 
SPECT/CT alone or even combined with pinhole have been reported (13). 
 
The aim of this study was to compare two protocols for parathyroid scintigraphy in the same 
patients with primary or secondary hyperparathyroidism: Tc-99m-sestamibi/I-123 
subtraction SPECT/CT alone or combined with additional pinhole imaging. 
 
PATIENTS AND METHODS 
Patients 
From March 2011 through June 2016, 175 patients were referred for parathyroid 
scintigraphy. All patients had biochemical evidence of hyperparathyroidism (elevated total 
serum calcium (Ca-ion) and parathyroid hormone level [PTH]). From this original cohort, 
patient data were included in this retrospective study if the patient proceeded to surgery 
and if post-operative Ca-ion and PTH results were available. Surgical and histopathological 
findings with post-operative Ca-ion and PTH levels were used as the gold standard. 
The final study group consisted of 94 patients (27 men and 67 women) with a mean age of 
64.0 years (range, 22.3–83.6 years). Of these, 84 patients had primary hyperparathyroidism 
(pHPT), and 10 had secondary hyperparathyroidism (sHPT). This study was exempt from 
approval by the institutional review board. The requirement for informed consent was 
waived. 
Parathyroid Scintigraphy Protocols 
Patients received 20 MBq (0.54 mCi) of I-123 intravenously. Two hours later, 750 MBq (20.3 
mCi) of Tc-99m-sestamibi was injected. SPECT/CT acquisition was started 10 minutes after 
the Tc-99m-sestamibi administration. All SPECT/CT acquisitions were performed with 
Siemens Symbia T or Siemens Intevo T2 imaging systems (Siemens, Erlangen, Germany). 
Immediately after the SPECT/CT acquisition, a static pinhole image of the neck was acquired 
with a SKYLight gamma camera (Philips Healthcare, USA) or with Siemens Symbia or Intevo 
T2 systems (Siemens, Erlangen, Germany) beginning in 2015. All acquisition parameters are 
shown in Table 1. 
  
  
TABLE 1. Acquisition parameters for SPECT/CT and pinhole imaging 
 
Acquisition Parameter SPECT/CT Pinhole 
Detector Configuration 180 - 
Orbit Body-contour - 
Distance from the patient skin - 10cm 
Collimators LEHR Pinhole, 5mm opening 
Matrix 128128 matrix 256256 
Zoom 1 2,19 
Pixel Size 4.8 mm  
Acquisition Mode Step-and-Shoot Static 
Views Over 360 96 (3,75 per projection) - 
Time Per Projection or Frame 33 s 10 min 
Energy Windows 
140 keV 10% 
167 keV 10% 
140 keV 10% 
167 keV 10% 
Voltage 130kVp - 
Collimation 22.5 mm - 
Rotation Time 0.8 s, - 
Pitch 1,5 - 
Dose Modulation CARE Dose AEC+DOM - 
Reference Exposure 80 mAs - 
 
Surgery and histologic analysis 
An endocrine surgeon performed all operations and was aware of all initial scintigraphic 
results prior to surgery. The mean interval between scintigraphy and surgery was 164 days 
(range, 8–1065 days). Histopathological analysis was performed on all excised tissue. 
Image processing 
Tc-99m-sestamibi and I-123 SPECT images (with attenuation correction) were anonymized 
and reconstructed on the Siemens Syngo workstation using the FLASH 3D-algorithm (8 
iterations, 8 subsets, Gaussian 9.00 filter). I-123 SPECT images were multiplied by a 
normalization factor (defined as the ratio of the corresponding thyroid maximum voxel 
counts in Tc-99m-sestamibi and I-123 SPECT images with manual adjustment based on 
visual evaluation, if necessary) to create normalized I-123 SPECT images, that were then 
subtracted from Tc-99m-sestamibi SPECT images. The final image sets consisted of Tc-99m-
sestamibi SPECT images, I-123 SPECT images, and subtraction SPECT images. Images were 
displayed in 3 axes (transverse, coronal, and sagittal) alone, fused together (as I-123 fused 
with subtraction images), or fused with CT images. Static pinhole images were anonymized 
and processed in a Siemens Syngo workstation. Subtraction images were created in a similar 
manner as previously described. The final image set consisted of Tc-99m-sestamibi images, 
  
I-123 images, and subtraction images. All image processing was performed by an 
experienced medical physicist. 
Image Interpretation 
Anonymized imaging data were reviewed for the purpose of this study by an experienced 
nuclear medicine physician who had no previous knowledge of images, patient information, 
or surgery results. The review was performed in two phases: the SPECT/CT data were 
reviewed first and each quadrant in relation to the thyroid gland (right upper, right lower, 
left upper, left lower, other/ectopic) was classified on a 2-point scale (negative or positive). 
The image review criteria for positive finding were as follows: clear abnormal residual 
activity on the subtraction SPECT images that had an anatomic correlation in the CT-images. 
Thereafter, the pinhole images were added next to the SPECT/CT data and images were 
reviewed together again in similar manner. 
To estimate the sensitivity, specificity, and accuracy for the localization for each image set, 
findings were classified as true-positive, false-positive, true-negative, or false-negative with 
histologic analysis and post-operative laboratory findings as the reference standard. For 
each patient, 5 scores, one for each quadrant plus other (referring as ectopic), were 
assigned. The false-positive image rate was defined as the ratio of false-positives to the sum 
of true-positives plus false-positives. 
Statistical Analysis 
The sensitivity, specificity, and accuracy of each image set were calculated. McNemar test 
was performed to compare the sensitivities, specificities, and accuracies between the two 
image sets. A p-value less than 0.05 was considered statistically significant. Statistical 
analyses were conducted using SPSS v.21 (IBM Corp., Armonk, NY). 
RESULTS 
Surgical and histological findings 
Altogether, 111 enlarged glands were found in 94 patients in surgery. Seventy-nine patients 
had a solitary parathyroid adenoma, 1 had parathyroid carcinoma, 12 had double 
adenomas, and 2 had multiglandular disease (1 with 3 enlarged glands and 1 with 4 
enlarged glands). The mean weight of the abnormal parathyroid glands was 1.42 g (0.07–11 
g). The smallest visible gland was 0.07 g in both image sets. 
Imaging Results 
Tc-99m-sestamibi/I-123 subtraction SPECT/CT was able to locate 104 enlarged glands 
correctly, and missed 7 enlarged glands that were located in surgery. Combined Tc-99m-
sestamibi/I-123 subtraction SPECT/CT with additional pinhole imaging was able to locate 
  
108 enlarged glands and missed 3 enlarged glands. A typical patient case with a true-
positive finding is shown in Figure 1. 
 
FIGURE 1. An example of a true-positive finding with SPECT/CT and with pinhole in primary 
hyperparathyroidism. A, Fusion SPECT/CT images. B, Anterior pinhole images (Left: Tc-99m-
sestamibi image; middle: I-123 image; right: subtraction image). A 230 mg adenoma 
(arrows) was resected behind the lower right quadrant of the thyroid. 
 
 
 
The sensitivity and specificity were slightly higher with SPECT/CT and pinhole combined than 
with SPECT/CT alone, but the difference was not significant. The false-positive rate was 6% 
with SPECT/CT and decreased to 3% with combined SPECT/CT and pinhole. Sensitivity and 
specificity were also calculated separately for patients with sHPT or pHPT. As expected, 
sensitivity was lower for patients with sHPT compared to patients with pHPT. There were no 
false positive findings in patients with sHPT. Results are depicted in Table 2. 
  
  
TABLE 2. Sensitivity and specificity of Tc-99m –sestamibi/I-123 subtraction SPECT/CT 
and combined SPECT/CT with anterior planar pinhole imaging for all patients 
 
Patient group Sensitivity/Specificity SPECT/CT SPECT/CT with pinhole p 
All patients 
Sensitivity 94% 97% NS 
Specificity 98% 99% NS 
Primary hyper-
parathyreosis 
Sensitivity 95% 98% NS 
Specificity 98% 99% NS 
Secondary hyper-
parathyreosis 
Sensitivity 89% 94% NS 
Specificity 100% 100% NS 
 
NS indicates not statistically significant 
False Negative Findings 
Four parathyroid glands were classified falsely as negative with SPECT/CT alone, but they 
were correctly classified as true positive with additional pinhole imaging.  Three parathyroid 
glands were falsely classified as negative in SPECT/CT and were also not visible in pinhole 
images. Two of these were small hyperplastic glands, and 1 was a small atypical adenoma. 
These 3 patients had more than 1 hyperplastic gland or adenoma, and smallest glands were 
not visualized in these cases. 
False Positive Findings 
Four parathyroid glands were classified falsely as positive with SPECT/CT alone, but were 
correctly classified as true-negative with additional pinhole imaging. Two of these were 
owing to uneven iodine uptake, with iodine-negative thyroid nodules more clearly visible in 
pinhole images. Two false-positive findings were subtraction artifacts, not visible in pinhole 
images.  
Three false-positive findings in patients with complex multi-glandular disease that were 
classified with SPECT/CT alone remained falsely classified with the additional pinhole 
imaging. 
Patient 1 had a true-positive adenoma at the upper left quadrant that was attached to a 
large thyroid cyst. There was weak residual activity at the lower left quadrant on both 
SPECT/CT and pinhole imaging classified as positive, but no adenoma was found during 
  
surgery (normal parathyroid gland was seen). There was also a small adenoma at upper 
right quadrant, but it was not visible in either SPECT/CT or pinhole imaging and was 
classified as a false negative. Post-operative Ca-ion and PTH were normalized for this 
patient.  
Patient 2 had 3 positive findings with both SPECT/CT and pinhole imaging. The upper right 
gland (small hyperplastic gland) was removed in surgery and classified as true-positive. 
Lower glands were visualized in surgery but not removed. Post-operative Ca-ion and PTH 
levels were normal. These 2 false-positive findings were classified as subtraction artifacts. 
DISCUSSION 
This retrospective study compared Tc-99m-sestamibi/I-123 –protocols using SPECT/CT alone 
or combined with an additional anterior pinhole image. The results indicate high sensitivity 
and specificity for both protocols. The use of the additional anterior pinhole image with 
SPECT/CT was able to improve both sensitivity and specificity, although the difference was 
not significant. The sensitivity and specificity of Tc-99m-sestamibi/I-123 –protocols using 
SPECT/CT alone or with pinhole imaging were equivalent in 2 recent studies (7, 18). 
However, no comparison to a combination of these protocols was made in either of the 
studies. 
 
Interesting results were published recently by Bhatt and colleagues showing that a Tc-99m-
sestamibi/I-123 pinhole protocol detected more adenomas than the Tc-99m-sestamibi/I-123 
SPECT/CT protocol and missed fewer adenomas than either the Tc-99m-sestamibi/I-123 
SPECT-CT protocol or the combined pinhole and SPECT-CT protocol (13). As Bhatt and 
colleagues suggested, one explanation for this result might be the rapid washout-
phenomena since the SPECT/CT was started 45 minutes after sestamibi injection in 
comparison to 5 minutes in this study. Another explanation could be related to the 
acquisition parameters of the SPECT, since imaging was performed with quite a large 
angular sampling (5.6). SPECT reconstruction parameters could also have had some effect, 
but this possibility cannot be evaluated because the parameters were not published. We 
have seen in our clinical work that reader’s level of experience has a great effect on the 
sensitivity and specificity of Tc-99m-sestamibi/I-123 SPECT/CT. This could possibly have had 
some effect in the study by Bhatt and colleagues, since their study was conducted soon 
after the installation of SPECT/CT and the reader may not have had sufficient time to train 
with the new protocol. 
 
The Importance of Pinhole Imaging 
 
The EANM parathyroid guidelines stated in 2009 that “Although SPECT and SPECT/CT 
imaging are becoming very helpful, they cannot replace the standard planar and “pinhole” 
protocols that are still essential for optimal resolution in the thyroid bed region and for a 
  
correct diagnosis” (10). This is still true, since the spatial resolution of the pinhole collimator 
cannot be reached with any parallel-hole collimator. The highest achievable resolution is 
important especially for detecting the thyroid nodules, especially the Tc-MIBI-Hot/I-123-
Cold phenotype which may indicate thyroid malignancy (19, 20). This phenotype also results 
in false-positive residual activity in subtraction images, which can be easily interpreted as 
parathyroid adenoma. 
The importance of pinhole imaging was also highlighted in this study, as both sensitivity and 
specificity were higher with the combined pinhole protocol although the difference was not 
statistically significant. However, it should be noted that the number of false-positive 
findings decreased to half and 4 more adenomas were correctly localized with the pinhole 
imaging. Although not statistically significant, there was a change in the final outcome of 
this study for 8 patients. The use of the additional pinhole imaging is fast, it does not 
increase the patient radiation dose or add to the total cost of the study. Thus we feel that 
the use of the additional pinhole imaging is justified to gain the highest possible sensitivity 
and specificity for each patient to avoid reoperation. 
The Edge Artifact 
Even optimal processing of Tc-99m and I-123 images does not give a flawless subtraction 
image, but leaves some activity around the edges of thyroid lobes; this activity is called the 
“edge artifact” (7). According to phantom measurements performed in our laboratory, this 
phenomenon could be reduced with careful implementation of acquisition and processing 
parameters, scatter/cross-contamination correction, and collimator selection. However, 
further studies are needed in order to implement this solution in clinical practice. 
False-Negative Findings 
There were only 3 enlarged parathyroid glands that were not visualized even with the 
additional pinhole image. Two of these were small hyperplastic glands, 1 was a small 
adenoma (0.14 g) which was a part of a complicated patient case with a true-positive 
finding, true-negative finding, false-positive finding, and a false-negative finding (the patient 
had a thyroid cyst and a double adenoma). 
False-Positive Findings 
It has been suggested that SPECT/CT is superior to SPECT alone because the specificity of 
SPECT/CT is significantly greater than that of SPECT alone. The false positive rate in this 
study with SPECT/CT was 6% which was in line with a Finnish study (6). 
In addition to multimodality imaging, the use of I-123 and subtraction images fused 
together gives a strong suggestion of the nature of the lesion in subtraction images. Also 
with additional pinhole imaging, we were able to avoid all false-positive findings due to 
iodine-cold nodules in the thyroid. 
 
  
The Effect of Reconstruction 
It has been shown in several publications that there are significant differences in image 
quality between commercially available algorithms and correction methods (21-23). The 
effect of reconstruction parameters were not studied here. To further improve the quality 
of Tc-99m-sestamibi/I-123 SPECT/CT in parathyroid imaging, the final step is to optimize the 
protocol to include reconstruction and the correction methods for scatter, attenuation, 
depth-dependent resolution, and cross-contamination. 
Limitations of the Study 
Three different cameras were used in this study. All SPECT/CT acquisitions were performed 
with Siemens cameras (Symbia/Intevo) and, according to clinical quality control 
measurements, there were no differences in image quality. Pinhole acquisitions were 
performed with older Philips SKYLight with Siemens cameras. According to quality control 
measurements, there was no significant difference in image quality (resolution, sensitivity) 
between these cameras and thus no effect on results. The main bias in this study is probably 
the large variation in the time between scintigraphy and surgery. 
  
CONCLUSION 
This study indicates that Tc-99m-sestamibi/I-123 subtraction SPECT/CT is a highly sensitive 
and specific protocol for parathyroid scintigraphy. The use of additional anterior pinhole 
imaging increases both sensitivity and specificity of parathyroid scintigraphy, although this 
increase is not significant in this cohort. Given the low cost and short time required for 
additional imaging with no added radiation dose to the patient, we believe that the use of 
this additional pinhole imaging is justified to achieve the highest possible sensitivity and 
specificity for each patient to avoid reoperation. 
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Abstract²The purpose of this study was to compare the 
physical characteristics of Low Energy High Resolution 
(LEHR), Low Energy Ultra High Resolution (LEUHR) and 
Medium Energy Low Penetration (MELP) collimators for 
simultaneous 99mTc and 123I imaging. MELP collimator per-
formed well with 123I high-energy gamma photons, but low 
resolution makes it unsuitable to use for acquisition of small 
structures such as parathyroid adenomas. LEUHR collimators 
optimized for 99mTc have highest resolution, but the differences 
in septal penetration and sensitivity in favor of LEHR collima-
tor needs to be tested with specific parathyroid phantoms. 
 
Keywords²dual-isotope, 99mTc, 123I, collimator, SPECT/CT. 
I. INTRODUCTION  
Modern SPECT/CT is a standard clinical tool for various 
nuclear medicine procedures. Clinical work is usually per-
formed with one radiopharmaceutical, but there are some 
applications using simultaneous dual-isotope imaging such 
as parathyroid scintigraphy with 
123
I and 
99m
Tc-sestamibi. 
Simultaneous use of 
99m
Tc and 
123
I is particularly challeng-
ing because of the close proximity of the photon energies 
(140keV and 158keV) and with limited energy resolution of 
a gamma camera. 
Collimator selection for dual-isotope applications is al-
ways a compromise in terms of resolution, sensitivity and 
septal penetration of photons. It has been shown previously 
WKDW³the physical characteristics for 123I imaging and dual-
isotope imaging differ even between low energy collimators 
that provide similar sensitivity and spatial resolution´>@  
The use of medium energy (ME) collimators reduces the 
influence of septal penetration of high-energy gamma pho-
tons of 
123
I. However, ME collimators generally provide 
lower spatial resolution compared to that of low energy 
(LE) collimator, which may influence the detection of small 
structures such as parathyroid adenomas [1,2]. If the LE 
collimator is used to acquire good quality 
99m
Tc images, the 
septal penetration of 
123
I photons may be elevated and im-
age contrast will be degraded [3]. The energy window selec-
tion, the contamination of one radionuclide photon into the 
energy window of the other (cross contamination), energy-
dependent uniformity and sensitivity also need to be exam-
ined [4].  
Several approaches are suggested for simultaneous 
123
I/
99m
Tc-imaging, e.g.: 
1. Using narrow or asymmetric energy windows [5,6]  
2. Using a subtraction method based on a single 
crossover factor [7] 
3. Using a scatter correction method (TEW)  [8] 
4. Using complex and time-consuming model-based 
correction methods [9]. 
The septal penetration of high-energy photons of 
123
I is 
also a potential cause of artefacts. It also effects on 
123
I 
sensitivity as a function of distance, as high-energy photons 
penetrate through the lead into the crystal and behave as 
camera would be without collimator [2]. That is why sug-
gested the physical characteristics should be investigated for 
each camera-collimator system used for dual-isotope imag-
ing [1,3]. 
 The aim of this study was to compare the physical char-
acteristics of Low Energy High Resolution (LEHR), Low 
Energy Ultra High Resolution (LEUHR) and Medium En-
ergy Low Penetration (MELP) collimators for 
99m
Tc and 
123
I 
imaging. 
II. MATERIALS AND METHODS 
A Siemens Symbia Intevo T2 SPECT/CT (Siemens, Er-
langen, Germany) in the Department of Nuclear Medicine 
of Satakunta Central Hospital was used in this study. All 
measurements were performed with three sets of collima-
tors: LEHR, LEUHR and MELP (Table 1). 
Table 1 Collimator specifications according to manufacturer 
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Intrinsic uniformity was measured separately with 
99m
Tc 
and 
123
I according to the quality control routine by Siemens. 
99m
Tc was measured using 140 keV 10% energy window 
and 
123
I was measured using symmetric (158 keV, 10%) and 
asymmetric (167keV, 10%) energy windows. 60 million 
counts were collected for each measurement. 
System sensitivity was measured for each collimator fol-
lowing the NEMA guidelines [10], using a 100mm plastic 
dish into which calibrated activity of (about 37MBq) each 
isotope (
99m
Tc or 
123
I) was instilled. Measurements were 
performed separately for each isotope using the above-
mentioned energy windows with 10 cm distance from the 
collimator surface. Sensitivity was calculated as cpm/µCi. 
System spatial resolution was measured in air with 
99m
Tc 
and 
123
I separately for each collimator following the NEMA 
guidelines [10]. A tube of 1mm inner diameter was filled 
with 
99m
Tc or 
123
I solution and placed at various distances 
from detector surface (0 cm, 10cm, 20 cm, 30cm, and 40 
cm) parallel to the x axis of the camera using non-scattering 
material as a spacer. Images were collected on a 1024x1024 
matrix with above-mentioned energy window settings. 
SPECT spatial resolution and uniformity with scatter 
were measured with Jaszczak phantom with hot spot insert 
(Data Spectrum Corporation, Durham, North Carolina). The 
phantom was filled with 1,5GBq of 
99m
Tc and acquired with 
clinical SPECT/CT acquisition protocol for all collimators 
(a noncircular orbit, 180q detector configuration, 128u128 
matrix; 140 keV 10%, step-and-shoot, 48 views for each 
detector, 33 s/projection).  
The CT acquisition was acquired after the SPECT acqui-
sition without moving the phantom and using the same scan 
area as for SPECT (130 kVp, 2u2.5 mm collimation, 0.8 s 
rotation time, 1.5 pitch, CARE Dose AEC+DOM, with the 
ref. exposure 80 mAs). 
99m
Tc images (with attenuation cor-
rection) were reconstructed on the Siemens Syngo work-
station using the FLASH 3D-algorithm with four different 
parameter settings (6, 8, 16 or 32 iterations, 8 subsets, 
Gaussian 9.00 filter, with TEW scatter correction). 
SPECT spatial resolution was evaluated visually, accord-
ing to the visibility of the hollow channels (12,7mm (1), 
11,1mm (2), 9,5mm (3), 7,9mm (4), 6,4mm (5) and 4,8mm 
(6)). To evaluate uniformity, a large circular ROI was 
drawn in uniform part of the phantom. The percent root 
mean square noise (%RMS) was calculated using the for-
mula: 
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Spectrum for both isotopes was measured in air and with 
scatter separately for each collimator at various distances 
(10cm, 20cm, 30cm and 40cm). Measurements were repeat-
ed also with scatter (5cm water as scattering material) be-
tween the source and the detector. 
Scatter-to-photopeak ±ratio was measured using 99mTc 
and 
123
I point sources of equal activity (80MBq) in air sepa-
rately for each collimator at various distances (10cm, 20cm, 
30cm and 40cm). Photopeak and scatter windows were set 
to 20% (photopeak and scatter windows being equal width 
in keV). Acquisition time per frame for each collimator was 
selected to avoid pixel overflow in any measurement. Uni-
formity correction was set off to avoid any adjustment of 
counts. Background counts were subtracted. Measurements 
were repeated also with scatter (5cm water as scattering 
material) between the source and the detector. 
Cross-contamination was measured using two identical 
1000 ml bottles filled with 
99m
Tc and 
123
I (~40MBq of 
each). A SPECT acquisition was performed with each bottle 
using previously mentioned acquisition protocol with both 
energy window settings and for all collimators. The cross-
contamination was expressed as percentage of 
99m
Tc counts 
in 
123
I window of 
99m
Tc counts in 
99m
Tc window. The 
123
I 
cross-contamination in 
99m
Tc window was calculated in a 
similar manner. 
III. RESULTS 
Integral uniformity at the useful field of view (UFOV) 
with symmetric energy windows were 3,1% and 2,2% with  
99m
Tc and 
123
I, respectively. With asymmetric 
123
I energy 
window the uniformity was 11,9%. 
System sensitivity with 
99m
Tc was well in line with speci-
fications given by Siemens. Sensitivity with 
123
I symmetric 
energy window was higher with low-energy collimators 
compared to sensitivity with 
99m
Tc, which is caused by 
septal penetration of high-energy gamma photons of 
123
I. 
Asymmetric energy window with 
123
I reduced sensitivity 
15,0%-43,2% compared to symmetric energy window. 
System sensitivity results are presented in Table 2. 
Table 2 System sensitivity for LEHR, LEUHR and MELP collimators 
measured with 99mTc and 123I using symmetric and asymmetric energy 
windows. 
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Measured FWHM for was similar for 
99m
Tc and 
123
I. For 
MELP collimator there was no difference in FWTM values 
for 
99m
Tc and 
123
I. For LE collimators, FWTM was larger 
with 
123
I than that with 
99m
Tc.  There was no difference with 
symmetric and asymmetric energy windows for 
123
I. The 
results are presented in Table 3. 
Table 3 System spatial resolution at 20cm for LEHR, LEUHR and MELP 
collimators measured with 99mTc and 123I using symmetric and asymmetric 
energy windows. 
ÁÂÃÃÄÅÆÇÂÈ
ÉÊËÌ ÍÅÅÎ FWTM (mm) 
ÏÏÐTc ÑÒÓI ÏÏÐTc ÑÒÓI 
ÌÔÕÖ ×ØÙÚ ×ÛÙÜ ÚÝÙÝ ÞßÙß
ÕÔËà ××ÙÚ ××Ùá ÞÝÙ× ÞÚÙÝ
ÕÔâËà ÜÙÚ ØÙÛ ×ãÙÜ ×ÛÙÝ
SPECT spatial resolution with MELP collimators was 
inadequate for acquisition of small structures. Only two 
largest channels could be identified. LEHR and LEUHR 
collimators performed better, as channels in sectors 3 and 4 
could be identified, respectively. SPECT uniformity de-
creased with increasing resolution and number of iterations. 
The results are presented in Table 4. 
Table 4 SPECT resolution and uniformity for LEHR, LEUHR and MELP 
collimators measured with 99mTc and 123I using symmetric and asymmetric 
energy windows. 
ä
Ç
å
ÈÆÇÄÂ
æç
Û Ü ×Û ÚÞ 
ÌÔÕÖ
à
åç
ÂÃèÇÄÂ
æ
× × Þ Þ
â
æ
ÄéÂÈÅÄÇê ÍëÈÅ
ç
Î Ú ÚÙÚ ãÙÞ áÙß
ÕÔËà
à
åç
ÂÃèÇÄÂ
æ
Ú Ú Ú Ú
â
æ
ÄéÂÈÅÄÇê ÍëÈÅ
ç
Î ÚÙ× ÚÙã ãÙã áÙÛ
ÕÔâËà
à
åç
ÂÃèÇÄÂ
æ
ã ã ã ã
â
æ
ÄéÂÈÅÄÇê ÍëÈÅ
ç
Î ÚÙá ÚÙß áÙ× ÛÙÞ
The shape of the spectrum in air for 
99m
Tc was similar for 
all collimators and distances. Scattering material increased 
the amount of scatter, but there was no change in the shape 
as a function of distance or between collimators. Spectrum 
for 
123
I in air was different for collimators (Figure 1) and 
also varied as a function of distance (Figure 2). 
Scatter to photopeak ±ratio in air with 99mTc was 13,0%-
14,7% for all collimators and distances. With scatter, the 
ratio increased to 46,8%-49,3%. Distance between the 
source and collimator surface did not have any significant 
effect. Scatter to photopeak ±ratio with 123I was very differ-
ent for all collimators and also as a function of distance 
(Table 5). 
 
 
Figure 1. Spectrum of 123I at 5 cm from detector in air for LEHR (blue), 
LEUHR (red) and MELP (black) collimators. 
 
Figure 2. Spectrum of 123I with LEHR collimator at 5 cm (red), 20cm 
(blue) and 40cm (black) from detector. 
Table 5. Scatter to photopeak ±ratio with 123I for collimators in air and 
with scatter with 10cm, 20cm, 30cm, and 40 cm distance between source 
and collimator surface. 
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Cross-contamination measurements showed similar con-
tamination of 
99m
Tc in 
123
I window for all collimators. 
Asymmetric energy window for 
123
I was reduced to approx-
imately half when using asymmetrical energy window. 
123
I 
contamination in 
99m
Tc window was highest with LEUHR 
collimator and lowest with MELP collimator (Table 6). 
Table 6 Cross-contamination of 99mTc and 123I. 
99Tc-contamination in 1	I contamination in 
1	I symmetric 1	I asymmetric 99Tc 
M
 4    28,3 % 

L 4  2  40,7 % 

L 5  2  50,6 % 
IV. DISCUSSION 
The advantages of dual isotope method with 
99m
Tc-
sestamibi and 
123
I for parathyroid scintigraphy have been 
acknowledged in several studies and is also recommended 
in the European Association of Nuclear Medicine (EANM) 
guideline for parathyroid scintigraphy [11]. Unfortunately 
dual isotope imaging with 
99m
Tc and 
123
I is a challenging 
task. Collimators optimized for 
99m
Tc have problems with 
123
I high energy photon septal penetration. ME collimators 
have less septal penetration, but the resolution is inadequate 
for detecting small structures as shown in this study. 
SPECT acquisitions are performed with elliptical orbit in 
order to gain highest resolution possible. However, as 
shown in this study, both sensitivity and cross contamina-
tion of 
123
I into 
99m
Tc window are dependent on the distance 
between the source and the collimator which degrades the 
quantitative precision. Cross contamination of 
99m
Tc into 
123
I window is low. Although the injected activity of 
123
I in 
clinical study is much lower than the activity of the 
99m
Tc-
sestamibi, the uptake of iodine in the thyroid gland is high-
er. The average activities of 
123
I and 
99m
Tc in the thyroid 
gland are thus comparable and the contamination of 
99m
Tc in 
123
I image is not significant. Shifting the 
123
I window to the 
right decreases the amount of cross contamination and al-
lows for wider scatter window between 
99m
Tc and 
123
I pho-
topeak but in the expense of uniformity. The contamination 
of 
123
I in 
99m
Tc image is much higher regardless of the col-
limator. Shifting the 
99m
Tc window to the left was not tested 
here, as being shown inappropriate previously [2]. 
The most important information in parathyroid scintigra-
phy is in the 
99m
Tc-sestamibi image. The 
123
I image is main-
ly used for removal of the thyroid gland. Although 
99m
Tc 
image is contaminated with 
123
I photons, their spatial distri-
bution is different as parathyroid glands are separated from 
thyroid glands (excluding rare cases of intrathyroidal para-
thyroid glands). High resolution images are thus of high 
importance. 
The choice of the collimator for simultaneous dual-
isotope imaging is a compromise. LEUHR collimator has 
highest spatial resolution, but due to thinner septa the 
123
I 
contamination in 
99m
Tc image is higher. LEHR collimators 
has twice the sensitivity but in the expense of resolution. 
The suitability of both LE collimators for parathyroid imag-
ing needs to be tested with specific phantoms in order to 
resolve the suitability for clinical work. 
V. CONCLUSIONS  
MELP collimator performed well with 
123
I, but low reso-
lution makes it unsuitable to use for acquisition of small 
structures. LEUHR collimators optimized for 
99m
Tc have 
highest resolution, but the small difference in septal pene-
tration in favor of LEHR collimator needs to be tested with 
specific parathyroid phantoms. This study pointed out that 
thorough testing before clinical application is of high im-
portance in order to understand physical limitations of the 
imaging process. 
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Abstract²The purpose of this study was to optimize effec-
tive, but technically challenging 99mTc-sestamibi/123I subtrac-
tion SPECT/CT protocol for parathyroid scintigraphy. An 
anthropomorphic parathyroid phantom was set up using a 
small sphere, a thyroid phantom and a thorax phantom with 
clinical range of activities of 123I and 99mTc. SPECT/CT acqui-
sitions were performed using three collimators (Low Energy 
High Resolution (LEHR), Low Energy Ultra High Resolution 
(LEUHR) and Medium Energy Low Penetration (MELP)) and 
two energy window settings. Images were reconstructed with a 
combination of four different numbers of iterations and with 
or without scatter correction. Images were subjected to visual 
and quantitative evaluation. The effect of collimator, energy 
window selection and reconstruction parameters had a signifi-
cant effect on visual appearance and adenoma contrast in 
parathyroid 99mTc-sestamibi/123I subtraction SPECT/CT. 
Symmetrical energy windows and ultra-high resolution colli-
mator yielded best results with some improvement with scatter 
correction. 
Keywords² parathyroid, SPECT/CT, phantom, optimiza-
tion, dual-isotope. 
I. INTRODUCTION  
The diagnosis of hyperparathyroidism is based on labora-
tory findings, with ionized calcium and parathormone levels 
being elevated. Patient should be referred for parathyroid 
scintigraphy only when above-mentioned diagnostic criteria 
are met. Parathyroid scintigraphy is thus not a diagnostic 
study, but a localization one. Localization of hyperfunction-
ing parathyroid glands before surgery is highly recommend-
ed to define surgical strategy. 
The only tracer available for parathyroid scintigraphy, 
99m
Tc-sestamibi is not parathyroid-specific but taken up also 
by adjacent thyroid tissue. This problem can be solved by 
using either a single isotope (dual-phase) or a dual-isotope 
method. 
The dual-phase method assumes that thyroid and para-
thyroid tissue have different washout kinetics for 
99m
Tc-
sestamibi. By acquiring images immediately after the injec-
tion and 2-3 hours later, the focally increasing uptake will 
reveal hyperfunctioning parathyroid gland. In the dual-
isotope method, 
99m
Tc-sestamibi is used together with 
123
I, 
which is taken up by the thyroid gland only. Subtracting the 
123
I image from the 
99m
Tc-sestamibi image leaves only en-
larged parathyroid glands in the subtraction image. Imaging 
findings are based on a visual appearance of subtraction 
image, confirmed with anatomical reference in the CT im-
age. 
The advantages of dual-isotope method with 
99m
Tc-
sestamibi and 
123
I for parathyroid scintigraphy have been 
acknowledged in several studies and are recommended in 
the European Association of Nuclear Medicine (EANM) 
guideline for parathyroid scintigraphy [1]. This method has 
been applied in Finland, as all nuclear medicine depart-
ments performing parathyroid scintigraphy are now using 
dual-isotope method with 
99m
Tc-sestamibi and 
123
I as their 
first method of choice in parathyroid scintigraphy [2]. 
Both planar and tomographic acquisition techniques are 
used clinically. Planar pinhole acquisition has its advantages 
due to superior spatial resolution, but modern SPECT/CT 
imaging offers three-dimensional images together with 
exact anatomical information. These techniques are often 
combined to increase sensitivity and specificity [3-4]. How-
ever, acquisition of an additional image requires the change 
of the collimator and increases the total length of the study. 
Thus, it would be attempting to simplify imaging protocol 
but this has to be done without decreasing image quality. It 
should be noted that a large, active parathyroid adenoma is 
clearly visible regardless of the imaging protocol used. The 
current clinical problem are patients with secondary hy-
perparathyroidism with relatively inactive hyperplastic 
glands, and patients with multiglandular disease, where 
patient has more than one enlarged parathyroid glands [5]. 
99m
Tc-sestamibi/
123
I subtraction SPECT/CT is technically 
challenging. Close proximity of the photon energies 
(140keV and 158keV) with limited energy resolution of a 
gamma camera detector leads to cross-contamination of 
isotopes. Asymmetric energy window for 
123
I is generally 
used to reduce 
99m
Tc contamination in 
123
I energy window, 
[6-7].  The septal penetration of high-energy photons of 
123
I 
is also a potential cause of artefacts in subtraction images. 
The selection of collimator (due to different septal thick-
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ness, resolution and sensitivity) has thus a marked effect on 
the final results [8]. Reconstruction parameters and the use 
of scatter correction will also have effect [9-10]. 
  The purpose of this study was to optimize the parathy-
roid scintigraphy 
99m
Tc-sestamibi/
123
I subtraction 
SPECT/CT - protocol using an anthropomorphic phantom. 
The effect of collimator choice, energy window settings and 
the reconstruction parameters (number of iterations, scatter 
correction) were studied. 
II. MATERIALS AND METHODS 
For the purpose of this study, a phantom mimicking para-
thyroid patient with a small, low intensity adenoma was set 
up (Figure 1). A thyroid gland phantom (Radiology Support 
Devices) was filled with 
123
I and 
99m
Tc (concentration of 
500 kBq/ml). A small sphere with inner diameter of 
7.86mm (Micro Hollow Sphere, Data Spectrum) was filled 
with lower 
99m
Tc ±concentration as thyroid gland 
(~300kBq/ml) to mimic small parathyroid adenoma or hy-
perplastic gland (0.25ml with ~125kBq of 
99m
Tc) and at-
tached behind the thyroid gland. The thyroid and parathy-
roids were inserted into the thorax phantom (Radiology 
Support Devices), which was then filled with 350MBq of 
99m
Tc. Activities were measured using a VIK-202 ionization 
chamber (Veenstra) used in clinical work and subjected to 
strict daily quality control measures. 
A series of SPECT/CT scans were performed with three 
sets of collimators: Low Energy High Resolution (LEHR), 
Low Energy Ultra High Resolution (LEUHR) and Medium 
Energy Low Penetration (MELP) and with two energy win-
dow settings, clinical and test windows (Table I).  
SPECT was acquired using normal clinical acquisition 
protocol (a noncircular orbit, 180q detector configuration, 
128u128 matrix; 4.8 mm pixel size; step-and-shoot, 48 
views for each detector, 33 s/projection). 
 
Figure 1. Thorax phantom, the thyroid gland and spherical phantom mim-
icking parathyroid adenoma. Images are not in scale. 
 
Table 1 Energy window settings 
E34567
Window 
Setting 
E34567
Window 
P9:;:<4=>
at 
W?3@:A
Width 
(%) 
W?3@:A
Limits 
(keV) 
CB?3?F=B
SF=;;45 G HJK HHL ± 133 
MMNTc HOQ >4R HQK HTT ± 147 
SF=;;45 G UK HOU ± 156 
XYZI H[U >4R HQK HJ\ ± 175 
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^
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MMNTc 
HOQ >4R HQK HTT
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HOU
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XYZI 
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_
>4R HQK HJQ
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The CT acquisition for attenuation correction and image 
fusion was acquired after the SPECT acquisition without 
moving the phantom and using the same scan area as for 
SPECT (130 kVp, 2u2.5 mm collimation, 0.8 s rotation 
time, 1.5 pitch, CARE Dose AEC+DOM, with the ref. ex-
posure 80 mAs). All acquisitions were performed with Sie-
mens Symbia Intevo T2 SPECT/CT ((Siemens, Erlangen, 
Germany) in the Department of Nuclear Medicine of Sa-
takunta Central Hospital.
 
99m
Tc-sestamibi and 
123
I SPECT images (with attenuation 
correction) were reconstructed on the Siemens Syngo work-
station using the FLASH 3D-algorithm with eight parameter 
settings (6, 8, 16 or 32 iterations, 8 subsets, Gaussian 9.00 
filter, with and without TEW scatter correction). 
123
I SPECT images were multiplied by a normalization 
factor (as the ratio of the thyroid maximum voxel counts in 
99m
Tc and 
123
I SPECT images to create normalized 
123
I 
SPECT images, which were then subtracted from 
99m
Tc 
SPECT images. All images were subjected to visual and 
quantitative evaluation. Image processing and evaluation 
was performed by an experienced medical physicist. All 
images were anonymized (no knowledge of collimator or 
acquisition or processing parameters) and scored from 0 to 
5. Scoring was based on clinical appearance (the intensity of 
adenoma, the presence of artefacts). 
For quantitative analysis, a VOI was drawn around the 
sphere using the fused CT image as a reference (with corre-
sponding background VOI). An image contrast C for sphere 
was calculated using the formula (1): 
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background
backgroundadenoma
C
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where: 
Cadenoma is the number of counts in the sphere, 
Cbackground is the number of counts in the background area 
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The mean values for contrast and visual scores were cal-
culated for each collimator (all energy windows and pro-
cessing parameters), for each energy window setting (all 
collimators and processing parameters) and for scatter cor-
rection (all collimators, energy windows and processing 
parameters). 
III. RESULTS 
The calculated contrast for adenoma was between 0,4%-
80,9%. The visual scores were between 0-5. The contrast 
and visual scores were in correlation (Figure 2). The mean 
values for contrast and visual scores were highest for 
LEUHR collimator and for test energy windows settings. 
Contrast values were higher with scatter correction, but 
visual scores were lower (Table 2). 
 
 
Figure 2. Visual score as a function of contrast. 
Table 2 Mean contrast values and visual scores calculated for collimators, 
energy window settings and with or without scatter correction 
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The mean values for contrast for reconstruction parame-
ters (for all collimators and energy window settings) were 
higher with an increasing number of iterations. However, 
visual scores were highest with 16 iterations, increasing 
iterations to 32 decreased the visual appearance of the im-
ages (Table 3). 
Table 3 Mean contrast values and visual scores calculated for eight 
reconstruction parameter settings for all collimators 
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The mean values for contrast for each combination of 
collimator, energy window and scatter correction are pre-
sented in Table 4. The highest mean values for contrast and 
visual scores were with LEUHR collimator with not-
corrected test energy window. Phantom images with highest 
visual scores and with current clinical protocol are present-
ed in Figure 3. 
Table 4 Mean contrast values and visual scores calculated for collimators 
with two energy window settings and with or without scatter correction 
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Figure 3. From left to right, transverse, sagittal, and coronal images of the 
phantom  (an adenoma is located at the crosshair).  A) LEHR Clinical, 8 
iterations, no scatter correction (current clinical protocol), B) LEHR Test, 
16 iterations, scatter correction, and C) LEUHR Test, 16 iterations, no 
scatter correction. The red arrow is showing ³WKHHGJHDUWeIDFW´ 
IV. DISCUSSION 
The findings of this study confirmed that the selection of 
collimator, energy window positioning and reconstruction 
parameters have a significant effect on the visual appear-
ance of images. Collimators with higher resolution yielded 
better results, as did increasing iterations in reconstruction. 
The energy window setting had a significant effect on the 
appearance of subtraction images, as symmetric window for 
123
I was always better than asymmetric window. Scatter 
correction increased calculated contrast, but at the same 
time, the visual appearance was decreased due to increased 
noise. 
Current clinical protocol for parathyroid scintigraphy 
with LEHR collimator, asymmetric energy window without 
scatter correction was able to visualize adenoma only faint-
ly. Switching to symmetric energy window for 
123
I and 
applying scatter correction with more iterations was able to 
increase visual score from 0,5 to 3,5. MELP collimator 
would be attempting choice for imaging with 
123
I due to 
thicker septa, but low spatial resolution is not adequate 
when searching for small, relatively inactive parathyroid 
gland. LEUHR collimator with symmetric energy windows 
had best contrast and visual scores. The scatter correction in 
fact decreased these results, probably due to statistics as 
LEUHR collimator has sensitivity of approximately 50% 
compared to LEHR collimator and subtraction-based scatter 
correction reduces counts even further. The visual effect of 
increasing noise is visible in the Figure 3, where the artifac-
WXDO³EOREV´KDYHDVLPLODUDSSHDUDQFHWRSDUDWK\URLGDGe-
noma. However, this misinterpretation can be avoided with 
the use of CT, and the search of the anatomical reference. 
The so-called edge artefact [11] is currently the main 
cause of false positive findings in 
99m
Tc-sestamibi/
123
I sub-
traction SPECT/CT (Figure 3). According to the results of 
this study, the edge-artefact is more present with lower 
resolution image and with asymmetric 
123
I window. LEUHR 
symmetric window images did not include any marked 
artefact. 
According to the results of this study, increasing the 
number of iterations to more than 16 decreased the visual 
scores due to increased noise. However, it should be noted 
that this is highly dependent on camera and collimator spec-
ifications, acquisition parameters and activity of 
99m
Tc-
sestamibi and 
123
I used. 
Due to large variation of adenoma contrast and visual 
scores in this study, we find that the protocols used in clini-
cal practice should be thoroughly tested using phantoms. 
Although clinical situation is different when comparing to 
phantom studies (patient movement, breathing, extra thyroid 
99m
Tc-sestamibi activity), the ultimate detection limit should 
be resolved. 
V. CONCLUSIONS  
The effect of collimator, energy window selection and 
reconstruction parameters have a significant effect on visual 
appearance and adenoma contrast in parathyroid 
99m
Tc-
sestamibi/
123
I subtraction SPECT/CT. Symmetrical energy 
windows and high-resolution collimator yielded best results 
with some improvement with scatter correction. 
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